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New drug discoveries and new approaches towards diagnosis and treatment have improved 
cancer therapeutics remarkably.  One of the most influential and effective discoveries in the field 
of cancer therapeutics was antimetabolites, such as the antifolates. The interest in antifolates 
increased as some of the antifolates showed responses in cancers, such as mesothelioma, 
leukemia, and breast cancers. When pemetrexed (PTX) was discovered, our laboratory had 
established that the primary mechanism of action of pemetrexed is to inhibit thymidylate 
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synthase (TS) (E. Taylor et al., 1992).  Preclinical studies have shown that PTX has a broad 
range of antitumor activity in human and murine models of cancer (Adjei, 2000; Adjei, 2004; S. 
Chattopadhyay, Moran, & Goldman, 2007; Miller et al., 2000).  Accordingly, in February 2004, 
the FDA issued first-line treatment approval for pemetrexed in malignant pleural mesothelioma 
and in 2008 for first line treatment for locally advanced or metastatic NSCLC (reviewed in 
(Rollins & Lindley, 2005). As an antifolate this level of therapeutic activity of PTX against lung 
cancers was surprising and atypical (Hazarika, White, Johnson, & Pazdur, 2004). This led us to 
the question whether the effects of pemetrexed on other folate-dependent targets could explain 
the clinical activity of the drug.  Our lab showed that, in addition to inhibiting thymidylate 
synthase, PTX also inhibits aminoimidazolecarboxamide ribonucleotide formyltransferase 
(AICART), the second folate-dependent enzyme of de novo purine synthesis.  Inhibition of 
AICART leads to massive accumulation of its substrate 5-amino-4-imidazolecarboxamide 
ribonucleotide (ZMP), causing activation of AMP-dependent kinase (AMPK), which ultimately 
leads to suppression of mTORC1 signaling, a central regulator of cell growth and proliferation. 
This secondary mechanism could explain the unusual activity of PTX against mesothelioma and 
lung cancers.  
 The large proportion of lung cancers are either null or mutant for p53 function.  
Therefore, this thesis focused on defining what the role of p53 is in the PTX-mediated AMPK 
activation and mTORC1 inhibition and how the loss of p53 affects mTORC1 signaling.  These 
two questions proved to be interlinked.  Chapter 2 investigates this relationship in detail. We 
found that, upon loss of p53, mTORC1 signaling is enhanced to a significant degree in colon 
carcinoma and lung cancer cell lines. Clearly, this observation required explanation. We found 
that the major factors responsible for these differences in mTORC1 activity upon loss of p53 
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were lower levels of two p53 target genes Tuberin (TSC2) and sestrin2.  Immunoprecipitation 
studies of mTORC1 complexes from p53 wt and p53 null cells revealed quite interesting 
differences in the components of the mTORC1 complex. Immunoprecipitates from p53 null cells 
had higher levels of mTOR and lower levels of TSC2 and PRAS40 bound to raptor. This 
suggested that, in comparision to p53 competent cells, p53 null cells have more mTORC1 
complex with enhanced activity due to decreased interaction of TSC2 and PRAS40, both of 
which are inhibitors of mTORC1. These observations explained the higher mTORC1 in p53 null 
cells and laid the foundation for determining the role of p53 in PTX-activated AMPK and 
mTORC1 inhibition. 
 In the experiments described in Chapter 3, we found that PTX-mediated AMPK 
activation inhibited mTORC1 regardless of the p53 status in colon carcinoma cells. This 
suggested that mTORC1 inhibition by PTX was either independent of p53 mediated negative 
regulation of mTORC1 or was somewhere bypassing it. Therefore, we compared the effects of 
PTX with the classic AMPK activator aminoimidazolecarboxamide ribonucleoside (AICAR).  In 
spite of a common mechanism of AMPK activation, namely, expansion of cellular ZMP levels, 
signaling from AMPK activated by PTX or AICAR were quite different. PTX-activated AMPK 
phosphorylated the mTORC1 component Raptor but not tuberin (TSC2), whereas AICAR-
activated AMPK phosphorylated both the targets. This differential behavior of two AMPK 
activators was due to differential behavior of p53 under these two treatments.  Both, AICAR and 
PTX treatment led to increase in p53 levels but the p53 that accumulated after AICAR treatment 
was transcriptionally active while the p53 that accumulated after PTX treatment was not.  
Transcription of p53 targets, including TSC2 and sestrin2, was activated in AICAR- but not in 
PTX-treated cells. In the absence of p53 function, TSC2 was deficient and mTORC1 activity 
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enhanced, but Raptor phosphorylation by AMPK following PTX was robust and independent of 
both p53 and TSC2. Therefore we concluded that p53 deficiency suppresses TSC2 and 
upregulates mTORC1, but AMPK-phosphorylation of Raptor after pemetrexed treatment was 
sufficient to suppress mTORC1, even in TSC2 deficiency.  This suggested pemetrexed as a drug 
for treatment of Tuberous Sclerosis, a genetic disease caused by functional inactivity of TSC1 or 
TSC2 due to point mutations in these genes.  
 Mutation of p53 is one of the most common genetic alterations in human cancers and 
tumors.  Cancers that express mutant p53 tend to be more aggressive, resistant to chemotherapy 
and show worse prognosis then p53-null tumors (Elledge et al., 1993; Olivier et al., 2006).  This 
tumor-promoting activity of mutant p53 has been correlated with acquired and novel 
transcriptional activities of mutant p53.  It has been shown that mutp53 can activate the 
transcription of cell growth promoting genes, such as, NFκB2, PCNA, MDR1, Axl, EGFR, 
hTERT, and HSP70, which are not usually transcriptional targets of wt p53.  Interestingly, we 
found that whereas DNA damaging drugs enhance the acquired oncogenic transcriptional 
activities of mutp53, PTX interferes with this transcription activation. We also found in Chapter 
4 that PTX can limit or block the DNA damaging drug-mediated increment of transcriptional 
activation of mutp53. This suggests that blockade of transcriptional activation of mutp53 by 
pemetrexed may provide an additional therapeutic benefit in mutp53 bearing cancers. 
 As discussed in Chapter Three, although pemetrexed (with TdR) increases the levels of 
p53 and its binding to the promoter of its target gene, p21, this p53 is transcriptionally inactive. 
In order to understand the mechanism of the pemetrexed-mediated transcriptional defect of wt 
p53, we studied the PTX-mediated signaling towards ATM and ATR and their effects on their 
substrates Chk2 and Chk1, respectively. These studies suggested that the difference between 
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signaling under AICAR treatment and PTX treatment was that, unlike PTX, AICAR treatment 
was leading to DNA damage, followed by Chk2 phosphorylation at Thr68.  
 We found there were three major differences between AICAR and pemetrexed (+ TdR) 
mediated signaling: AICAR caused DNA damage, followed by ATM mediated phosphorylation 
of Chk2 at Thr68 and phosphorylation of p53 at Ser15 all of which lead to activation of p53 
transcriptional activity, events which do not take place under PTX treatment. Studies aimed at 
understanding the effects of PTX on wt and mutp53 transcriptional activities are discussed in 
detail in Chapters Three and Four of this dissertation.  
 Overall, we concluded that PTX interferes with the transcription activity of wild type as 
well as gain-of-function mutant p53. The blockade of DNA damaging agent-mediated 
enhancement of mutp53 transcription activity by PTX, suggests the clinical relevance of PTX in 
carcinomas with mutp53. We suggest that this could be one of the contributing factors in the 
effects of PTX against human lung cancers. 
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Chapter 1 
1 Overview and Introduction  
1.1 STRUCTURAL, ABSORBTIVE AND TRANSPORT CHARACTERISTICS OF 
NATURALLY OCCURRING FOLATES 
 Folic acid (also known as folate, vitamin M, vitamin B9, vitamin Bc (or folacin), and pteroyl-L-
glutamic acid) is a water soluble vitamin. Folates were first discovered in the early 1940's from 
yeast and liver extracts as a responsible factor for reversing macrocytic anemia in pregnant 
women (Hoffbrand & Weir, 2001). Folic acid was isolated and crystallized from spinach and its 
structure was determined (C. Baugh & Krumdieck, 1971). Folic acid is the most oxidized and 
stable form of the folates that can be utilized for cellular metabolism. Our current understanding 
of folates, their absorption at the cellular levels, metabolism and utilization at the molecular level 
is a result of a combined effort of basic and clinical research.  Antifolates have been very useful 
tools in understanding these pathways. Three distinct moieties of folic acid are; (A) 2-amino-4 
hydroxy-pteridine ring which is conjugated through a methylene group to (B) para-aminobenzoic 
acid (PABA), which forms a peptide linkage to (C) glutamic acid (Fig1-1). Tissue folates are 
commonly reduced forms of folic acid, which are formed due to its reduction to tetrahydro forms 
at the 5,6, 7,8 positions of pteridine ring.  
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The N5 or N10 nitrogen atoms of 5,6,7,8- tetrahydrofolate (H4PteGlu) can be linked to methyl 
(CH3), formyl (CHO), methenyl (=CH+), or methylene (=CH2) groups. Additional glutamate 
residues are processively added to the γ−carboxyl tail by the enzyme folylpoly-γ-glutamate 
synthetase (FPGS), forming H4PteGlun (Fig 1-1) (C. Baugh & Krumdieck, 1971; Tomsho, 
Moran, & Coward, 2008).  
Humans obtain folates from dietary sources, including vegetables (particularly dark green leafy 
vegetables), fruits, fruit juices, nuts, beans, peas, dairy products, poultry, meat, eggs, seafood, 
grains and supplemental sources.  Spinach, liver, yeast, asparagus, and brussels sprouts are 
among the foods with the highest levels of folates. Although the human body can synthesize all 
the components of a folate molecule individually, but it cannot produce two enzymes associated 
with folate de novo synthesis, present in microorganism. Microorganisms have dihydropteroate 
synthase, which conjugates the pteridine and a PABA ring to make dihydropteroic acid, and 
dihydrofolate synthetase, an activity of bacterial FPGS.  A lack of dietary folates can lead to 
folate deficiency. A normal individual can store up to 500- 20,000µg of folate; therefore, even 
with a complete lack of folates in the diet, it can take months before the signs of folate deficiency 
appear. This deficiency can result in many health problems, such as megaloblastic anemia and 
neural birth defect in developing embryos. Other folate deficiency related health problems 
include pregnancy complications, mental confusion, forgetfulness or other cognitive deficits, 
mental depression, sore or swollen tongue, peptic or mouth ulcers, headaches, heart palpitations, 
irritability, and behavioral disorders. The human body needs folate to synthesize DNA, repair 
DNA, and methylate DNA (C. Baugh & Krumdieck, 1971). It is especially important in aiding 
rapid cell division and growth such as in infancy and pregnancy, to produce healthy red blood 
and prevent anemia  (Tomsho et al., 2008). In the US, grains, such as wheat flour, all purpose 
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flour, bread, juice, breakfast cereals etc., are fortified with folic acid to complete the daily 
requirement of the folic acid in human body; the concept of fortifying food with folic acid is now 
being accepted all around the world, including developing countries like China and India. 
1.1.1 Intracellular uptake and compartmentalization of folate 
 The most abundant natural forms of folate found in the diet are polyglutamated derivatives of 5-
CH3-H4PteGlu and 10-CHO-H4PteGlu (Fig1-1). As polyglutamation limits the transport of 
folates across membranes; nature has provided a group of enzymes called γ−glutamyl 
carboxypeptidases, which are located in the brush-border of the proximal jejunum. These 
enzymes hydrolyze 5-CH3-H4PteGlu polyglutamates to monoglutamates, that are substrate for 
transport (Halsted, 0321). Due to the hydrophilic nature of the charged folate molecule, its 
passive diffusion across cell membrane is minimal. The efficient transport of folates across 
membranes, its intestinal absorption and transport to systemic tissue involves four classes of 
transporters: 
• The Reduced folate carrier (RFC) 
• Folate receptors FRα  and FRβ  
• The proton-coupled folate transporter (PCFT) 
• Folate transport mediated by ATP-binding cassette transport proteins and members 
of the SLC21 and SLC22 families of solute carrier 
Reduced folate carrier (RFC)-The RFC (SLC19A1) was the first folate transporter studied at 
the kinetic, thermodynamic and molecular levels. The human RFC (hRFC) encoding gene is 
located on chromosome 21q22.3 (I. D. Goldman, Lichtenstein, & Oliverio, 1968; I. Goldman & 
Matherly, 1985; Matherly & Goldman, 2003; Sirotnak & Tolner, 1999). At neutral pH, the 
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reduced folate carrier (RFC) facilitates the transport of systemic 5- CH3-H4PteGlu, the principal 
folate found in mammalian serum, into cells. (G. I. & Oliverio, 1122; I. D. Goldman et al., 1968; 
Matherly, Seither, & Goldman, 1987; Matherly et al., 2007; Matherly, Hou, & Deng, 2007) 
(Fig1-2). Folates are negatively charged due to the two carboxyl groups in the glutamate side 
chain that are fully ionized at physiological pH. In order to facilitate transport via the RFC, there 
must be a substantial electrochemical potential difference for folates across the cell membranes 
(G. I. FAU et al., 1122). RFC mediated transport is highly sensitive to the transmembrane anion 
gradient, especially the organic phosphate gradient. This provides a driving force for RFC-
mediated uphill transport to folates into cell (I. D. Goldman, 1971; Henderson & Zevely, 1983) 
(Fig. 1-3). The low affinity of the RFC for folic acid and its neutral pH optimum clearly 
distinguishes it from the PCFT.  However, both RFC (Liu et al., 2005) and PCFT (Qiu et al., 
2007) expression are markedly increased in the small intestine of mice when they are fed a folate 
deficient diet. The regulatory mechanism lying under this response is not well understood. 
Folate receptors, FRα ,β  and γ)- FRs, are encoded by three distinct genes designated α, β, and 
γ, all located on chromosome 11, are very high affinity folate binding proteins (Lu & Low, 2002; 
Salazar & Ratnam, 2007). These three FRs are homologous proteins (68– 79% identical amino 
acid sequences) but show differential expression in different tissues.  FRα is expressed in 
epithelial cells of the kidney, choroid plexus, retina, uterus, and placenta (Parker et al., 2005; 
Salazar & Ratnam, 2007) . FRβ is expressed during normal myelopoiesis and is present in 
placenta, spleen, thymus, and in CD34+ monocytes (Ratnam, Marquardt, Duhring, & Freisheim, 
1998; Reddy et al., 1999; Ross et al., 1989; H. Wang, Zheng, Behm, & Ratnam, 2000). The FRs 
have high affinity for folic acid (Kd 1–10 nM). FR-mediated folate internalization involves 
receptor mediated endocytosis (B. G. FAU, FAU, FAU, & Moran, 0207; Kamen, Wang, 
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Streckfuss, Peryea, & Anderson, 1998; Lu & Low, 1217; Ross et al., 1989).  
 
 
 
 
 
 
 
 
(Adapted from PhD. Dissertaion of Scott Rothbart, 2010) 
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Figure 1-1.  Chemical structures of folic acid and tetrahydrofolate. 
 
Folic Acid 
Tetrahydrofolate 
Figure 1-1 Chemical structure of Folic acid and Tetrahydrofolate.  
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Enzyme abbreviations are AICART – aminoimidazole carboxamide ribonucleotide 
formyltransferase ; cSHMT – cytosolic serine hydroxymethyltransferase isoform ; DHFR – 
dihydrofolate reductase ; GART – glycinamide ribonucleotide formyltransferase ; TS – 
thymidylate synthase. Single arrows representing the direction of the reaction show irreversible 
reactions and reversible reactions are represented by double arrow. 
 
 
 
Figure 1-2. Schema of folate metabolism and folate-dependent reactions that occur in the 
cytosolic subcellular compartment of cells.  
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When folate molecules bind to the FR on the cell surface, in causes invagination of the plasma 
membrane surface at that site, leading to formation of a vesicle (endosome). This endosome 
migrates to the cytoplasm, where it is acidified to a pH of ~ 6.5, resulting in dissociation of the 
folate from the FR complex (Yang, Chen, Vlahov, Cheng, & Low, 2007). The folate ligand is 
exported into the cytoplasm (Kamen, Peryea & Anderson, 1998; Rothberg, Ying, Kolhouse, 
Kamen, & Anderson, 1990) (Fig. 1-3). While FRs α and β can transport folate into cells, this is 
inefficient compared to transporters such as RFC (Sierra, Brigle, Spinella, & Goldman, 1995; 
Spinella, Brigle, Sierra, & Goldman, 1995). 
ii) Proton-coupled folate transporter (PCFT)- The proton- coupled folate transporter (PCFT) 
is used to transport folate monoglutamates (including folic acid) across the apical surface of the 
proximal jejunum. PCFT symports folates optimally at pH 5.5 against its concentration gradient 
with protons along their concentration gradient into the enterocytes, explaining why the acidic 
microenvironment of the small intestine is favorable for PCFT- mediated folate transport (Qiu et 
al., 2006; Zhao & Goldman, 2007) (Fig. 1-3).  
Folate transport mediated by ATP-binding cassette transport proteins and members of the 
SLC21 and SLC22 families of solute carrier- It has been suggested that there are other folate 
transport routes other than these highly specific transporters. The multidrug resistance-associated 
proteins MRP1-5 (ABCC1-ABCC5) and the breast cancer resistant proteins BCRP, (ABCG2) 
are relevant ATP-binding cassette exporters (Assaraf, 2006; Kruh & Belinsky, 2003; Wielinga et 
al., 2005)(Fig. 1-3). These are low affinity, high capacity transporters (Kms ~0.2 – 2 mM for 
folates/antifolates). Members of this family are widely expressed in mammalian cells and 
suppress the level of free folates or antifolates that accumulate in most cells grown in vitro (Fry, 
Yalowich, & Goldman, 1982).  
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Figure 1-3. Schema of the known folate transporters.  
Abbriviation of various transporters are as follows; PCFT= Proton-coupled 
folate transporters, RFC= Reduced folate carrier, FR= Folate receptors, 
MRPs and BCRP= multidrug resistance proteins and breast cancer resistant 
protein 
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Some of the shorter chain-length polyglutamate folates may be weak substrates for MRPs (Fry et 
al., 1982). The physiological importance of MRP2 in folate export is demonstrated by impaired 
biliary secretion of MTX in MRP2 (-/-) mice (Masuda et al., 1997). 
In summary, it is during intestinal uptake that folic acid from fortified foods is reduced to 5-
CH3-H4PteGlu. 5-CH3-H4PteGlu, which is absorbed in small intestine enters the portal 
circulatory system and is first delivered to the liver, where it can be passed through to the 
systemic circulation, can be secreted into the bile for reabsorption, or can be polyglutamated for 
storage. Systemic 5-CH3-H4PteGlu can be transported into cells by folate receptor-mediated 
endocytosis, a high affinity and low capacity process. The detailed discussion of this process is 
as follows. 
1.1.2 Folate absorption in intestine  
During intestinal absorbtion, polyglutamated folates are converted into monoglutamates and are 
transported across the apical brush border membrane of the proximal jejunum mediated by the 
PCFT. As PCFT transport is very efficient, concentrative and driven by a transmembrane proton 
gradient, the amount of folate transported to enterocytes is high enough to facilitate folate efflux 
across the basolateral membrane into the periserosal space and then enter the vascular system. 
The mechanism of folate export from enterocyte is unclear as neither PCFT not RFC are 
expressed at the basolateral membrane. However, MRPs, particularly MRP3 (Kruh & Belinsky, 
2003) are expressed at this site and may be involved in the export of folates through this route.  
After intestinal absorption, folates enter the hepatic portal system and are delivered to hepatic 
sinusoids. Once folates are in the liver, they have three potential destinations. i) Folate can be 
converted to polyglutamate storage forms mediated by FPGS ; ii) they can be secreted in the bile 
at the hepatic canalicuar membrane, by MRP2 mediated process (Masuda et al., 1997), return to 
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the deudenum and jejunum for reabsorption and thus completing the cycle of enterohepatic 
circulation or iii) they can stay as monoglutamates or get converted into monoglutamates from 
stored polyglutamates in hepatocytes, and delivered directly from the hepatic portal vein , 
ultimately reaching the systemic circulation where they accumulate and participate in the 
processes of the one-carbon requirement of peripheral tissue. 
1.1.3 Transport into systemic tissues 
At neutral pH 7.4, RFC mediate the membrane transport of folate into systemic tissue. Although 
PCFT is co-expressed with the RFCin many tissues at the plasma membrane, due to the neutral 
pH at these sites, the function of the PCFT is minimal at these sites. 
1.1.4 Polyglutamation and storage of folate 
Polyglutamation of folates is attributed to the enzyme folylpoly-γ-glutamate synthetase (FPGS) 
(Moran, Werkheiser, & Zakrzewski, 1976). Polyglutamation is not only essential to increase the 
stability and retention of folates within the cell, but also to increase the affinity of folates for 
their target enzymes. Humans have two isoform of FPGS, cytosolic and mitochondrial, coded 
from same gene. These two isoforms help in maintaining the equal distribution of folate 
polyglutamate between the cytosol and the mitochondria (Cook & Blair, 1979; Freemantle, 
Taylor, Krystal, & Moran, 1995; S. M. Taylor, Freemantle, & Moran, 1995). Folates are 
transported into the mitochondria by the mitochondrial folate transporter (MFT), a family 
member of the inner mitochondrial membrane transport carriers that was cloned and 
characterized by our lab (McCarthy, Titus, Taylor, Jackson-Cook, & Moran, 2004; Perchiniak et 
al., 2007; Titus & Moran, 2000). Folate monoglutamates are the substrates for mitochondrial 
transport, suggesting substrate competition between cytosolic FPGS and the MFT (Freemantle et 
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al., 1995; Perchiniak et al., 2007). Chinese hamster ovary (CHO) cells that lack functional FPGS, 
known as AuxB1 cells, are unable to accumulate any cellular folates and therefore require an 
exogenous supply of purines, thymidine and glycine to the growth culture medium (T. R. FAU & 
Hanna, 0812; McBurney & Whitmore, 1974). These studies suggested that the purpose of 
mammalian folate metabolism is to produce purines, thymidine and glycine. 
1.1.5 Intracellular folate metabolism  
Folate metabolism takes place in both cytosolic and mitochondrial compartments and allow the 
recycling of folate molecules. Although, in the mammalian cells all the enzymes required to 
synthesize purines, thymidine, methionine and glycine are present in the cytosol. Cytosolic folate 
metabolism contributes to and is limited to purine, thymidine, and methionine synthesis. A study 
showed that the cytosolic isoform of FPGS when transfected into AUXB1 cells, relived the 
exogenous requirement of the purine and thymidine but not of glycin (Garrow et al., 1993; Lin, 
Huang, & Shane, 1993). It was found that mitochondrial folate metabolism fulfills the 
requirement of glycine supply to the cells (McCarthy et al., 2004) and cytosolic folate 
metabolism is essential for purine and pyrimidine synthesis. Synthesis of purines, thymidine and 
methionine is done in the cytosol using folate molecules as cofactors (Fig. 1-3). First, 5-methyl-
tetrahydrofolate and homocysteine are converted into tetrahydrofolate and methionine. The 
tetrahydrofolate then can be converted to either 10-formyl-tetrahydrofolate or 5,10-methylene-
tetrahydrofolate. The conversion of tetrahydrofolate (H4PteGlun) to 10-formyl tetrahydrofolate 
consumes a formate molecule. Conversion of tetrahydrofolate to 5,10-methylene-tetrahydrofolate 
is done by the cytosolic serine hydroxymethyltransferase isoform (cSHMT).  The two folate-
dependent enzymes of purine synthesis, glycinamide ribonucleotide formyltransferase (GART) 
and aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), use the formyl 
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carbon of 10-formyl-tetrahydrofolate. 5,10-methylene-tetrahydrofolate can be converted either to 
5-methyl-tetrahydrofolate or to dihydrofolate (H2PteGlun). Thymidylate synthase (TS) uses 5,10- 
methylene-tetrahydrofolate and deoxyuridylate to produce thymidylate and dihydrofolate. The 
dihydrofolate produced during thymidylate synthesis is then converted to tetrahydrofolate by 
dihydrofolate reductase (DHFR) (Fig. 1-3). 
Mitochondrial folate metabolism is also important for glycine synthesis (Fig. 1-4). Cells keep 
separate pools for cytosolic and mitochondrial folate reactions (Appling, 1991). All the 
molecules required for folate metabolism such as glycine, serine and formate appears to get 
exchanged between the mitochondrial and cytosolic compartments (Pasternack, Laude, & 
Appling, 1994). In mitochondria, folates are utilized as cofactors to metabolize glycine. 
Conversion of serine and tetrahydrofolate into glycine and 5,10-methylene-tetrahydrofolate is 
mainly done by mitochondrial isoform of serine hydroxymethyltransferase. CHO-derived GlyA 
cells, that lack activity of the mSHMT isoform, but have an active cytosolic isoform, are 
auxotrophic for glycine (Kao, Chasin, & Puck, 1969). Later it was shown that GlyA cells have 
increased amounts of intracellular serine and decreased amounts of glycine when compared to 
wild-type CHO cells (Narkewicz, Sauls, Tjoa, Teng, & Fennessey, 1996). For a better regulation 
of glycine metabolism, mitochondria also contain a unique system known as glycine cleavage 
system (GCS). The GCS catabolizes glycine into formate, ammonia, and 5,10-methylene-
tetrahydrofolate and NADH+ by using tetrahydrofolate and NAD (Kikuchi, Motokawa, Yoshida, 
& Hiraga, 1114). 
 
 
 
 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1-4. Schematic of folate metabolism and folate-dependent reactions that occur in the 
mitochondrial subcellular compartment.  
 Enzyme abbreviations are GCS – glycine cleavage system; mSHMT – mitochondrial serine 
hydroxymethyltransferase isoform. Single arrows represent the direction of irreversible reactions and 
double arrows represent reversible reactions. The two reversible reactions catalyzed by mSHMT and 
GCS, converting tetrahydrofolate to 5,10-methylene-tetrahydrofolate, do not occur simultaneously; 
they are separate reactions that use the same molecules in different reactions with different enzymes. 
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In an in-silico study, mathematical models were generated to stimulate hepatic folate metabolism 
and suggested that both the mSHMT and GCS reactions are reversible, but are predicted to run in 
the direction of tetrahydrofolate to 5,10-methylene-tetrahydrofolate which ultimately is to 
generate 10-formyl- tetrahydrofolate (Nijhout et al., 2006). Although, both the reactions, by 
mSHMT and GCS, generate formate, they oppose each other in glycine regulation. While 
catabolizing glycine, the GCS directly generates formate. The 5,10-methylene-tetrahydrofolate 
converts into 10-formyl-tetrahydrofolate in two steps, and 10-formyl-tetrahydrofolate can be 
metabolized into formate and tetrahydrofolate. Later, it was shown that the mitochondrial folate 
metabolism is very important in yeast, especially in term of formate generation, as ~25% of the 
carbon units used in purine synthesis were from mitochondrially-derived formate (Pasternack et 
al., 1994). In-silico studies done by Pastenack et. al showed that in the absence of mitochondrial 
folate metabolism in in-silico mathematical models, thymidine and purine synthesis were 
reduced by ~40% and 60% respectively, and that other cytosolic folate-dependent processes were 
relatively unaffected (Pasternack et al., 1994). Thus, the role of mitochondrial folate metabolism 
is to produce glycine that can be metabolized into formate for the use in cytosolic synthesis of 
purines and thymidine. 
1.1.6 Development of Cancer chemotherapy 
The origin of effective cancer chemotherapy goes back to World War I. It began in the 1940's 
with the use of mustard gas by the German army as the first introduction of chemical warfare. 
Soldiers exposed to mustard gas showed dramatic symptoms like atrophy of lymphoid and 
testicular tissue and died within 2-3 weeks due to hypoplasia of the bone marrow (Krumbhaar & 
Krumbhaar, 1919). Later, Berendulum et. al  showed the anticancer properties of mustard gas 
(BERENBLUM & SCHOENTAL, 1947). Studies on the effects of mustard gas on biological 
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systems led to an understanding of its selective toxicity towards proliferating cells 
(Gilman & Philips, 1946). On animal models, the most striking benefit of mustard gas was noted 
in chronic myelogenous leukemia, although quite significant responses was observed in 
Hodgkin's disease (cross ref. (GILMAN, 1963; Papac, 2001). Studies done by Gilman and other 
groups using mustard gas suggested that systemic administration of cytotoxic drugs could be a 
possible therapeutics for cancer. 
1.1.6.1 Discovery and development of antifolates as cancer therapeutics 
The origin of effective cancer chemotherapy goes back to World War I. It began in the 1940's 
with the use of mustard gas by the German army as the first introduction of chemical warfare. 
Soldiers exposed to mustard gas showed dramatic symptoms like atrophy of lymphoid and 
testicular tissue and died within 2-3 weeks due to hypoplasia of the bone marrow (Krumbhaar & 
Krumbhaar, 1919). Later, Berendulum et. al  showed the anticancer properties of mustard gas 
(BERENBLUM & SCHOENTAL, 1947). Studies on the effects of mustard gas on biological 
systems led to an understanding of its selective toxicity towards proliferating cells 
(Gilman & Philips, 1946). On animal models, the most striking benefit of mustard gas was noted 
in chronic myelogenous leukemia, although quite significant responses was observed in 
Hodgkin's disease (cross ref. (GILMAN, 1963; Papac, 2001). Studies done by Gilman and other 
groups using mustard gas suggested that systemic administration of cytotoxic drugs could be a 
possible therapeutics for cancer.  
1.1.6.2 Discovery and development of antifolates as cancer therapeutics 
The discovery of antifolates led to a great advancement in the cancer chemotherapy.  Syndey 
Farber showed that administration of folic acid to children suffering from acute lymphocytic 
 41 
leukemia (ALL) stimulated the proliferation of cancer cells and exacerbated the disease 
(FARBER & DIAMOND, 1948). Further, Farber and colleagues demonstrated that the antifolate 
aminopterin (Fig.1-5) could induce remission of pediatric acute leukemia (FARBER & 
DIAMOND, 1948). Initially, it was thought that the mechanism of action of antifolate 
specifically targeted the fast dividing cells and thus supported the concept of targeting therapy to 
inhibit cell division.  These effects of antifolates on cancer led to the modern era of 
antimetabolite cancer drugs starting in the late 1940's. 
Antimetabolites such as aminopterin, methotrexate, pemetrexed, hydroxyurea, or N-
(phosphonacetyl)-L-aspartic acid (PALA) interfer with DNA and RNA production and therefore 
cell division and the growth of tumors.  Thus, antimetabolite therapy is very effective for some 
cancer cells. Aminopterin, an antifolate (Fig. 1-4), was first synthesized by Dr. Yellapragada 
Subbarow et al, and was subsequently was first used by Sidney Farber in 1947 to induce 
remission among children (FARBER & DIAMOND, 1948). Aminopterin was used in the United 
States from 1953 to 1964 for the indication of pediatric leukemia. Later, aminopterin was 
replaced by methotrexate due to manufacturing difficulties and to a better therapeutic index of 
methotrexate in a rodent tumor model (GOLDIN et al., 1955). In a study in 2005, Cole et. al 
suggested that aminopterin has greater cellular accumulation, metabolism and more reliable 
bioavailability than methotrexate. They concluded that considering the tolerable toxicity at the 
recommended dose and schedule, aminopterin deserves further study as an alternative to 
methotrexate. (Cole et al., 2005).  In the 1950’s, several more antimetabolites were discovered 
such as the purine analog 6- mercaptopurine (Hitchings and Elion, 1954), which was shown to 
have anti-cancer activity in mice with acute leukemia (Hitchings and Elion, 1954; Skipper, 
Thomson, Elion and Hitchings,1954).  
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5-Florouracil (5-FU), a pyrimidine analog, is a suicide inhibitor (mechanism based irreversible 
inhibitor) for thymidylate synthase. It is one of the oldest chemotherapeutic drugs which is still 
being used in the treatment of several human cancers including colorectal, breast, stomach and 
pancreatic cancers, suggesting that “cytotoxic” chemotherapy is still one of the most useful and 
prevalent method of cancer treatment.  
Due to dramatic results against various cancers, the efforts toward making new and better 
antifolates continued. Several of these agents have been rationally designed to target specific 
folate dependent enzymes or circumvent known mechanisms of resistance to classical antifolates. 
One of the most extensively studied and widely used antifolate is methotrexate (Fig. 1-5). 
Shortly after the discovery of methotrexate and its analogs, the primary folate-dependent 
therapeutic target of this drug was identified to be DHFR (Werkheiser, 1963) (Fig. 1-3, 1-6). 
Methotrexate is a tight-binding inhibitor of DHFR (Ki ~ 0.004 nM) (C. Shih, Habeck, 
Mendelsohn, Chen, & Schultz, 1998). DHFR inhibition by methotrexate prevents DNA and 
RNA synthesis by preventing the reduction of H2PteGlun to H4PteGlun, the vital precursor for 
thymidylate and purine biosynthesis cofactors (Fig. 1-3 and 1-7). Additional H4PteGlun-
dependent reactions, such as serine-glycine interconversions and methionine synthesis, are also 
hindered.  It is now known that, like natural folates, methotrexate is polyglutamated in cells (C. 
M. Baugh, Krumdieck, & Nair, 1973). This is important, as polyglutamation of methotrexate 
enhances intracellular retention of the drug and permits methotrexate to inhibit DHFR for longer 
periods of time, expanding the H2PteGlun pool (Rosenblatt et al., 1978). Polyglutamation also 
broadens the spectrum of target inhibition. Significant to cancer therapy, polyglutamation adds a 
layer of selectivity to methotrexate, as metabolites accumulate in tumor cells to a much greater 
extent than in bone marrow and intestinal tissues (Poser, Sirotnak, & Chello, 1981). Various 
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analogs of methotrexate were synthesized and tested as cancer therapeutics with the goal of 
maintaining the potency against DHFR while enhancing the substrate specificity of transport and 
polyglutamation, and limiting the uptake in normal tissues. Most attempts failed, as methotrexate 
was indeed a superior drug in this sense. However, the analog pralatrexate (10-propargyl-10-
deazaaminopterin, Folotyn®) has been shown to meet these criteria and showed remarkable 
responses in some T-cell lymphomas.  That study (Thompson, 2009) ultimately led to the U.S. 
Food and Drug Administration (FDA) approval of pralatrexate for relapsed peripheral T-cell 
lymphoma, a rare form of non-Hodgkins lymphoma, in 2009 (Thompson, 2009).  Other 
rigorously studied antifolate that has proven itself to be promising, is Pemetrexed.  The most 
sensitive cellular target of pemetrexed is thymidylate synthase. 
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Figure 1-5. Chemical structures of; A) aminopterin, the first antifolate. B) 
methotrexate 
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1.1.6.3 Second- generation antifolates targeting thymidylate synthase and purine synthesis 
pathway 
In 1980s and 1990s, the efforts towards antifolate drug discovery has been shifted away from 
targeting DHFR, focusing on pharmacophores targeting the folate-dependent enzymes of 
thymidylate and purine biosynthesis. The first potent antifolate thymidylate synthase inhibitor 
(Ki ~ 3 nM) to come from this effort was CB3717 (Jones et al., 1981).  CB3717 (Fig. 1-8) had 
antitumor activity in breast, ovarian, and liver cancers, but was ultimately withdrawn from the 
clinic due to life-threatening renal toxicity caused by poor solubility at the low pH of urine in the 
collecting ducts (Calvert et al., 1986; Jackman et al., 1991). Keeping this same 5,8-dideazafolate 
pharmacophore, analogs of CB3717 were synthesized in an attempt to increase solubility while 
maintaining specificity for thymdylate synthase.  Ultimately, Raltitrexed (Tomudex®, ZD1694) 
was identified from this effort. Raltitrexed is a 2-desamino-2-methyl-N10-substituted-5,8-
dideazafolate analog with a thiophene substitution for the PABA ring (Fig. 1-8) (Jackman et al., 
1991). Compared to CB3717, these characteristics not only increased solubility, they made 
raltitrexed a superior substrate for both RFC-mediated transport and polyglutamation by FPGS 
(Jackman et al., 1991). 
In addition to intracellular trapping of raltitrexed metabolites, polyglutamation increases the 
potency of raltitrexed as a TS inhibitor by more than 100-fold. Raltitrexed showed significant 
clinical response rates in colorectal and breast cancer patients. It is currently in widespread use 
outside the United States for the treatment of colorectal cancer, but never gained U.S. FDA 
approval, as it was not determined to be superior to the current standard of care for colorectal 
cancer, 5-fluorouracil (5-FU, also a TS inhibitor) with leucovorin, a reduced folic acid (Maughan 
et al., 2002; Popov et al., 2008).  
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The discovery of the first antifolate inhibitor of de novo purine biosynthesis, 5,10- dideaza-
H4PteGlu (DDATHF, lometrexol) was serendipitous (Figure 1-8). The structure was originally 
proposed by G. Peter Beardsley as a potential TS inhibitor, but cell culture end-product reversal 
experiments performed in our lab showed it was targeting purine synthesis (Moran, Baldwin, 
Taylor, & Shih, 1989). Subsequently, enzyme kinetic studies demonstrated that DDATHF was a 
potent inhibitor of GART, the first folate-dependent enzyme of de novo purine synthesis 
(Baldwin et al., 1991; Moran et al., 1989; Sanghani & Moran, 1997) (Fig. 1-3 and 1-7).  
DDATHF is transported into cells via the RFC as well as the PCFT (Beardsley et al., 1989). 
DDATHF showed potent antitumor activity against a broad spectrum of carcinomas, but the 
development of DDATHF was halted in Phase I clinical testing due to induction of severe 
thrombocytopenia (Ray et al., 1993). Oral supplementation with folic acid ablated the 
unfavorable toxicity of lometrexol (DDATHF) (Alati et al., 1996; Roberts et al., 2000). These 
findings set a precedent for future clinical regimens to include folic acid and vitamin B12, 
although the protective mechanism is still not fully understood.   Lometrexol posed a problem; it 
was made by a very complex 23 step process, and the product was mixture of diastereomers 
about carbon 6. The diastereomers needed to be separated before clinical trails, to meet FDA 
administration requirements. The fractional crystallization approach was not efficent and proved 
to have low yield. This led to the evaluation of alternative approaches to avoiding the preparation 
of diastereomeric mixtures.  One strategy was to replace the 5-deazapteridine ring of lometrexol 
with the pyrrolopyrimidine ring, which removed the chiral center of lometrexol and resulted in 
the compound LY231514, which became known as pemetrexed (E. Taylor et al., 1992). 
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Figure 1-6. Human DHFR with bound dihydrofolate and NADPH.  
 
Adapted from http://en.wikipedia.org/wiki/dihydrofolate_reductase 
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Figure 1-7. Folate metabolism and its key targets of chemotherapy.  
In the beginning of the concept of the antimetabolite for cancer therapy started 
with targeting DHFR and later it shifted towards TS. Multitargeted antifolate 
Pemtrexed also targets AICART. Adapted from Muhsin M et al., 2004. Nat. Rev. 
Drug Disc. 3(10):825-826 {{ Muhsin,M. et al, 2004;}} 
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1.1.6.4 Pemetrexed: a multi-targeted antifolate  
Pemetrexed (L-glutamic acid, N-(4-(2-(2amino-4,7- dihydro-4-oxo-1H-pyrrolo(2,3-d) pyrimidin-
5-yl)ethyl)benzoyl)) is arguably the most interesting of the new generation antifolates (Fig.1-8, 
1-9).  Although an analogue of folic acid, structurally and chemically it can be differentiated 
from MTX and DDATHF, as it has a 6-5 fused pyrrolo (2,3-d) pyrimidine nucleus (E. Taylor et 
al., 1992).  Pemetrexed (LY231514, Alimta) was discovered from synthetic approaches aimed at 
eliminating the chirality of carbon 6 of DDATHF, in which a pyrrolopyrimidine ring replaced 
the 5-deazapteridine (E. Taylor et al., 1992) Surprisingly, this modification also changed the 
target profile. Pemetrexed polyglutamates were potent inhibitors of thymidylate synthase both in 
vitro (Ki ~ 1.3 nM) and in cell culture {{; 234 Taylor 1228;}}.  Pemetrexed was reported to have 
effects on multiple enzymes involved in the folate metabolism, but the importance of some of 
these steps is questionable. End-product cell culture reversal experiments suggested that higher 
doses of pemetrexed had a significant secondary target, reversible with the addition of preformed 
purine (C. Shih et al., 1997; E. Taylor et al., 1992) This suggested that, like its predecessor 
DDATHF, pemetrexed was also targeting de novo purine synthesis.  As structural analogues of 
folic acid, antimetabolites also use the same transporters (Westerhof et al., 1995).  Pemetrexed 
enters the cells using the reduced folate carrier (RFC), a bidirectional transporter and major 
cellular transport system for folates (Zhao, Babani, Gao, Liu, & Goldman, 2000). Pemetrexed 
also uses folate receptor- α, a cellular membrane receptor. A low pH transporter, the PCFT, is 
also involved in pemetrexed internalization (S. Chattopadhyay, Wang, Zhao, & Goldman, 2004; 
Sierra & Goldman, 1998; Y. Wang et al., 2004; Y. Wang, Zhao, & Goldman, 2004; Zhao et al., 
2000).  As the microenvironment surrounding carcinoma cells is acidic due to secretion of lactic 
acid as a byproduct of anaerobic respiration, it has been suggested that the PCFT is, in fact, the 
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primary transporter of pemetrexed in solid tumors. Pemetrexed is one of the most efficient 
substrate of FPGS ever tested. Pemetrexed is polyglutamated 90 to 195 times more efficiently 
than methotrexate and 6 to 13 times more efficiently than lometrexol (Habeck et al., 1995). As 
pharmacological activity is achieved by polyglutamation, higher levels of glutamation not only 
increase retention of the pemetrexed inside the cell but also increase its specificity for its targets 
enzymes. Pentaglutamated pemetrexed has a Ki of 1.3 nm for its primary target TS in 
comparison to monoglutamated pemetrexed, which has Ki of 109 nM (I. D. Goldman & Zhao, 
2002; Schultz, Patel, Worzalla, & Shih, 1999; C. Shih et al., 1997). Pentaglutamated pemetrexed 
is a potent inhibitor of TS, which catalyzes the transformation of deoxyuridine monophosphate to 
deoxythymidine monophosphate (dTMP). Inhibition of TS decreases formation of dTMP, a 
progenitor of the nucleoside deoxythymidine triphosphate (dTTP) needed for the DNA synthesis. 
The enzyme deoxycytidine deaminase is negatively regulated by dTTP. (I. D. Goldman & Zhao, 
2002; Rustum et al., 1997; Schultz et al., 1999; Westerhof et al., 1995). As polyglutamated 
pemetrexed is also an inhibitor of GART and AICART, inhibition of these enzymes leads to 
inhibition of de novo purine synthesis. The DHFR-binding of pemetrexed is 1000 times less avid 
than methotrexate, and inhibition of DHFR by pemetrexed is reportedly minimal (I. D. Goldman 
& Zhao, 2002; C. Shih et al., 1997; Zhao & Goldman, 2007; Zhao et al., 2008) 
1.1.6.4.1 De novo purine synthesis 
Actively dividing cells require continuous availability of purine nucleotides due to active 
replication and transcription. This demand is mainly fulfilled by synthesis of purines in a de novo 
process known as de novo purine synthesis. The two parent nucleotides of purines in nucleic 
acids are adenosine monophosphate (AMP) and guanosine monophosphate (GMP). The de novo 
purine synthesis is an energy-consuming process consisting of 10 sequential enzymatic reactions 
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(Fig. 1-10).  
The whole purpose of this biosynthetic pathway is to build an end product, inosine 
monophosphate (IMP) from a 5-carbon molecule PRPP. Cells can also make IMP from the 
breakdown of nucleic acid using salvage pathways. Addition of preformed purines like 
hypoxanthine or inosine, can rescue cells from de novo purine synthesis inhibition or deficiency. 
Hypoxanthine can be converted into IMP by hypoxanthine-guanine phosphoribosyl transferase 
(HGPRT).  De novo purine synthesis is subjected to feedback inhibition by the end products of 
the pathway. The first and committed step of de novo purine synthesis is catalyzed by 
phosphoribosylpyrophosphate amidotransferase (PPAT). In this step, an amino group is donated 
by glutamine is attached at C-1 of PRPP, resulting into 5-phosphoribosylamine, a highly unstable 
intermediate with a half-life of 30 sec at pH 7.5. The activity of PPAT is inhibited by purine 
nucleotides IMP, AMP, GMP, and ATP (WYNGAARDEN & ASHTON, 1959). Out of ten 
reactions, two reactions of this pathway are dependent on the folate cofactor 10-CHO-H4PteGlu 
(HARTMAN & BUCHANAN, 1959). The third step of de novo purine synthesis and the first 
folate dependent step of this pathway, is catalyzed by Glycinamide ribonucleotide Pemetrexed 
has been tested in and showed dramatic effects against various carcinomas including bladder, 
breast, cervix, colon, gastrointestinal tract, and pancreas (Adjei, 2000; Adjei, 2004; Britten et al., 
1999). In the past, typical antifolates, especially TS inhibitors, have been ineffective against 
NSCLC but pemetrexed has been proven to have strong therapeutic effects against these 
diseases.   
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Figure 1-8. Chemical structure of inhibitors representing various classes of inhibitors of folate 
metabolism 
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Figure 1-9. Mechanism of action of pemetrexed.  
 THF= tetrahydrofolate; DHF= dihydrofolate; DHFR= DHF reductase; PRPP= 
phosphoribosyl pyrpphosphate; GAR= glycinamide ribonucleotode; fGAR= N-
formylglycinamide ribonucleotide; AICAR = 5-aminoimidazole-4-
carboxamine ribonucleotide; fAICAR= 5-formylaminoimidazole-4-
carboxamide ribonucleotide; IMP = inosine monophosphate 
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Figure 1-10. Folate dependent steps of de novo purine synthesis pathway.  
 De novo purine biosynthesis consists of ten sequential enzymatic reactions in which 
phosphoribosyl-1-pyrophosphate (PRPP) is converted to inosine monophosphate (IMP). 
IMP is converted to AMP and GMP thorough additional enzymatic steps (not shown). 
The two folate- dependent formyl transfer reactions of this pathway are catalyzed by 
GART and AICART. AICAR, after entering mammalian cells, gets converted into 
ZMP, leading reaction in forward direction thus feeds into the reaction. PTX inhibits 
AICART, causing its substrate ZMP to accumulate. Additionally, IMP can be produced 
by salvage of the preformed purine, hypoxanthine, by hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) and the cofactor PRPP. Adapted from the 
Racanelli AC. et al., Cancer Res. 2009 Jul 1;69(13):5467-74. 
 
 55 
 
Also pemetrexed is very effective against malignant pleural mesothelioma (MPM), a highly 
aggressive malignancy of the pleural cavities lining the lungs and chest usually associated with 
the exposure of asbestos fibers (Craighead et al., 1982). The median survival following diagnosis 
of MPM is approximately 11 months. This disease is resistant to most of the chemotherapeutic 
regimens including methotrexate and 5-FU with leucovorin (Harvey, Slevin, Ponder, Blackshaw, 
& Wrigley, 1984; Hazarika et al., 2004; Price, 1997; Solheim, Saeter, Finnanger, Finnanger, & 
Stenwig, 1992). A rigorous clinical study conducted in an area of northern Germany where 
exposure of asbestos was abnormally high, hence enriched in MPM patients, showed very 
effective results of pemetrexed on MPM (Hughes et al., 2002; Thodtmann et al., 1999). Also, 
cell-based combination studies of pemetrexed with cisplatin on MPM cells showed synergism 
and its extension to clinical study showed a survival benefit in this disease (Britten et al., 1999; 
Vogelzang et al., 2003). This led to the approval of pemetrexed and cisplatin as a first line 
treatment for MPM (Hazarika et al., 2004).  Due to high retention of pemetrexed in the target 
tissue following plasma clearance, a dosage of 500 mg /m2 pemetrexed infused every 21 days 
was chosen as a very effective treatment modality for various cancers (S. Chattopadhyay et al., 
2007). Folic acid and B12 supplementation with pemetrexed help in limiting toxicity (Hazarika 
et al., 2004). 
Pemetrexed was also approved as a second line, single- agent treatment of locally advanced and 
metastatic NSCLC in 2004.  The majority (90-95%) of lung cancers are of non-small cell origin 
and over a million of people are diagnosed with lung cancer each year worldwide (Parkin, Bray, 
Ferlay, & Pisani, 2001; Parkin, Bray, Ferlay, & Pisani, 2005).  NSCLC is a highly progressive 
disease with a survival of 6 months following diagnosis if left untreated (Chemotherapy in 
addition to supportive care improves survival in advanced non-small-cell lung cancer: A 
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systematic review and meta-analysis of individual patient data from 16 randomized controlled 
trials.2008). This unusual success of pemetrexed against MPM suggested that it might be helpful 
in treatment of NSCLC.  The effect of pemetrexed on NSCLC was initially tested in comparison 
to docetaxel (Taxotere), which was the standard treatment of the care for NSCLC at that time 
(Hanna et al., 2004). Although the median survival time of patients treated with pemetrexed and 
docetaxel were not significantly different (8.3 vs. 7.9 months median survival respectively), 
pemetrexed was significantly less toxic. This study played a favorable role in convincing FDA to 
approve pemetrexed for second-line treatment of NSCLC. 
Various kind of tumors which have grown resistance against other antifolates have been shown 
to preserve sensitivity for pemetrexed (Jackman et al., 1995; Schultz et al., 1996; Zhao, 
Chattopadhyay, Hanscom, & Goldman, 2004; Zhao, Hanscom, Chattopadhyay, & Goldman, 
2004).  Pemetrexed retained activity in MCF-7 breast carcinoma and H630 colon carcinoma cells 
resistant to 5-FU and other TS inhibitors due to TS amplification (Schultz et al., 1996). The 
retention of pemetrexed antitumor activity in these cell lines was attributed to GART inhibition 
and other secondary targets of metabolites.  Methotrexate resistance in patents with acute 
leukemia has been associated with low RFC expression (Gorlick et al., 1997) and these patient 
preserve sensitivity for pemetrexed.  This presumably was because of the uptake of pemetrexed 
by the PCFT (Zhao et al., 2004).  
Various studies were done with pemetrexed in combination with cisplatin chemotherapy in early 
stage NSCLC. Most of the evidence supporting this combination therapy, are based on the results 
of the trial on refinement of early stage lung cancer adjuvant therapy (TREAT), which included 
132 patients with completely resected stage pIB-T3N1 NSCLC (Kreuter et al., 2013). The study 
showed a statistically significant improved feasibility rate of 95.5% for the pemetrexed- cisplatin 
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compared with 75.4% for the vinorelbine cisplatin treatment. Overall, the incidence of Grade 3/4 
hematologic toxicities was significantly higher in vinorelbine cisplatin treatment.  
In 2009, due to its favorable toxicity profile, results and convenient route of drug administration, 
FDA approved pemetrexed for maintenance therapy of NSCLC (Ciuleanu et al., 2009). This 
treatment strategy entails administering pemetrexed prior to disease progression following a 
platinum-based treatment cycle. Although this limits the treatment-free period following therapy, 
the low overt toxicity of pemetrexed combined with best supportive care has shown significance 
in survival benefit (Ciuleanu et al., 2009).  
1.1.6.5 AICAR  
AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide), enters the cells and is 
converted into ZMP, an analog of AMP that is capable of stimulating AMPK-dependent protein 
kinase activity (AMPK).  
AICAR is being clinically used to treat and protect against cardiac ischemic injuries which, if left 
untreated, may lead to a myocardial infarction. Cardiac Ischemia is caused by insufficient blood 
flow to the myocardium (J. Corton , Gillespie, Hawley, & Hardie, 1999). The drug was first used 
in the 1980s as a method to preserve blood flow to the heart during surgery (Galinanes, Bullough 
D FAU - Mullane,,K.M., FAU, & Hearse, 0903). Currently, the drug has also been shown as a 
potential treatment for diabetes by increasing the metabolic activity of tissues by changing the 
physical composition of muscle [Zarembo, Alan. An article in the Los Angeles Times  claimed 
AICAR to be an “Exercise pill' could take the work out of workouts." Los Angeles Times].  
Activation of AMPK by AICAR can inhibit basal or insulin stimulated glucose uptake, 
lipogenesis, glucose oxidation and lactate production on rat adipocytes (Gaidhu, Fediuc, & 
Ceddia, 2006). 
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1.1.6.5.1 Mechanism of action of AICAR 
AICAR (commonly under the name Acadesine) is an analog of adenosine that enters cardiac 
cells to inhibit adenosine kinase and adenosine deaminase. In cardiac myocytes, AICA-riboside 
is phosphorylated to AICA-ribotide (ZMP) to activate AMPK without changing the levels of the 
nucleotides (Zhang, Frederich, He, & Balschi, 2006). Corton et al. showed similar results, where 
incubation of rat hepatocytes with AICAR, results in accumulation of the monophosphorylated 
derivative, ZMP, within the cell (J. M. Corton, Gillespie, Hawley, & Hardie, 1995). ZMP, an 
AMP mimetic, mimics both activating effects of AMP on AMPK, i.e. direct allosteric activation 
and promotion of phosphorylation by AMPK kinase.  Due to activation of AMPK, AICAR 
affects several catabolic pathways (glycolysis, fatty acid oxidation), anabolic pathways 
(lipogenesis, glycogen synthesis, gluconeogenesis) and cell growth and survival pathways 
(mTORC1 and autophagy). In this dissertation, AICAR is used as an AMPK activator and its 
effects on the mTORC1 pathway were compared to those of PTX which were also shown to 
activate AMPK and inhibit mTORC1 (Racanelli, Rothbart, Heyer, & Moran, 2009; Rothbart, 
Racanelli, & Moran, 2010). 
1.1.6.5.2 Clinical evaluation of AICAR against cardiac ischemic injuries 
A brief period of coronary arterial occlusion followed by reperfusion prior to prolonged ischemia 
is known as preconditioning and has been shown to be protective of the effects of the prolonged 
ischemic peroid.  Preconditioning preceding myocardial infarction may delay cell death and 
allow for greater salvage of myocardium through reperfusion therapy (Murry, Jennings, & 
Reimer, 1986). AICAR has been shown to precondition the heart shortly before or during 
ischemia (Burckhartt B, 1995). AICAR triggers a preconditioning anti-inflammatory state by 
increasing NO production via endothelial nitric oxide synthase. When AICAR is given 24 hours 
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prior to reperfusion, it prevents post ischemic leukocyte-endothelial cell adhesive interactions 
with increased NO production (Gaskin et al., 2009). AICAR also increases AMPK-dependent 
glucose uptake through translocation of GLUT-4, which is beneficial for the heart during post-
ischemic reperfusion (3rd, Bergeron R, Shulman,,G.I. & Young, 1999).  The increase in glucose 
levels during AICAR preconditioning lengthens the period for preconditioning up to 2 hours in 
rabbits and 40 minutes in humans undergoing coronary ligation (Burckhartt et al., 1995; Murry et 
al., 1986).  As a result, AICAR reduces the frequency and size of myocardial infarcts up to 25% 
in humans allowing improved blood flow to the heart.  As well, the treatment has been shown to 
decrease the risk of an early death and improve recovery after surgery from an ischemic injury 
(Murry et al., 1986). This clearly suggests the importance of AICAR as a pharmacological agent 
in clinical therapeutics of heart diseases and cardiac surgeries. However, due to activation of 
AMPK, AICAR has been shown to act by inhibit mTORC1, a central pathway for cell growth 
and proliferation. Therefore, AICAR has attracted the attention of researchers for its anti-cancer 
properties.  
1.1.6.5.3 Clinical Evaluation of AICAR as a cancer therapeutic agent 
With the gradual inclination of chemotherapeutics towards targeted therapy, emerging evidence 
suggests that targeting cancer cell metabolism can be a promising and future therapeutic 
approach against human cancers. AMP-activated protein kinase (AMPK) is a known cellular 
metabolic sensor and plays an important role in the control of energy homeostasis in response to 
external stresses (Carling, 2005; Hardie, 2008; Kuhajda, 2008; Witczak, Sharoff, & Goodyear, 
2008). The activation of AMPK is a signal of energy stress and the cell responds to AMPK 
activation by inhibiting or slowing down cell growth process and biosynthetic process and 
activating catabolic processes (Fogarty & Hardie, 2010). Therefore, the AMPK activators 
 60 
AICAR and metformin has been intensively studied to determine their potential as cancer 
therapeutic agents (Fogarty & Hardie, 2010). 
It has been shown that activation of AMP-activated protein kinase (AMPK) by AICAR, 
Metformin or the direct AMPK activator A23187 hampers cervical cancer cell growth through 
blocking the Wnt/β-catenin signaling activity (Kwan et al., 2013). This same group later reported 
that activated AMPK (p-AMPK) also inhibits cervical cancer cell growth by counteracting 
Forkhead box M1 (FOXM1) function (Yung, Chan, Liu, Yao, & Ngan, 2004). FOXM1 regulates 
a number of key cell cycle regulators that control the G1 to S and the G2 to M transitions (I. C. 
Wang et al., 2005).  Some studies have shown that over-expression of FOXM1 might stem from 
the constitutively active ERK which confers metastatic activity to ovarian cancer cells and 
inhibition of ERK/FOXM1 has also been shown to repress the growth of ovarian cancer (Chan et 
al., 2012; Lok et al., 2011). Therefore activation of AMPK by AICAR followed by inhibition of 
ERK/FOXM1 and/ or Wnt/β-catenin signaling has been suggested to be an effective therapeutic 
approach against ovarian and cervical cancers. Despite significant progress and success in the 
treatment of ALL, a significant number of children continue to relapse and for them, overall 
outcome remains poor. Some studies have studied the response of AICAR against ALL cells in 
culture.  AICAR-mediated AMPK activation was found to be an antiproliferative agent in ALL.  
The mechanism of its anti-proliferative and apoptotic effects appear to be mediated via activation 
of p38-MAPK pathway, increased expression of cell cycle inhibitory proteins p27 and p53, and 
downstream effects on the mTOR pathway. Therefore, AICAR exhibits therapeutic potential as a 
targeted drug for the treatment of childhood ALL (Sengupta et al., 2007). The proliferation of 
various cancer cell lines was significantly inhibited by AICAR due to arrest in S- phase (Rattan, 
Giri, Singh, & Singh, 2005).  Signaling pathway analysis suggested that this S-phase arrest was 
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accompanied by increased levels of p21, p27 and p53 proteins and attenuation of PI3K/AKT 
pathway.  This inhibition of in vitro cell growth was also mimicked in vivo with a similar pattern 
of modulation of signaling pathways.  AICAR mediated inhibition of cell proliferation due to S-
phase blockade, occurs to a similar extent in both LKB1 wild-type and LKB1 knockout mouse 
embryonic fibroblasts. This suggests that AICAR mediated activation of AMPK can be LKB1 
independent, a surprising outcome. (Rattan et al., 2005). 
A considerable level of research has been performed with AICAR to understand the AMPK 
mediated mTORC1 inhibition.  AICAR activated AMPK phosphorylates the Raptor subunit of 
the mTORC1 complex and inhibits mTORC1 signaling, causing cell cycle arrest at G1/S phase 
(Gwinn et al., 2008). As mTOR is a central regulator of cell growth and proliferation, its 
inhibition blocks cancer cells proliferation and cancer progression. 
1.2 FOCUS OF THIS DISSERTATION 
Whereas the evolution of cancer chemotherapy is continuing, the understanding of molecular and 
genetic mechanisms involved in the development and progression of cancer has been undergoing 
revolutionary growth, continually changing the landscape for chemotherapy. This also 
encouraged the molecular approach for cancer diagnosis and treatment. FDA approvals of the 
antifolate pemetrexed for NSCLC and MPM boosted the enthusiasm for antifolates as cancer 
therapeutics. As other TS inhibiting antifolates (5-FU/ leucoverin and raltitrexed) have shown 
minimal response against MPM and NSCLC, the approval of pemetrexed as a first line therapy 
drug for these diseases suggested that the mechanism of action which is effective in NSCLC, is 
other then inhibition of TS. (Cunningham et al., 1996; Porta et al., 2005). Our lab recently 
showed that this TS- independent mechanism of action is due to inhibition of the enzyme 
AICART in the de novo purine synthesis pathway, which causes accumulation of the substrate of 
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this enzyme ZMP, leading to activation of the AMP-dependent protein kinase and to subsequent 
inhibition of mTORC1 (Racanelli et al., 2009; Rothbart et al., 2010).  The studies of this 
dissertation are focusing on understanding the role of p53 in mTORC1 regulation, which is 
discussed in detail in Chapter 2.  Understanding of the p53 mediated regulation on mTORC1 
allowed us to address the question of how PTX effects are modulated by the p53 regulation on 
this pathway.  In order to address this question, the differences in the downstream signaling of 
two AMPK activators, AICAR and pemetrexed were studied and directly compared during this 
dissertation.  Although both of these agents cause activation of AMPK by increasing the amount 
of ZMP, the signaling downstream from AMPK was significantly different.  Chapter 3 of this 
thesis is focused on understanding the causes for these differences, which seems to be due to 
differential behavior of p53 under these two drug treatments.  Chapter 4 is mainly focused on 
determining the effects of pemetrexed on transcriptional activity of gain-of-function mutant p53. 
The overall finding of this thesis work indicates that the atypical response of pemetrexed against 
several cancers including lung cancers may involve its effects on the transcriptional activity of 
wild type and mutant p53. 
1.3 MATERIALS AND METHODS     
1.3.1 Chemicals and reagents  
Pemetrexed (LY231514, PTX) was obtained from Eli Lilly and Company (Indianapolis, IN). In 
some experiments, pemetrexed was purchased from LC Laboratories (#P-7177 Woburn, MA). 
AICAR (#A611700) was purchased from Toronto Research Biochemicals. PTX and AICAR 
were dissolved in PBS. Etoposide was purchased from Sigma Aldrich (#E1383) and was 
dissolved in DMSO. TRIzol Reagent (#15596026), DNAse 1 (Invitrogen, # AM2222) 
SuperScript III First-strand Synthesis System (#18080), primers were from Invitrogen (Carlsbad, 
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CA) or Eurofin. Bradford Reagent (#5000006) was from Bio-Rad Laboratories. All other 
reagents were from Fisher Scientific (Waltham, MA) or Sigma Aldrich (St. Louis, MO) and were 
of the highest available purity.  
 Stock solutions of thymidine (560 µM) were routinely made by dissolving 0.00678 g of 
thymidine powder in 48 ml of 1x PBS. The concentration was determined by measuring 
absorbance at 267 nm from a 1:10 dilution of the stock solution in 1x PBS using an extinction 
coefficient of 9.7 mM-1 cm-1. The volume was adjusted accordingly with 1x PBS for a final 
concentration of 560 µM. This solution was filter-sterilized and was stored in single-use aliquots 
at -20°C. Thymidine was typically used at a final concentration of 5.6 µM in rescue experiments. 
DharmaFECT transfection reagent no. 2, siGENOME SMARTpool siRNAs targeting human p53 
and scrambled siRNA pool no. 1 were purchased from Dharmacon (GE Healthcare, Lafayette, 
CO, USA).  Four TSC2 siRNAs were purchased from Qiagen (Catalog # SI0001718, 
SI03027339, SI00011697, SI00011711) and mixed in equal amounts to make a pool. Complete 
EDTA-free Protease Inhibitor Cocktail tablets (#11873580001) were from Roche Applied 
Science (Indianapolis, IN). Thirty % Acrylamide/BIS solution 37.5:1 (#1610158), Laemmli 
Sample Buffer (#1610737), and Dual Color Precision Plus Protein Standard (#1610374) were 
from Bio-Rad Laboratories. Immobilon polyvinylidene fluoride (PVDF) membrane 
(#IPVH00010) was from Millipore (Billerica, MA). StartingBlock Blocking Buffer (#37542), 
Goat anti-rabbit IgG (#31462), and Goat anti-mouse IgG (#31348) secondary antibodies were 
from Thermo Scientific. Blotting Grade Blocker Non-fat Dry Milk (#1706404) was from Bio-
Rad Laboratories. A list of antibodies and their sources can be found in Table 1 -1  
1.3.2 Cell culture and reagents   
HCT116 cell lines were a gift from Dr Bert Vogelstein. H460, A549, H441 and H661 cell lines 
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were purchased from ATCC (Manassas, VA, USA.) and grown in RPMI 1640 with 10% 
dialyzed fetal bovine serum (dFBS).  H1299 cells expressing a ponasterone A-inducible p53 
gene were made in Jennifer A. Pietenpol’s laboratory and were given to us by Dr. Sumitra Deb. 
Mutant p53 containing H1437 and H1048 NSCLC cells were generous gift form Dr. sumitra 
Deb. Mutant p53 conatining H661 and H441 NSCLC cells were purchased from ATCC. All 
these cell lines were grown and maintained in RPMI 1640 with 10% dFBS and at 37°C with 5% 
CO2 with fresh media replacement after every 2-3 days. Immortalized p53-/-TSC2-/- MEFs and 
Sestrin 2 -/- MEFs were generous gifts from Dr. Andrei Budanov and were grown in DMEM 
(#11995 Gibco/Invitrogen Carlsbad, CA) supplemented with 10% dFBS and maintained at 37°C 
with 10% CO2 and given fresh media every 2-3 days.  All cell lines were passaged by seeding in 
T-75 flasks at a density of 106 cells/ flask every 2-3 days. Passaging of adherent cell lines 
included washing with 1x phosphate buffered saline (#10010 Gibco/Invitrogen) and trypsinizing 
for 5 minutes at 37°C with 1x trypsin-EDTA (#15400 Gibco/Invitrogen).  
1.3.3 Generating p53 mutant stable cell lines 
HCT116 p53-/- or H1299 cells were plated in 6 well plates at a density of 2x105 cells per well 
and transfection was performed 24 hrs later with 2 µg of various mutant p53 plasmids containing 
different mutant form of p53. Forty-eight hrs later transfection media was replaced with RPMI + 
10% dFBS. Cells were allowed to grow for 24hrs. 24 hrs later cells were trypsinized and replated 
in 10 cm dishes. These plasmids have selection marker for Zeocin. Thus, the cells which receive 
the plasmid and express it will be resistant to the Zeocin. Therefore, in parallel, cell survival 
assays were performed using the range of zeocin concentration from 20 µg/ml to 200 µg/ml on 
untransfected HCT116 and H1299 cells. Cells were plated in 24 well plate and 24 hrs later each 
well was supplied with a certain concentration of Zeocin containing media. Cellswere left in the 
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zeocin containing media for 2 weeks with replacing zeocin contatining media at the interval of 2-
3 days. The lowest concentrations of Zeocin which were able to kill 100% of cells were choosen 
for each cell line to use it for selection of cells expessing mut p53.  The lowest concentration 
with 100% cell kill was found to be at 100 µg/ml for HCT116 and 40 µg/ml for H1299 cells.  
Therefore to select the transfected cells, cells were exposed to 100 µg/ml (HCT116) or 40 µg/ml 
(H1299) zeocin for 2 weeks, with selection media change after every 2-3 days. Cells were 
trypsinized and replated in 10cm dishes with Zeocin contining media. After two generations cells 
were plated to perform a western blot analysis to check the expression of mutant p53. As we 
found that the each plamid was being expressed to the similar levels, we froze a batch of the cells 
in FBS  with 10% DMSO. One batch was carried on for further experimental analysis. 
1.3.4 Immunoblotting  
Total Protein Isolation: Protein was typically harvested from 2-5 x 106 cells grown on 100 mm 
dishes.  Prior to total protein harvest, one protease inhibitor cocktail tablet (manufacturer, catalog 
#) was dissolved in 50 ml 1x PBS and placed on ice. Tissue culture plates were kept cold 
throughout the harvesting procedure. Cells were washed once with cold 10 ml PBS (containing 
protease inhibitor), scraped, and pelleted at 1,000 rpm for 5 minutes at 4°C.  Cells were lysed in 
cold buffer containing 62.5 mM Tris-HCl pH 6.5, 2% SDS, 5% glycerol, 5% 2-mercaptoethanol, 
50 mM NaF, and a 1x concentration of Complete EDTA-free Protease Inhibitor Cocktail 
(manufacturer). Lysates were sheared through a 21-gauge needle for 30 times before being 
centrifuged at 14,000 rpm for 2 minutes.  This shearing procedure was repeated, and lysates were 
spun at 14,000 rpm for 5 minutes. The protein concentration was determined using the Bradford 
Reagent according to the manufacturers protocol with BSA as a standard. Typical protein 
concentrations in lysates were 2-5 µg/µl.  Protein was placed in single-use aliquots and stored at -
 66 
80°C.  
SDS-PAGE and Protein Transfer: Gel electrophoresis and wet membrane transfers were 
performed using the Mini PROTEAN-3 Cell system (#1653301) from Bio-Rad Laboratories. 
Total protein was mixed with an equal volume of Laemmli Sample Buffer, boiled for 5 minutes, 
and 20 µg of protein was loaded onto 1.5 mm SDS-polyacrylamide gels, poured according to the 
recipe provided with 30% Acrylamide/Bis 37:5:1 (#1610158) from Bio-Rad Laboratories. An 
aliquot (5-10 µl) of Dual Color Precision Plus Protein Standard was also loaded onto every gel 
for mass determination.  Typically, protein was resolved on 7.5% or 12% gels in running buffer 
(25 mM Tris base, 250 mM glycine, 0.1% SDS) at 50 volts for 30 minutes (or until protein 
migrated out of the stacking gel) followed by 120 volts for 1-1.5 hours to optimally separate the 
protein of interest.  
Polyvinylidene fluoride (PVDF) membrane that had been pre-soaked in methanol was rinsed in 
water along with the gels and PVDF, gels, and sponges for the transfer were equilibrated for at 
least 20 minutes in cold transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine, 10% methanol). 
Six pieces of Whatman paper per gel were cut to the approximate size of an electrophoresis 
plate, and the transfer sandwich was assembled as follows: Layering on the black face of a 
transfer cassette, 3 pieces of Whatman paper (dipped in transfer buffer) were placed on top of 1 
sponge.  Air bubbles were removed by rolling with a 5 ml plastic pipette. The gel was centered 
on the Whatman paper, and a PVDF membrane was placed on top of the gel.  Again, it was 
important to remove all air bubbles from the transfer sandwich by rolling.  It also helped to keep 
the sandwich as wet as possible with transfer buffer during assembly. Whatman papers (dipped 
in transfer buffer) were placed on top of the membrane, followed by another sponge.  The 
transfer cassette was closed, placed in its holder in the gel box along with a plastic ice block, and 
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the gel box was then filled with cold transfer buffer.  Transfers were either ran on ice or in the 
cold room (4°C) at 100 volts for 45 minutes (one gel) or 50 minutes (2 gels). Following the 
transfer, membranes were dipped in methanol and dried on the lab bench for 15 minutes before 
being immunoblotted.  
Antibody Detection: A general antibody detection procedure is described in this section. For 
detailed conditions for each antibody, refer to Table 1-1.  Dried membranes were soaked briefly 
in methanol and non-specific proteins were blocked for 1 hour in either StartingBlock Buffer or 
5% Blotting Grade Blocker Non-fat Dry Milk/0.1% TBS-T (0.5 M Tris-HCl pH 7.5, 0.14 M 
NaCl, 2.7 mM KCl, 0.1% Tween 20).  Membranes were washed three times for 5 minutes in 
0.1% TBS-T.  Primary antibodies diluted in either StartingBlock Buffer or 5% BSA (#A4503) 
from Sigma were incubated on the membranes overnight at 4°C with rotation in sealed plastic 
bags to minimize antibody consumption.  Membranes were washed 3 times with 0.1% TBS-T for 
5 minutes and incubated for 1 hour in horseradish peroxidase-conjugated secondary antibody. 
Membranes were then washed 3 times with 0.1% TBS-T for 10 minutes. It was found that 
washing more stringently during this step greatly diminished non-specific background during 
exposure. Membranes were incubated with West Pico or West Dura SuperSignal 
chemiluminescence substrate (Pierce) for 5 minutes. Blots were exposed to autoradiography film 
and processed on an automated film developer. If the chemiluminescent conditions were not 
known, West Pico was applied first. If no signal was apparent, the blot was rinsed with 0.1% 
TBS-T, and West Dura (diluted by 40% with PBS) was applied. Signal was usually observed 
with one of these conditions, and rarely was a more stringent detection reagent applied. Blots 
presented in this dissertation are representative of findings from at least two biological replicates.   
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1.3.5 RNA interference  
Cells were plated at 2 x 105 cells/well of a 6-well plate late in the day. Cells were transfected 24 
hrs after seeding.   siGENOME SMARTpool siRNAs (Dharmacon) (50 nM) were transfected 
with 0.1% DharmaFECT reagent according to the manufacturer’s instructions. For p53 
knockdown the transfection media remained on the cells for 24 hours, at which time cells were 
washed with PBS and fresh media was replaced.  Longer incubations resulted in visually 
apparent toxicity under a microscope. All experiments were controlled with a non-targeting 
siRNA SMARTpool (scrambled). Protein was harvested after 72 hours. Levels of proteins, 
targeted to knockdown, was analyzed by western blotting and knockdown was apparent by 48 
hours and persisted at 72 hours post-transfection. For TSC2 knockdown, cells were transfected 
with transfection media for 24 hrs, followed by replacement with normal media. Cells were 
treated with the indicated drugs 36 hrs after transfection. Twenty-four hrs later, protein was 
harvested and western blot analysis was used to analyze protein levels.  
1.3.6 Over-expression of WT and Mutant Raptor.    
p53-/- TSC2-/- MEFs were plated in 6 well plates at a density of 2 x107 cells per well. 
Transfection was performed 24 hrs later with 3ug DNA using polyjet (SignaGen Laboratories) 
maintaining a ratio of 1:3 of DNA: polyjet. After 24 hrs, cultures were split into two 6 well 
plates. After 12 hrs, cells were treated with TdR or PTX + TdR.  Twenty-four hr after treatment, 
cells were lysed for western blot analysis. Vectors used for transfection, pBABE Hygro-empty 
vector (ID-1765), pBABE-myc Raptor (ID- 18116) and pBABE myc-Raptor S722A/S792A (ID- 
18117) were originally made in the laboratory of Dr Reuben Shaw (Gwinn et al., 2008) and were 
purchased from Addgene. 
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1.3.7 Cellular growth assay 
Adherent cells were seeded at a density of 20,000 cells/well of a 12-well plate and allowed to 
adhere overnight. Conditions were usually plated atleast in duplicate and experiments were 
performed at least twice. Fresh media containing drugs were added the next day. Experiments 
typically lasted 72 hours after drug treatment.  Following the incubation period, cells were 
washed 1x with PBS, trypsinized in 1.5 ml 1x trypsin-EDTA, and 1 ml of a single-cell 
suspension was counted electronically using a Z1 Coulter Particle Counter (Beckman Coulter 
Brea, CA). Data is presented as percent cell growth of experimental samples relative to controls 
grown in the absence of drug. 
1.3.8 Total RNA Isolation 
 Total RNA was extracted from HCT116 cells grown to 75% confluency on a 100 mm tissue-
culture dish using TRIzol Reagent according to the manufacturers protocol. All materials and 
reagents used were sterile and RNAse-free.  Diethylpyrocarbonate (DEPC) H2O (0.01% v/v) 
was prepared by incubating at room temperature overnight and autoclaving before use. Pipettes 
were cleaned with RNAse ZAP (Invitrogen), and crosslinked with a UV Stratalinker 2400 
(#400075 Stratagene La Jolla, CA). Cells were placed on ice, washed 1x with cold PBS, and 
lysed directly in 2 ml cold TRIzol Reagent. Cells were scraped, the slurry was transferred to a 14 
ml round bottom Falcon tube, and the sample was incubated at room temperature for 5 minutes. 
An aliquot (400 µl) of chloroform was added to the sample in the fume hood. The sample was 
shaken vigorously for 15 seconds and incubated at room temperature for 3 minutes. The sample 
was spun at 7,000 rpm for 15 minutes at 4°C. The mixture separated into 3 phases. RNA 
remained exclusively in the aqueous upper phase. This aqueous phase was transferred to a fresh 
14 ml tube and 1 ml of isopropanol was added to precipitate the RNA. This sample was 
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incubated at room temperature for 10 minutes before being centrifuged at 7,000 rpm for 10 
minutes at 4°C.  The supernatant was removed, and the RNA pellet was washed 1x with 75% 
ethanol in DEPC H2O.  The sample was mixed and spun at 7,000 rpm for 5 minutes at 4°C.  The 
ethanol was removed and spun again to remove excess ethanol.  The pellet was re-suspended in 
200 µl DEPC-treated H2O.  For storage purposes, 75 µl dissolved RNA was suspended in 225 µl 
100% ethanol and stored at -80°C. This sample could then be re-precipitated and solubilized if 
necessary. RNA concentration and purity was determined using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies Wilmington, DE).  Pure RNA has an OD260/280 of 
2.0.  The OD260/230 ratio was also used as a secondary indicator of RNA purity, and values 
below the range of 1.8-2.2 indicated the presence of copurified contaminants.  RNA integrity 
was also determined by resolving RNA on a 1% TAE agarose gel at 100 volts for 30 minutes and 
then staining with ethidium bromide.  A distinct banding pattern and intensity difference between 
28s and 18s rRNA indicated that the RNA was intact.  
cDNA Synthesis: cDNA was reverse-transcribed from 3 µg of total RNA using the SuperScript 
III First-strand Synthesis System from Invitrogen. SuperScript III Reverse Transcriptase is 
similar to the Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT), but has 
been engineered to diminish RNase H activity and enhance thermal stability.  RNA was mixed 
with a final concentration of 5 µM oligo(dT)20 primer and 1 mM dNTP mix in a volume of 10 µl 
adjusted with DEPC-H2O.  The mixture was incubated at 65°C for 5 minutes, then placed on ice 
for at least 1 minute.  The cDNA synthesis mix was prepared in a separate tube by combining 2 
µl of 10x RT buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 4 µl 25 of mM MgCl2, 2 µl of 0.1 
M DTT, 1 µl of RNaseOUT (40 U), and 1 µl of SuperScript III Reverse Transcriptase (200 U) 
per reaction.  Ten µl of the cDNA synthesis mix was added to the RNA/primer mixture, the tube 
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was gently mixed, and cDNA was reverse-transcribed by incubating at 50°C for 50 minutes.  The 
reaction was terminated by incubating at 85°C for 5 minutes before being held on ice.   One µl of 
RNase H (2 U) was added to each tube and the tube was incubated for 20 minutes at 37°C.  
cDNA was stored at -20°C until use.  
Primer design:  
Primers to amplify the p21, Puma, HDM2, Bax, Pig3, TSC2, Sestrin2, 4EBP1, NFκB2, PCNA, 
HSP70, hTERT, EGFR, MDM2, Axl and β-actin were designed with a 50-60% GC content, 
melting temperature between 55-75°C, and were 18-30 nucleotides in length. Six random 
nucleotides were added upstream of the restriction site on the 5’ end to allow for recognition and 
digestion by restriction enzymes. Strings of 3 or more G’s, C’s, or T’s were avoided in the 3’ 
end, but 1 G or C was placed at the 3’ end to help tack down the primer during annealing. 
Lyophilized primers were dissolved in HPLC-grade H2O to stock concentrations of 100 µM and 
were further diluted in HPLC-grade H20 to a working stock concentration of 15 µM before being 
added to Polymerase Chain Reactions (PCR). Primers were routinely stored as 100 µM stocks at 
-20°C as well as 15 µM working stocks in single-use aliquots.  Sequences of primers are listed in 
table 1-2. 
 
1.3.9 Chromatin Immunoprecipitation (ChIP) 
Formaldehyde cross-linking and chromatin shearing The ChIP assay was adapted from Bronder 
et al (Bronder & Moran, 2003). Approximately 1 x 107 cells per condition were crosslinked at 
room temperature with 1% formaldehyde for 10 minutes, the reaction was then quenched for 5 
minutes by the addition of 0.125 mM glycine. Cells were washed twice with PBS, scraped, 
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washed in buffer I containing 10 mM HEPES pH 7.5, 0.5 mM EGTA pH 7.5, 10 mM EDTA pH 
8.0, 0.25% Triton X-100, then in buffer II containing 10 mM HEPES pH 7.5, 0.5 mM EGTA pH 
7.5, 1 mM EDTA pH 8.0, 200 mM NaCl. All ChIP buffers contained 1 µγ/µΛ aprotinin, 1 
µγ/µΛ leupeptin, 1 µγ/µΛ pepstatin, 1 mM PMSF, 0.2 mM Na3VO4 and 10 mM NaF. Cells were 
lysed in lysis buffer containing 25 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 150 mM NaCl, 1% 
Triton X-100, 0.1% SDS, 0.5% Na Deoxycholate. Aliquots of 2 x 106 cells in 600 µΛ lysis 
buffer were sonicated with a Diagenode bath bioruptor for a total of 20 minutes with consecutive 
duty cycles of 30 seconds on, 30 seconds off at 4oC (5 minute cycles repeated a total of 4 times). 
These conditions were found to yield DNA fragments less than 1000 bp in size. 
1.3.9.1 Immunoprecipitation 
Lysates corresponding to 2 x 106 cells were precleared for 1 hour at 4oC with a 50% slurry of 
protein G-Sepharose (Amersham Biosciences) beads previously blocked with 8 µγ of BSA and 
either 5 µγ of sonicated lambda DNA or 6 µγ of sonicated salmon sperm DNA, then incubated 
with 2 µγ p53 Ab-6 (Calbiochem) antibody or 2 µγ IgG (Millipore) antibody overnight. 
Antibody-protein-DNA complexes were captured by the addition of 30 µΛ of 50% blocked 
protein G-Sepharose bead slurry for 1 hour at 4oC. Beads were pelleted at 4,500 x g for 5 
minutes at 4oC and the supernatant from the IgG immunoprecipitation was saved and the DNA 
contained within was referred to as input DNA. Beads were washed extensively twice with RIPA 
buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 0.5% Na Deoxycholate, 1% NP- 40), 
once with High Salt Buffer (500 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 1% Na 
Deoxycholate), once with LiCl Buffer (250 mM LiCl, 50 mM Tris pH 8.0, 0.5% Na 
Deoxycholate, 1% NP-40), and twice with TE (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0) for 10 
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minutes each at 4oC rotating end-over-end. Protein-DNA complexes were eluted with elution 
buffer (2% SDS, 10 mM DTT, 0.1 M NaHCO3) while rotating end over end at 25oC for 15 
minutes and the cross-links were reversed by the addition of 0.2 M NaCl and incubation at 65oC 
overnight. DNA was treated with 10 µγ of RNase for 30 minutes at 37oC and with 20 
µγ Proteinase K in 10 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 0.25% SDS for 1 hour at 42oC, 
phenol-chloroform extracted, ethanol-precipitated and dissolved in 100 mL TE. 
1.3.9.2 Quantitative PCR (Q-PCR) 
Quantitative PCR was performed with 1µL of input DNA or ChIP DNA for each 25 µL 
reaction containing 12.5 µL Quantitect SYBR Green PCR Master Mix (Qiagen) and 0.3 µΜ of 
each primer.. The amplification conditions were 95oC for 15 minutes, 40 cycles of 95oC for 45 
seconds, for the noted Tm of each primer, for 45 seconds, 72oC for 45 seconds with a plate read, 
and concluding with a 5 minute extension at 72oC and a melting curve from 45oC to 100oC. 
Absolute quantities were calculated using a standard curve ranging from 100 ng to 0.8 ng of 
input DNA. The sequences of the primers flanking the p53 binding sites of the p21 promoter are; 
p21 3’RE- Fwd -5′-GAGGTCAGCTGCGTTAGAGG-3′, Rev-5′-
TGCAGAGGATGGATTGTTCA-3′ and Tm used was 58 oC. 
1.3.10 m7GTP-CAP pulldown  
To determine whether pemetrexed treatment enhanced residence of 4EBP1 at mRNA with a m7- 
guanosine CAP, cell lysates were incubated with m7GTP-sepharose beads, which have been 
previously shown to bind both eIF4E and 4E-BP1 (Holz, Ballif, Gygi, & Blenis, 2005). 
Following the indicated drug treatments, cells were lysed on ice for 30 min in IP buffer (25 mM 
HEPES pH 7.5, 1% NP40, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 1 mM 
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PMSF, 0.1% 2- mercaptoethanol, and 1x Roche Complete Protease Inhibitor Tablet). Cleared 
lysate (500 µg) was incubated with 40 µl of a 50% slurry of m7GTP-Sepharose (GE 
Lifesciences) for 2 hr at 4°C with rotation. Cap complexes were washed with IP buffer four 
times, resuspended in Laemmli Sample Buffer, and boiled for 5 min before being resolved on a 
12.5% SDS-PAGE gel and immunoblotted as described above.  
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    Table 1-1 Antibody sources and conditions 
 
 
 
Antibody Company Catalog# MW 
 
Blocking 1°Ab 2° Ab 
β-actin Abcam 8226 42 Starting block (SB) 1:5000 (SB) 1:10000 (SB) 
p-S172 AMPK Cell signaling 2532S 62 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
AMPK Cell signaling 2531S 62 Starting block (SB) 1:500 (SB) 1:2000 (SB) 
p-S792 Raptor Cell signaling 2283 150 Starting block (SB) 1:5000 (SB) 1:2000 (SB) 
Raptor Cell signaling 2282 150 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S1387 TSC2 Cell signaling 5584 250 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
TSC2 Cell signaling 3990 250 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-T389 S6K1 Cell signaling 9234 70 Starting block (SB) 1:500 (SB) 1:2000 (SB) 
S6K1 Cell signaling 2708 70 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-T70 4EBP1 Cell signaling 9455S 15-20 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-T37/46 4EBP1 Cell signaling 2855 15-20 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
4EBP1 Cell signaling 9452 15-20 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S473 AKT Cell signaling 9271 60 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-T308 AKT Cell signaling 4056 60 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
AKT Cell signaling 9272 60 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
eIF4E Cell signaling 2067 25 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
Rictor Cell signaling 9476 180 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S2448 mTOR Cell signaling 2971 290 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
mTOR Cell signaling 2983 290 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-T246 PRAS40 Cell signaling 2640 40 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
PRAS40 Cell signaling 2610 40 Starting block (SB) 1:500 (SB) 1:2000 (SB) 
Rheb Abcam Ab92313 21 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
Sestrin2 Protientech grp 10795-1-AP 55 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p53 Calbiochem OP43 53 Starting block (SB) 1:100 (SB) 1:2000 (SB) 
Ac-382 p53 Cell signaling 2525 53 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
Ac-379 p53 Cell signaling 2570 53 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S15p53 Cell signaling 9284 53 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S20p53 Cell signaling 9287 53 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S46p53 Cell signaling 2521 53 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S37 p53 Cell signaling 9289 53 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S 392 p53 Cell signaling 9281 53 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p21 BDPharminogen 556430 21 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
MDM2/HDM2 Santa Cruz 813 90 Starting block (SB) 1:500 (SB) 1:2000 (SB) 
Bax Oncogene PC66 20 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S345Chk1 Cell signaling 2348 56 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
Chk1 Cell signaling 2345 56 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-T68Chk2 Cell signaling 2662 62 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
Chk2 Cell signaling 2661 62 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
p-S139H2A.X Cell signaling 9718 15 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
H2A.X Cell signaling 7631 15 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
Axl Cell signaling 8661 15 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
NFkB2 Santa Cruz sc-7386 15 Starting block (SB) 1:1000 (SB) 1:2000 (SB) 
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        Table 1-2 Primer sequences used for RT-qPCR 
 
 
 
 
S.N 
 
Genes 
 
Primer Sequences 
1 p21 Fwd-5’GACCTGTCACTGTCTTGTACCCT-3' 
Rev- 5'GGTAGAAATCTGTCATGCTG GTCTG-3’ 
2 PIG3 
 
Fwd-5’TCTCTGAAGCAACGCTGAAATTC- 3’ 
Rev-5’GTAGGATCCGCCTATGCAGTCTA-3’ 
3 PUMA 
 
Fwd- 5'TGTGAATCCTGTGCTCTGCC-3’ 
Rev- 5'TTCCGGTATCTACAGCAGCG 3'  
4 BAX 
 
Fwd-5’TCTGACGGCAACTTCAACTG3’ 
Rev-5’ACAGGGACATCAGTCGCTTC3’ 
5 TSC2 
 
Fwd-5'TCGTGTTCCTGCAGCTCTACCATT-3'   
Rev-5'ACCGCTCAAAGGACTGTGACTCAT-3'  
6 Sestrin2 
 
Fwd-5’ACAAGTGTTGTGGCCTT CCTGAAC-3'  
Rev-5'ATGGGTGAATGGCAAGTAGGAGGT-3 
7 NFkB2 
 
Fwd-5'GGG GCA TCA AAC CTG AAG ATT TCT-3  
Rev-5′TCC GGA ACA CAA TGG CAT ACT GT-3 
8 PCNA Fwd-5'AGGTGTTGGAGGCACTCAAG 3' 
Rev-5'GTAGGTGTCGAAGCCCTCAG 3' 
9 HSP70 Fwd-5'ACCAGCCAAAGCAAGTTTATGT 3' 
Rev- 5'ACTGGTCCTCCTTGTTTTTGAA 3' 
8 hTERT Fwd-5' CTT GGC TTT CAG GAT GGA GTA GCA-3' 
Rev-5'-GGC TTC AAG GCT GGG AGG AAC-3' .  
9 Axl Fwd-5’TGT TTG GTG TTT CTG GGA CA-3′  
Rev-5′- TCG CAG GAG AAA GAG GAT GT-3′  
8 EGFR Fwd-5’ AGCCTCCAGAGGATGTTCAA-3′  
Rev- 5′ GGAATTCGCTCCACTGTGTT-3’ 
9 MDR1 Fwd-5′ CCCATCATTGCAATAGCAGG-3′  
Rev-5′ GTTCAAACTTCTGCTCCTGA-3′ 
10 
 
Rheb Fwd-5' GGCTGGGTTACAGCTGATTG-3’ 
Rev-5’CTGACACGGACATCGAGCTA-3’  
110 β-actin Fwd-5' CACGAAACTACCTTCAACTCC-3'   
Rev-5' TCATACTCCTGCTTG CTGATCC-3' 
121 18S Fwd-5’ GTAACCCGTTGAACCCCATTCG   
Rev-5’ CATCCAATCGGTAGTAGCGACG   
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1.3.11 Immunoprecipitation and Kinase Assays 
HCT116 cells were plated at 2x106 cells/ 15 mm dish and allowed to adhere for 48 hrs.  Cell 
were harvested, lysed and immunoprecipitation was performed with 1mg protein under lower 
salt conditions (100mM) as suggested previously using anti-Raptor and anti-Rictor antibodies 
(37) . Immunoprecipitation of mTORC1 or mTORC2, and subsequent in vitro kinase assays 
were carried out essentially as following:, the cells were lysed with lysis buffer (50 mM Tris-
HCl, pH 7.5, 100 mM NaCl, 0.3% CHAPS, and 1 mM EDTA, 10 mM β-glycerophosphate, 1 
mM Na3VO4) supplemented with 1× Complete Protease Inhibitor Mixture from Roche Applied 
Sciences. The supernatant from the centrifugation at 15,000 × g for 20 min at 4 °C was 
immunoprecipitated using indicated antibodies and protein G- or protein A-Sepharose 4FF beads 
(Amersham Biosciences).  The immunoprecipitates were washed three times with the lysis 
buffer. For in vitro kinase assay, the immunoprecipitates were further washed with wash buffer B 
(20 mM Tris-HCl, pH 7.5, 10 mM MgCl2).  The immunoprecipitates were then mixed with 0.5 
µg of recombinant 4EBP1(cat# SRP0253 from Sigma Aldrich) and 0.5 µg of recombinant Rheb 
(cat# SRP0225 from Sigma Aldrich) for mTORC1 in kinase buffer (20 mM Tris-HCl, pH 7.5, 10 
mM MgCl2, 0.2 mM ATP) and incubated for 20 min at 37 °C. The kinase reaction was stopped 
by the addition of 1× SDS sample buffer (3% SDS, 5% glycerol, 62 mM Tris-HCl, pH 6.7) and 
subsequent incubation at 95 °C for 5 min. The proteins were resolved by SDS-PAGE and 
transferred onto a nitrocellulose membrane.  All proteins were detected by Western blotting. 
GTPγS was purchased from Millipore. All antibodies used for western blot of IPs were from Cell 
Signaling, Inc. 
1.3.12 Competative peptide block for antibody specificity 
Same set of protein lysates or immunoprecipitaes are run on SDS-PAGE in duplicate and 
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proteins are transferred onto the PVDF membrane. Then, membrane is cut vertically in two parts 
separating the two sets of samples. One membrane is incubated overnight at 4°C with 1:500 
dilutaion of α-Rheb antibody and other membrane is incubated with 1:500 dilution of α-Rheb 
Abs + cometetive Rheb-peptide solution (Rheb antibodies are preincubated with 500ng or 1µg of 
Rheb-peptide for 30 min at RT). Secondary antibody incubation and exposure to the Licore was 
done as suggested above in the immunoblotting section. 
1.3.13 Overexpression of HA-TSC2 and Flag-Sestrin2 
 HCT116 p53 null cells were transfected with 3 µg DNA using Polyjet (DNA:Polyjet at 1:3). 
Cells were lysed and immunoblotted 48 hr after transfection.  For m7GTP pulldowns, cells were 
plated in 10 cm dishes and transfected using 3 µg DNA; 48 hr later, cells were lysed in m7GTP 
buffer.  4EBP1-eIF4E complexes were captured on m7GTP beads, as described (Holz et al., 
2005). Samples were resolved on 12.5% SDS-PAGE gels.  Flag-Sestrin2 plasmid was obtained 
from Dr. Andrei Budanov and HA-TSC2 was purchased from Addgene (Plasmid 24939, 
deposited by Dr Kunliang Guan (Inoki, Li, Xu, & Guan, 2003). 
 
 79 
Chapter 2 
2 Deletion and hot-spot mutations of p53 enhances mTORC1 activity by 
decreasing TSC2 expression and lysosomal localization 
2.1 INTRODUCTION 
AKT, AMPK and mTORC1 are three main nodes of the central control system for responses 
against metabolic changes and/or metabolic stress in the cells, which branch out into a number of 
signaling forward and feedback loops.  An equally important tumor suppressor protein, p53, is 
thought to also play direct and indirect roles in influencing these pathways, although the 
understanding of the mechanism of this control is limited.  This chapter will investigate the 
molecular mechanism of regulation of p53 on mTORC1 signaling and the importance of its 
functional status in control of mTORC1 in human colon and lung carcinoma cells.  
2.1.1 Discovery and structure of the tumor suppressor p53 
p53 was first identified in 1979 as a phosphoprotein that co-immunoprecitated along with SV40 
large and small t antigen, with sera from mice or hamster bearing SV40- induced tumors. This 
co-immunoprecipitated protein traveled at 53000 daltons on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS- PAGE) (Linzer & Levine, 1979). Linzer et al. Later, a 
temperature sensitive mutant of the SV40 large T-antigen gene was found which caused the 
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accumulation of p53 after a temperature shift. This observation suggested that p53 was involved 
in SV40-mediated transformation and thus p53 was hypothesized to have oncogenic properties 
(Linzer & Levine, 1979).  Subsequent rigorous studies on p53 and SV40 showed that this 
accumulation of p53 was actually the result of inactivation of p53 due to binding with large T- 
antigen rather then being involved in induction of the tumors directy.  In 1984 when p53 was 
reconstituted in a p53 null Ab-MuLV-transformed cell line, the expression of p53 was found to 
be essential for tumor cells to exhibit a fully transformed phenotype, manifested in lethal tumors 
in syngeneic mice (Rotter, Wolf, & Nicolson, 1984; D. F. Wolf, Harris, & Rotter, 0926).  In 
1983, Oren et al. cloned the p53 gene and did genetic manipulation of its sequence; they studied 
the consequences of such manipulations on cell growth and survival (Oren & Levine, 1983).  
Later they studied the mechanism of varying levels of p53 in transformed and non transformed 
cells (Reich, Oren, & Levine, 1983) and suggested that levels of p53 are regulated at the level of 
mRNA as well as the protein stability level.  Until then the mechanistic role of p53 in cancer 
progression was not clear. However, in 1989, Levine and group published a landmark paper 
which demonstrated p53 as a tumor suppressor gene. This led to change in understanding of p53 
function and its role in preventing tumor progression.   Later studies by Levine's group supported 
the idea of p53 being a tumor suppressor and suggested that the p53 proto-oncogene can act 
negatively to block transformation (Finlay, Hinds, & Levine, 1989) 
The p53 gene is located on the short arm of human chromosome 17 (17p13) and consists of 11 
exons spanning approximately 20 kb of DNA (Benchimol et al., 1985; Lamb & Crawford, 1986). 
The p53 protein consists of 393 amino acids organized into four functional domains (Fig 2-1). 
The amino terminus of p53 contains two acidic transactivation domains, amino acids 1-42 and 
43-60 (Fields & Jang, 1990) that play an important role in the transactivation mechanism of its 
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target genes; various transcription factors, e.g, TATA binding proteins (TBP) and TBP 
associated factors  (TAFs) bind to these regions (Seto et al., 1992; Thut, Chen, Klemm, & Tjian, 
1995).  The p53 transactivation domain has one nuclear export sequence located at amino acids 
12-27 containing two serine residues (serine 15 and serine 20), which are known to be 
phosphorylated after DNA damage, resulting in nuclear retention of p53 (Y. Zhang & Xiong, 
2001) and both of these phosphorylation sites play an important role in deciding the functional 
fate and stability of p53. Downstream from the transactivation domain there is a proline rich 
domain (amino acids 64-92). This domain consist of five repeats of the src homology 3 (SH3) 
binding motif PXXP where P represents proline and X any other amino acid (Walker & Levine, 
1996). This region has been linked to p53-mediated apoptosis but suggested to be dispensable for 
transactivation and cell growth arrest (Sakamuro, Sabbatini, White, & Prendergast, 1997).  The 
proline rich sequence is followed by a DNA binding domain that stretches from amino acids 102 
to 292 and enables p53 to specifically bind to a specific consensus binding sequence (p53 
response element, p53RE) within gene promoters (Kern et al., 1991). Typically these sequences 
contain two copies of the 10 bp motif 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ separated by 10-13 
bps where Pu is a purine base and Py is a pyrimidine base (el-Deiry, Kern, Pietenpol, Kinzler, & 
Vogelstein, 1992).  The DNA binding domain contains the majority of the mutational hotspots in 
human cancer; the most frequently occurring mutations are in the peptides that make the closest 
contacts with DNA, explaining why many p53 mutants are unable to bind DNA (Cho, Gorina, 
Jeffrey, & Pavletich, 1994) or binds to complete different and newly recognized targets (also 
discussed in chapter 4).  
The C-terminal region of p53 consist of a flexible linker and a tetramerization domain.  The 
linker region connects the central core domain (N terminal domain) to the tetramerization 
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domain, a 32 amino acid peptide required for the formation of tetramers.  p53 binds to DNA  in 
tetramer form (Jeffrey, Gorina, & Pavletich, 1995). The tetramer is formed from 4 identical 
monomers. Each monomer contains a turn, a β-strand, a second turn and an α-helix. Two 
monomers form a dimer in which the α-helix is anti-parallel to the β-strand in the corresponding 
monomer. Tetramers are formed by two dimers interacting through their α-helices and therefore 
the p53 tetramer is known as a dimer of dimers (Jeffrey, Gorina S, and Pavletich,N.P., 1994). 
This tetramerization is required for efficient p53 transactivation in vivo and subsequent growth 
suppression (Pietenpol et al., 1994). A nuclear export sequence (NES) is located at amino acids 
340-351 within the oligomerization domain and tetramerization masks the NES resulting in 
nuclear retention of p53 (Stommel et al., 1999). The extreme C-terminal basic domain, amino 
acids 363-393, was initially thought to be a negative regulator of sequence specific binding 
(Hupp & Lane, 1995). However it is widely accepted that p53 binds nonspecifically to DNA via 
the C-terminal domain (CTD) and then slides along the DNA searching for p53 consensus 
sequences and that, therefore, the CTD promotes DNA binding (McKinney, Mattia, Gottifredi, & 
Prives, 2004). There are three known nuclear localization signals within p53, one located in the 
flexible linker sequence and the other two within the CTD (Addison et al., 1990; Shaulsky et al., 
1990).  
2.1.2 Functional importance of p53 
The p53 pathway can rapidly respond to cellular stimuli, especially to stresses that endanger 
genomic instability.   p53 is known as “the guardian of genome”  (Deppert, 2007; Efeyan & 
Serrano, 2007) or “cellular gatekeeper” (Levine, 1997) because of its central role in coordinating 
the cellular responses to the broad range of cellular stress factors.   p53 functions as a mediator 
and often decision maker for deciding whether the cell should respond to stress with cell cycle 
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arrest, senescence, DNA repair, cell metabolism changes or apoptosis.  All these decisions are 
mediated through the transcription activation or repression of p53 target genes (B. Vogelstein, 
Lane, & Levine, 2000; Vousden & Lane, 2007).  As a transcription factor, p53 upregulates and 
down-regulates a broad spectrum of genes, thus regulation of p53 demands very tight and finely 
tuned controls (Menendez, Inga, & Resnick, 2010). 
The conventional models for the regulation of p53 function are focused on three mechanisms: 
p53 stabilization induced by ATM/ATR mediated phosphorylation after DNA damage, 
sequence-specific DNA binding, and target gene activation by docking of p53 on the gene 
promoter or interaction with transcriptional machinery.  Some recent studies suggest that the 
regulation of p53 cannot be categorized solely by these three levels of regulation (Iwakuma & 
Lozano, 2000; Marine et al., 2006; Menendez et al., 2010). This chapter will focus not on the 
mechanisms of control of p53, but rather on the mechanism of the p53 dependent regulation of 
mTORC1 in cancer cells. 
2.1.3 AKT- AMPK- mTORC1 Pathway 
As a evolutionary mechanism, cells respond to changes in the intracellular and extracellular 
environment by altering either gene expression or by the even faster and often transient set of 
effects collectively known as signal transduction.   The expression of a protein is regulated firstly 
at the transcriptional level with the synthesis of RNA from DNA and secondly at the 
translational level in which protein-encoding information in mRNA is read. As a very integral 
and efficient process, translation demands substantial amounts of energy and cellular material 
(Calkhoven, Muller, & Leutz, 2002). Before initiating the process of growth and proliferation, 
cells must ensure the availability of resources of energy and required raw material like amino 
acids, nucleic acids, etc.  It is necessary for cells to keep an account of the energy status of the 
 84 
cells before committing to growth and proliferation. 
A key pathway that senses and responds to change in environment is the AKT-AMPK-mTORC1 
cascade.  AKT and AMPK are antagonistic in this pathway and have opposing regulatory effects 
on the signaling through mTORC1, which in turn controls initiation of cap-dependent translation 
(Fig. 2-2). AKT, also known as Protien Kinase B, is a downstream effector for PI3K, which 
directly phosphorylates TSC2 (Tuberous sclerosis complex 2) on the number of residues 
including Ser 939, Ser 981 and Thr 1462. (Cai et al., 2006; K. Inoki, Li, Zhu, Wu, & Guan, 
1011; Manning, Tee, Logsdon, Blenis, & Cantley, 2002; Potter, Pedraza, & Xu, 2002).  
Although TSC2 is an important target of AKT but it is not the sole target for this kinase. Recent 
studies have shown that AKT can positively regulate mTORC1 by phosphorylating PRAS40 
(Proline-rich AKT substrate 40), a recently discovered binding partner and inhibitor of mTORC1 
(Y. Sancak et al., 2007; Vander Haar, FAU, Bandhakavi S FAU - Griffin, Timothy,J., FAU, & 
Kim, 0424).  In the presence of growth signal, AKT is phosphorylated at Ser-473 (by mTORC2) 
and Thr-318 (by PI3K) and activated.  Activated AKT phosphorylates TSC2 and/or PRAS40. 
This phosphorylation of PRAS40 leads to conformational changes of PRAS40 causing 
dissociation from the mTORC1 complex.  Dissociation of PRAS40 from the mTORC1 complex 
causes activation of mTORC1 signaling to its downstream targets, suggesting PRAS40 to be an 
inhibitor of mTORC1.  Prior studies proposed this phenomenon to be mediated through 14-3-3 
binding of the phosphorylated PRAS40 (Oshiro et al., 2007; Vander Haar et al., 0424; L. Wang, 
Harris, Roth, & Lawrence, 2007).  Inhibition of mTORC1 upon dissociation of PRAS40 was 
nicely demonstrated by in vitro kinase assays done by Sancak Y et al. using immunoprecipitated 
mTORC1 complex and recombinant S6K1 as a substrate (Y. Sancak et al., 2007).  
Thus, AKT can regulate and activate mTORC1, independent of TSC2 by phosphorylating and 
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dissociating an mTORC1 inhibitor PRAS40.   Interestingly, PRAS40 also contains a TOR 
signaling motif that has been proposed to negatively regulate the mTORC1 activity by 
competing with the binding of 4EBP1 and S6K to Raptor (L. Wang et al., 2007). Therefore, 
PRAS40 is a direct inhibitor of mTORC1 that antagonizes the activation of mTORC1 by 
Rheb.GTP (Y. Sancak et al., 2007).  Because the TSC1-TSC2 complex is absent in some lower 
eukaryotes, higher eukaryotes might have evolved a TSC1/2 complex-Rheb.GTP regulation 
module to fine tune the regulation of mTORC1 for more complex and suddenly changing 
environmental stimuli . Due to its critical role, mTORC1 is tightly regulated by forward and 
feedback mechanisms.  Some recent studies have proposed that PRAS40 is not only an inhibitor 
of mTORC1 but also a substrate.  mTORC1 mediated phosphorylation of PRAS40 inhibits its 
inhibitory activity and augments the removal of inhibition on signaling downstream from 
mTORC1(Fonseca, Smith, Lee, MacKintosh, & Proud, 2007; Oshiro et al., 2007; L. Wang et al., 
2007).  This was proposed to be a positive feedback mechanism for AKT induced mTORC1 
signaling.  As TSC2 is an inhibitor of mTORC1, TSC2 null mouse embryonic fibroblasts have 
constitutive mTORC1 signaling, and show insensitivity towards insulin-mediated activation of 
AKT.   AKT signaling is largely inhibited due to a negative feedback mechanism, suggesting 
that hyperactive Rheb can overcome PRAS40-mediated inhibition of mTORC1 (Y. Sancak et al., 
2007). 
When the TSC1/2-Rheb-GTP-mTORC1 module of signaling is regulated by AKT, activated 
mTORC1 also participates in regulation of the activity of insulin-PI3K-AKT signaling by at least 
one feedback mechanism. Some early studies suggested that activated mTORC1 suppresses AKT 
signaling by inhibition of insulin receptor substrate 1(IRS1) (Haruta et al., 2000; Takano et al., 
2001). Recent studies suggested that S6K, the downstream target of mTORC1, when 
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phosphorylated, further phosphorylates and represses IRS1 (Harrington et al., 2004; Um et al., 
2004). It is becoming increasingly clear and accepted that this feedback regulation is not only 
important for maintaining cell homeostasis but also plays an important role in insulin resistant 
diabetes and in cancer therapeutics by rapamycin analogs (Easton, Kurmasheva, & Houghton, 
2006; Um, D'Alessio, & Thomas, 2006). Whereas insulin-PI3K-AKT signaling senses the 
availability of growth hormones and promotes growth and anabolic processes, the cell has an 
antagonist effector molecule for this mechanism to maintain the cell's energy homeostasis called 
AMP-activated protein kinase (AMPK).  
2.1.4 AMP- activated protein Kinase (AMPK) 
AMPK is a central metabolic switch found in all eukaryotes wthat regulates glucose and lipid 
metabolism in response to alteration in nutrients and intracellular energy status.  Activation of 
AMPK in response to diminished energy (ATP) in cells promotes catabolic processes to generate 
ATP, while inhibiting anabolic processes that consume it (Hardie, 2007).  On a daily basis, 
mammalian cells are exposed to factors that can lead to genetic abnormalities in the PI3K- AKT 
and MAPK signaling pathways that lead to constitutive activation of cell proliferation and 
growth pathways through mTORC1 (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011; 
Hay & Sonenberg, 2004; Shaw & Cantley, 2006). AMPK mediates an endogenous regulatory 
mechanism and negatively controls cell growth and proliferation and thus represents a effective 
and new approach for cancer therapeutics (W. Wang & Guan, 2009). 
2.1.4.1 AMPK sensitivity for AMP: ATP levels 
 Today we know that AMPK recognizes the ratio of AMP:ATP and is very sensitive to this ratio 
in the cell (Hardie & Hawley, 2001).  Initially it was thought that AMPK is allosterically 
 87 
modulated by adenosine-5'-monophosphate (AMP) (Yeh, Lee, & Kim, 1980). The AMPK is 
sensitive to the AMP:ATP and , to a lesser extent, the ADP:ATP ratio. In cells ratio of ADP:ATP 
is maintained by an enzyme adenylate kinase which maintains the reaction of ADP to AMP and 
ATP  in equilibrium (2ADP ↔ ATP+ AMP). Healthy cells keep the ATP:ADP ratio at 
approximately 10:1 by ATP synthase (ADP + Pi → ATP).  The driving force for ATP synthase 
comes from the downhill flow of protons across the inner mitochondrial membrane, a gradient 
maintained by oxidative phosphorylation pumping protons against this gradient (Yoshida, 
Muneyuki, & Hisabori, 2001) 
2.1.4.2 Interplay between ATP synthase and adenylate kinase 
ATP synthase disrupts the equilibrium imposed by adenylate kinase in that is it drives the above 
equation towards increasing levels of ATP.  Therefore, to maintain equilibrium, the adenylate 
kinase reaction is driven from the right to left, generating ADP from AMP.  The adenylate kinase 
reaction together with ATP synthase reaction maintains the ATP:AMP ratio at approximately 
100:1 under the conditions of ATP homeostasis. When cells are under stress, the consumption of 
ATP increases and in order to maintain equilibrium, the adenylate kinase reaction is driven from 
left to right giving rise to an increased level of AMP in the process.  AMPK is a heterotrimeric 
kinase complex composed of a catalytic (α) subunit and two regulatory (β and γ) subunits.  
Under energy starvation conditions, when glucose or the ATP/AMP ratio decreases below a 
threshold, AMP binds to the γ subunit leading to the phosphorylation of the catalytic (α) subunit 
at Thr 172 (Hawley et al., 2010). 
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Figure 2-2. Post-translational modifications of p53.  A map of the post translational 
modifications of p53 where each residue known to be modified is shown. Phosphorylation (P) 
sites are indicated in yellow, acetylations (A) in pink, ubiquitination (U) in grey, methylation 
(M) in as blue and neddylation (N) in green.  
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Figure 2-1. Structure of p53 protein.  
 Map of the functional domains of the p53 protein, the amino-acid residues 
spanning each domain are indicated below the domain name. p53 consists of 
two amino terminal acidic transactivation do ains (TAD), a pro ine rich 
(PRD), a central DNA bin ing domain (DBD), a flexible l nker (L), a 
tetramerizat on domain (4DE) followed by the C-terminal regulatory domain 
(CTRD). Th uclear export s quence (NES) and nuclear localization signals 
(NLS) are also noted 
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Figure 2-2. Schematic diagram of mTORC1 upstream and downstream targets.   
Where does p53 fit in this pathway? 
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Phosphorylated and activated AMPK phosphorylates TSC2 at Ser1387 (D. M. Gwinn et al., 
2008) and turns on its GAP (GTPase activating protein) activity towards Rheb.  Biochemical 
studies confirmed that Rheb-GTP is a substrate of TSC2.   Increase in GTPase  activity of TSC2 
leads to conversion of Rheb-GTP into Rheb-GDP (Garami et al., 2003; K. Inoki, Li, Xu, & 
Guan, 2003; T. Sato, Nakashima, Guo, & Tamanoi, 2009; Tee, Manning, Roux, Cantley, & 
Blenis, 2003b; H. Zhang et al., 2003).  Rheb-GTP is an essential factor for mTORC1 kinase 
activity even in vitro (T. Sato et al., 2009).  In the absence of TSC2 function, Rheb GTP levels 
increase leading to hyperactivity of mTORC1 (Roccio, Bos, & Zwartkruis, 2000).  Recently, it 
was shown that phosphorylation of Raptor by AMPK is required for the inhibition of mTORC1 
activity (D. M. Gwinn et al., 2008). This study discovered that AMPK negatively regulates 
mTORC1 pathway by phosphorylating two proteins upstream of mTORC1 leading to the 
concept that activation of AMPK can be used for mTORC1 inhibition. 
2.1.5 mTOR 
mTOR (mammalian target of rapmycin), a 290 KDa Ser/Thr kinase of the phsophatidylinositol 
3-kinase related protein kinase (PIKK) family, is a highly conserved, nutrient-responsive 
regulator of cell growth and proliferation.  mTOR is present as two biochemically and 
functionally distinct complexes: a complex with Raptor known as mTORC1 or a complex with 
Rictor known as mTORC2 (Wullschleger, Loewith, & Hall, 2006; Y. Zhang, Billington, Pan, & 
Neufeld, 2006).  A major source of information and knowledge about mTOR came after the 
discovery of the antifungal and immunosupressent drug rapamycin, a macrocyclic lactone, which 
is a potent and specific inhibitor of mTOR.  Rapamycin forms an intracellular complex with the 
peptidyl-prolyl cis–trans isomerase FKBP12 (FK506-binding protein). This drug/receptor 
complex binds to the FRB domain of mTOR located N-terminal to the kinase domain (Fingar & 
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Blenis, 2004). Although the mechanism of mTORC1 inhibition by rapamycin is still poorly 
understood but some studies suggest that it could be due to weakening of Raptor-mTOR 
interactions (Kim et al., 2002; Murakami et al., 2004). Prior studies focused on understanding the 
influence of TOR on overall metabolism, used transcriptional profiling of rapamycin treated  
yeast, drosophila and mammalian cells; the results suggested that the inhibition of mTORC1 by 
rapamycin affects translation of approximately 5% of all genes in the genome (Hardwick, 
Kuruvilla, Tong, Shamji, & Schreiber, 1999).  Guertin et al. reported that treatment with 
rapamycin mimics the signals of glucose and amino acid starvation, which clearly suggested the 
critical role of TOR complexes in energy sensing pathways (Guertin, Guntur, Bell, Thoreen, & 
Sabatini, 2006; Hardwick et al., 1999; Peng, Golub, & Sabatini, 2002) 
Rapamycin inhibits mTORC1 signaling. Interestingly, effects of rapamycin on the two targets of 
mTORC1 are different. Whereas rapamycin strongly inhibits phosphorylation of S6K1, it’s 
effects on 4EBP1 phosphorylation are minimal after short intervals of exposure.  4EBP1 is an 
essential protein for inhibition of mTORC1 mediated cap-dependent translation initiation (Fig. 2-
3). Also, it has been shown that tumors develop resistance towards Rapamycin or Rapalogs and 
re-occurrence of cancer is prevalent with this drug treatment (Vignot, Faivre, Aguirre, & 
Raymond, 2005). mTORC2 is insensitive to Rapamycin upon short exposure but mTORC2 
complex diminishes upon longer exposure of Rapamycin.  mTORC1 is composed of at least four 
subunits: mTOR, mLST8/Gbl, PRAS40, and Raptor (Reiling & Sabatini, 2006).  The 36 kDa 
protein mLST8/GL interacts with the TOR kinase domain but has no intrinsic catalytic activity. 
It consists almost entirely of seven WD40 repeats, a motif known to facilitate protein–protein 
interaction and signal transduction (Kim et al., 2003; T. F. Smith, Gaitatzes, Saxena, & Neer, 
1999).  Seven WD40 repeats can also be found in Raptor in addition to a novel RNC domain and 
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three HEAT repeats, also known to facilitate protein-protein interaction (Hara, Maruki, Long, 
Yoshino, Oshiro, Hidayat, Tokunaga, Avruch, & Yonezawa, 0820a; Kim et al., 2002). Raptor 
acts as a scaffold for the recruitment of the 4EBP1 and P70S6K1 substrates to mTORC1 (Nojima 
et al., 2003; Schalm, Fingar, Sabatini, & Blenis, 2003).  mTORC2 plays a very important role in 
the feedback regulation of the mTORC1.  Increased levels of P-389 S6K1 downstream of 
mTORC1 leads to the single site phosphorylation of Rictor (T1135) that in turn exerts a negative 
regulatory effect on the mTORC2 dependent phosphorylation and activation of PI3K/AKT. This 
way mTORC1 can directly regulate mTORC2 and vice-versa (Dibble, Asara, & Manning, 2009). 
mTORC2 is believed to be rapamycin insensitive. However, recent findings show that prolonged 
(>24h) rapamycin treatment can disrupt mTORC2 assembly and function by sequestering newly 
synthesized mTOR molecules (Sarbassov, Ali, Kim, Guertin, Latek, Erdjument-Bromage, 
Tempst, & Sabatini, 2004a; Sarbassov et al., 2006).  Rictor shares conserved domains among 
eukaryotes, but their functions have so far not been elucidated (Jacinto et al., 1206; Sarbassov, 
Ali, Kim, Guertin, Latek, Erdjument-Bromage, Tempst, & Sabatini, 2004b). The domain 
structure of the TOR complex is quite complex and sophisticated suggesting the probability of 
many other proteins are likely to interact, perhaps transiently, an indication that there may be a 
much more complex mechanism of mTORCs regulation than currently understood.  mTORC1 is 
active when the energy status of the cell is high.  However, AMPK is activated when the cell is 
under energy stress, limiting mTORC1 activity. This antagonistic regulation by mTORC1 and 
AMPK critically decides cell fate and whether to allow cell growth is allowed or whether cell 
growth is suppressed based on insufficient energy charge. 
 
 
 93 
 
  
Figure 2-3. Regulation of Cap dependent translation by mTORC1 target, 4EBP1and 
S6K1. 
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2.1.6 AMPK activators 
Recently, AMPK activators have been studied as potential chemotherapeutic drugs due to the 
role of AMPK in cell growth control and its signaling crosstalk between critical metabolic and 
oncogenic pathways. Treatment of MEFs with an AMPK activator, 5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside (AICAR) inhibits mTORC1 activity and cell growth  (Jones 
et al., 2005). AICAR mediated activation of AMPK was also found cytotoxic in Acute 
Lymphoblastic Leukemia (ALL) cells via inhibition of mTORC1 pathway and increased 
expression of cell cycle inhibitors and apoptotic proteins, p53 and p27 (Sengupta et al., 2007). 
Use of Metformin, a LKB1-dependent AMPK activator (D. Gwinn et al., 2008) is associated 
with a statistically significant lower incidence of cancer in those diabetic patients using this drug 
versus patients with similar disease on other therapeutic agents (Libby et al., 2009). There was a 
detailed discussion on AICAR in chapter 1 of this thesis.  Intraperitoneal injections of metformin 
in mouse models of lung tumorigenesis activated AMPK and inhibited mTORC1 in liver tissue, 
but in lung tissues mTORC1 was inhibited due to inhibition of insulin-lime growth factor-I 
receptor (IGF-1R/IR) mediated signaling (Memmott et al., 2010). Metformin inhibits mTORC1 
activity in MCF-7 cells in an AMPK dependent manner (Zakikhani, Dowling, Fantus, 
Sonenberg, & Pollak, 2006). 
Studies from this laboratory recently showed (Racanelli, Rothbart, Heyer, & Moran, 2009; 
Rothbart, Racanelli, & Moran, 2010) that pemetrexed, an antifolate, also activates AMPK and 
leads to inhibition of the mTORC1 pathway. In this thesis we demonstrate for the first time that 
this effect of PTX, although affected by loss or mutation of p53, is still p53-independent and 
mTORC1 inhibition is easily observed regardless of p53 status. 
We recently showed that pemetrexed, an AMPK activator has a strong effect on both 
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downstream targets of mTORC1, S6K1 and 4EBP1 (Racanelli et al., 2009; Rothbart et al., 2010). 
Treatment with an AMPK activator not only blocks the mTORC1 signaling but also modifies 
lipid synthesis, apoptosis and many major pathways involved in cell survival and growth 
(Hardie, 2007; Mihaylova & Shaw, 2011).  Due to involvement of AMPK in several other 
catabolic and metabolic processes, the activation of AMPK leads to a multifaceted attack on 
tumor cells.  Thus, AMPK activators can be used as chemotherapeutic agents. 
2.1.7 TSC1/TSC2 complex 
Tuberous sclerosis (TSC) is an autosomal dominant genetic disease with an estimated prevalence 
of about 1 in 6000 newborns, which is caused by the loss of function of either TSC1 or TSC2 
tumor suppressor genes. Loss of function of these genes leads to the formation of benign but 
progressively growing tumors in several vital organs including kidney, brain, heart and skin.  
The tumors that form in the brain can lead to mental retardation and then seizures, causing poor 
quality of life and ultimately, death.  The tumor-like growths formed in this disease are named 
hamartomas in the brain, skin, kidneys, heart and other organs. Common clinical features are 
facial angiofibromas, renal angiomyolipomas, hypopigmented macules, cardiac rhabdomyomas, 
and cortical tubers and subependymal glial nodules in the brain. The greatest source of morbidity 
is the brain tumors, which cause seizures in 80-90% of affected individuals, mental retardation in 
about half of affected individuals, and behavioral abnormalities (mostly autism) in over half of 
affected individuals.  (Cheadle, Reeve, Sampson, & Kwiatkowski, 2000; Gomez MR, Sampson 
JR, Whittemore VH. 1999; Young & Povey, 1998) Two genes causative of TSC have been 
identified, TSC1 and TSC2.  TSC1 is located on chromosome 9q34 (van Slegtenhorst et al., 
1997) and encodes a 130 kDa protein named hamartin while TSC2 ((Identification and 
characterization of the tuberous sclerosis gene on chromosome 161993)The European 
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Chromosome 16 Tuberous Sclerosis Consortium, 1993) is located on chromosome 16p13.3 and 
encodes a 200 kDa protein named tuberin.  A variety of mutations have been reported in these 
genes, which include point mutations, large deletions/ rearrangement/ insertion for TCS2 and 
insertion, deletion, nonsense and splicing mutation for both the genes. (Reviewed in (Cheadle et 
al., 2000; Young & Povey, 1998). TSC1 contains two coiled-coil domains, which have been 
shown to mediate binding to tuberin (Hodges et al., 2001) the TSC1/TSC2 heterodimer has been 
shown to function as a tumor suppressor (Plank, Yeung, & Henske, 1998; van Slegtenhorst et al., 
1998).  Histological studies of tumor lesions of TSC patients show some diversity, however, the 
tumors that arise as a result of loss of function of either TSC1 or 2 shares common features 
suggesting that TSC1 and TSC2 are involved in the regulation of the same pathway which feeds 
into the cell cycle, cell growth control, and vesicular trafficking and adhesion (van Slegtenhorst 
et al., 1998). Some recent studies showed that the TSC1/TSC2 heterodimer is involved in the 
regulation of cell growth and proliferation downstream of PI3K- AKT in a signaling pathway 
feeding into mTORC1 in both D. melanogaster and mammalian cells, suggesting that 
TSC1/TSC2 are a regulator of the mTORC1 pathway (K. Inoki, & Guan 2003; Manning & 
Cantley, 2003).  Within the TSC1- TSC2 complex, TSC1 stabilizes TSC2 (Benvenuto et al., 
2000; Chong-Kopera et al., 2006) while TSC2 acts as GTPase activating protein (GAP) for the 
small GTPase Rheb (Ras homolog enriched in brain) (Garami et al., 2003; K. Inoki, Li, Xu, & 
Guan, 2003; T. Sato, Nakashima, Guo, & Tamanoi, 0721; Saucedo et al., 2003; Stocker et al., 
2003; Tee & Blenis, 0123; Y. Zhang, Saucedo, Ru, Edgar, & Pan, 2003).  GTP bound Rheb 
potently activates mTORC1 (Y. Sancak et al., 2007).  When active TSC1-TSC2 complex 
converts Rheb-GTP to Rheb-GDP and inhibits mTORC1, thus, loss of TSC2 promotes cell 
growth and tumorigenesis.  TSC2 has multiple sites for AKT, MAPK, RSK, and extracellular 
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signal-regulated kinase (ERK) phosphorylation (Ballif et al., 2005; Dan et al., 2002; Liu, Cai, 
Espejo, Bedford, & Walker, 2002; Manning et al., 2002; Roux, Ballif, Anjum, Gygi, & Blenis, 
2004; Tee, Manning, Roux, Cantley, & Blenis, 2003a), all of which appear to be inhibitory to its 
function.  It was clear that in the presence of growth factor or insulin stimulation AKT blocks the 
TSC2 mediated inhibition of mTORC1 by its phosphorylation at several sites (K. Inoki, Li, Zhu, 
Wu, & Guan, 2002; Manning et al., 2002), but the mechanism by which that AKT mediated 
phosphorylation inhibits TSC2 tumor suppressor function is still unknown.  Also, there are 
several contradictory studies which suggest that TSC2 can be located in the cytoplasm (Nellist et 
al., 1999),the membrane portion of cell (Wienecke, Konig, & DeClue, 1995) or even in nucleus 
(Lou, Griffith, & Noonan, 2001). This clearly suggests that the possible mechanism central to 
control of TSC2 could be the translocation of the TSC1-TSC2 complex between cellular 
compartments.  To address this question Cai et al. (Cai et al., 0609) fractionated nuclear, 
cytoplasmic and membrane fractions and showed that tuberin subcellular translocation is 
dependent on AKT mediated Ser/Thr phosphorylation of TSC2 and thus dependent on the status 
of the growth factors available to cells. They also showed that upon growth factor stimulation 
14-3-3 proteins mediate the translocation of TSC2 into the cytosol; however, TSC1 enhances 
TSC2 retention at the membrane. The most interesting finding of this study was that upon growth 
factor stimulation, Rheb and TSC2 co-localization are disrupted, suggesting that the regulation of 
TSC2-Rheb-GTP on mTORC1 is mechanistically regulated by the translocation of TSC2 
between cytosol and membrane bound Rheb-GTP.  They suggested that when TSC2 and Rheb 
are co-localized, TSC2 GAP activity converts Rheb GTP into Rheb GDP and in the absence of 
Rheb- GTP, mTORC1 signaling is not activated (Cai et al., 2006).  A follow-up study (J. Zhang 
et al., 2013) from the same group was done to understand the mechanism of interaction of 
 98 
TSC1/TSC2-Rheb-mTORC1.  They showed that the tuberous sclerosis complex localizes to 
peroxisomes, including TSC1, TSC2, and also Rheb.  This signaling node regulates mTORC1 in 
peroxisomes in response to reactive oxygen species (ROS).  This study also suggested that 
peroxisome-localized TSC2 functioned as a GTPase for Rheb-GTP and converted it to Rheb-
GDP in response to ROS leading to mTORC1 inhibition; this mTORC1 inhibition was 
diminished in cells expressing peroxisome-localization deficient mutants of TSC2 (J. Zhang et 
al., 2013). Menon et al. in their very recent study addressed the similar question of how TSC2-
Rheb regulates mTORC1 in the presence of growth factor and amino acid availability conditions.  
They showed that upon insulin stimulation there is no change either in the GAP activity of TSC2 
or in the stability of the TSC complex (Menon et al., 2014). It has been known before that both 
low levels of growth factors or amino acids can inhibit mTORC1 activity (Y. Sancak et al., 
2010b). Study of Menon et. al (Menon et al., 2014) added further understanding of how these 
two factors (insulin and amino acids) are quite independent of each other in regulating the 
localization of the TSC complex and mTORC1 to the lysosome.  They also showed that activity 
of the PI3K-AKT pathway induces the dissociation of the TSC complex from the lysosome in an 
AKT dependent manner.  This sophisticated study unified the mechanism by which independent 
pathways affect the recruitment of mTORC1 and the TSC complex to Rheb at the lysosomal 
surface and raises the concept that lysosomal localization serves to integrate growth signals and 
the decision between survival or proliferation (Menon et al., 2014). This suggest that the 
presence or absence of TSC2 function plays an important role in deciding the control of 
PI3K/AKT vs mTORC1 on S6K1 (Jaeschke et al., 2002).  
2.1.8 Rheb 
Rheb is a small GTPase initially isolated as a Ras homolog enriched in brain (Yamagata et al., 
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1994).  Rheb expression was also induced in quiescent fibroblast cells after the addition of serum 
(Yamagata et al., 1994). In addition, Rheb expression was induced in PC12 cells, a cell line 
derived from a pheochromocytoma of the rat adrenal medulla after the addition of EGF or FGF 
(Yamagata et al., 1994).  Rheb has been found to be highly conserved during evolution and was 
found to play critical roles in cell growth, cell cycle, autophagy and amino acid uptake (Aspuria 
& Tamanoi, 2004; Patel et al., 2003).  Rheb is a monomeric 21 KDa protein which belongs to the 
Ras superfamily of GTPases (Wennerberg, Rossman, & Der, 2005). For a long time, Ras 
superfamily G-proteins were classified into one of five subfamilies, Ras, Rho, Rab, ARF, and 
Ran (depending on what for the classification?); members of each subfamily share high sequence 
homology in their effector domain and they also have similar functions (Bourne, Sanders, & 
McCormick, 1991; Mackay & Hall, 1998; Moore, 1998; Moss & Vaughan, 1998; Schimmoller, 
Simon, & Pfeffer, 1998; Vojtek & Der, 1998).  Rheb proteins are highly conserved during 
evolution and are found from yeast to humans but are absent in plants.  Mammalian cells have 
two different Rheb genes: RHEB1 and RHEB2 (also called RHEBL1) but lower eukaryotes such 
as yeast or Drosophila have only one gene.  The translation products of these two genes share 
54% identity and 74% similarity and it is thought that they perform similar functions.  However, 
their tissue expression profiles differ, with Rheb1 ubiquitously expressed while Rheb2 
expression is more limited (Saito, Araki, Kontani, Nishina, & Katada, 2005).  For the purposes 
of this dissertation study, only Rheb1 will be discussed further.  Recently, Rheb has received 
significant attention, partly because Rheb proteins play roles in regulating growth and cell cycle, 
an effect thought due to its role in the insulin/mTOR/S6K signaling pathway.   Rheb acts 
downstream of AKT and activates S6K phosphorylation dependent on TOR.  Rheb is known to 
be an activator of mTORC1 (Aspuria & Tamanoi, 2004; T. Sato, Nakashima, Guo, & Tamanoi, 
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2009; Tee, Manning, Roux, Cantley, & Blenis, 2003b).  Like other Ras superfamily proteins, 
Rheb also activates downstream effectors only when bound with GTP. All Rheb proteins contain 
short stretches of sequences involved in the recognition of the guanine ring and phosphates of 
guanine nucleotides, known as G1 – G5 boxes,  (Aspuria & Tamanoi, 2004). Tamanoi’s group 
have made a number of contributions to the understanding of Rheb proteins. They showed that 
Rheb family members share some very critical features (Urano, Tabancay, Yang, & Tamanoi, 
2000) first, an arginine residue corresponding to the glycine at the 12th codon of Ras is 
conserved in all the Rheb homologues. Second, they have very similar effector domain 
sequences in which 10 of the 17 residues are identical, and 4 of the remaining residues are 
similar.  Third, they all terminate in the CAAX motif (C is cysteine, A is an aliphatic amino acid, 
and X is the C-terminal amino acid that is usually methionine, alanine, serine, glutamine, or 
cysteine) that is required for farnesylation (Clark et al., 1997; Urano et al., 2000; Yang, Urano, & 
Tamanoi, 2000) a posttranslational modification, important for membrane localization and 
function of Rheb.  
2.1.8.1 Rheb Expression and cancer 
Rheb is frequently overexpressed in human carcinoma and has been shown to markedly sensitize 
the epidermis of transgenic mice overexpressing Rheb in basal epidermal keratinocytes; these 
mice show squamous carcinoma induction following a single dose of Ras-activating carcinogen 
7,12-dimethylbenz(a)anthracene (Lu et al., 2010). A meta-analysis of previously published 
cancer cytogenetic and transcriptional databases suggested that the chromosome 7q36.1–q36.3 
region containing the RHEB gene is frequently amplified in some human cancer histologies: an 
increased RHEB expression was observed in liver, lung and bladder cancers.  A direct 
correlation between Rheb mRNA levels and breast cancer prognosis and progression has been 
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shown by microarray database mining (Jiang & Vogt, 2008).  Studies done to determine the 
significance of Rheb in the oncogenic transformation of chicken embryonic fibroblast suggested 
that Rheb played an essential role in oncogenic transformation (Jiang & Vogt, 2008).  The 
expression of Rheb Q64L and N153T in these fibroblasts induced morphological changes, 
including increased size and vacuolization, and conferred upon the cells the ability for anchorage 
independent growth. 
2.1.8.2 Subcellular localization of Rheb 
The initial studies on Rheb were mainly done using ectopicly overexpressed Rheb; some of these 
studies indicated that Rheb localizes on perinuclear and vesicular structures. (Buerger, DeVries, 
& Stambolic, 2006; Saito et al., 2005; Takahashi, Nakagawa, Young, & Yamanaka, 2005). There 
have been reports of Rheb localizing to several endosomal membrane fractions:  lysosomes, 
peroxisomes, and mitochondria.  A literature consensus on the location of Rheb in the cell has 
not yet been reached.  Sudies done by Sancak et al using overexpression of Rheb showed that 
exogenously expressed Rheb is localized in lysosomal membranes, based on colocalization with 
the lysosomal marker LAMP2 (Y. Sancak et al., 2010a).  Later this observation was confirmed 
using antibodies to detect endogenous Rheb (Menon et al., 2014). Subcellular membrane 
localization of Rheb is dependent on its farnesylation and postprenylation modification events 
including Rce1 cleavage and Icmt-mediated carboxyl methylation (Hanker et al., 2010; 
Takahashi et al., 2005).  
2.1.8.3 Interconversion of Rheb-GTP and Rheb-GDP  
As with other Ras superfamily members, Rheb binds to both guanine nucleotides GTP and GDP  
as reported in rat, S. pombe and M. drosophila (Yamagata et al., 1994; Yan et al., 2006; Zheng et 
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al., 2011).  Extensive biochemical studies with S. pombe suggested that Rheb binds to GDP 
(Zheng et al., 2011).  This binding was specific to guanine nucleotides as excess GDP or GTP 
competed with bound GTP but this was not seen with CTP, UTP or ATP.   It is also well known 
that Rheb has an intrinsic GTPase activity (Zheng et al., 2011).  Some studies showed that the 
rate of GTPase activity of Rheb was much slower than seen with Ras but some studies reported 
these rates to be comparable (Yamagata et al., 1994). TSC2, upon activation, works as a GTPase 
activating protein and enhances the intrinsic GTPase activity of Rheb.  In the presence of excess 
GTP, GDP dissociates form Rheb suggesting that Rheb shuttles between GDP-bound and GTP-
bound forms (Zheng et al., 2011).  
 
2.1.9 Sestrin1/2 
The GADD (Growth arrest and DNA damage) genes that are induced in response to genotoxic 
treatments encode several functionally distinct proteins.   The proteins encoded by these genes 
are centrally involved in adaptive or detrimental responses to cellular stresses (Fornace, 1992; 
Fornace, Jackman, Hollander, Hoffman-Liebermann, & Liebermann, 1992; M. L. Smith & 
Fornace, 1996).  One very recently added gene in the list of GADD genes is Sestrin2 also known 
as Hi95.  Budanov et al., while studying the genes affected by long term oxidation stress, 
reported the Hi95 gene to be involved in regulation of cell viability in response to genetic and 
oxidative stress conditions (A. V. Budanov et al., 2002). Oxygen homeostasis is tightly regulated 
and controlled by an oxygen sensing mechanism and by oxidative stress responsive genes, which 
are induced to compensate for oxygen deficiency (hypoxia).  In order to identify novel genes 
induced under prolonged hypoxic conditions, Budanov et al. compared gene expression profiles 
in human glioblastoma A172 cells maintained under normoxic conditions and following 
 103 
prolonged hypoxia, using microarrays (A. V. Budanov et al., 2002).  Hi95 was one of the genes 
to be induced under this hypoxia; this  was of interest because of the strong homology to the p53 
responsive gene PA26, a GADD gene (Velasco-Miguel et al., 1999).  Budanov et al further 
demonstrated that this induction of Hi95 was p53-independent after hypoxia but was p53-
dependent after DNA damage (A. V. Budanov et al., 2002).  Hi95 induction in MCF7 cells 
suppresses growth, sensitizing them to DNA damaging drug and serum deprivation but 
protecting them from H2O2 treatment and ischemia.  Hi95 is now called sestrin 2.  Sestrin1 and 
Sestrin2 have been recently described as p53 target genes (A. V. Budanov et al., 2002; Peeters et 
al., 2003; Velasco-Miguel et al., 1999) involved in the regulation of mTORC1.  DNA damage 
and oxidative stress induce Sestrin1 and Sestrin2 and show cytoprotective function (A. V. 
Budanov, Sablina, Feinstein, Koonin, & Chumakov, 2004).  Recent studies by Budanov and 
Karin showed that sestrin1/2 also play important roles in the inhibition of mTORC1.  Exogenous 
expression of Sestrin1/2 activates AMPK and TSC2 phosphorylation and lead to mTORC1 
inhibition.  They showed that induction of p53 by genotoxic stress induces Sestrin2 which 
further leads to activation of AMPK and TSC2 leading to inhibition of mTORC1 and they 
concluded that sestrin1/2 work as the connecting link between AMPK and TSC2 (A. V. Budanov 
& Karin, 2008b). This chapter also involves the role of Sestrin 2 on p53 and its regulation on 
mTORC1.  
2.1.10 Raptor 
Raptor, the regulatory associated protein of mTOR not only interacts with mTORC1 but also 
with mTORC1 substrates S6K1 and 4EBP1. These two proteins interact with Raptor via a 
domain known as a TOR signaling motif and become phosphorylated by the mTORC1 kinase 
domain. Therefore Raptor works as a scaffold protein that facilitates the recruitment of the 
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substrates of mTORC1. This recruitment allows phosphorylation by mTORC1 of S6K1 at a 
single site, Thr389, and of 4EBP1 at 4 different sites (Ser65, Ser70, Ser37/46) (Fingar et al., 
2004;, Maruki, Long, Yoshino, Oshiro, Hidayat, Tokunaga, Avruch, & Yonezawa, 2002; 
Loewith et al., 2002; Ma & Blenis, 2009; Nojima et al., 2003; Schalm & Blenis, 2002; Schalm & 
Blenis, 2002; Schalm et al., 2003). mTORC1 mediated phosphorylation of S6K1 is essential for 
the assembly of the eIF3 translation initiation complex  Fig. 2-2 (M. K. Holz, Ballif, Gygi, & 
Blenis, 2005b). On the other hand, 4EBP1 is a strong translational repressor which binds to the 
complex of capped mRNA with initiation factor eIF4E, blocking further enucleation of the 
translational initiation complex by other factors.   Only after phosphorylation of 4EBP1 by 
mTORC1 will 4EBP1 release eIF4E and allows its interaction with other factors, prompting the 
initiation of cap dependent translation (Ma & Blenis, 2009).  
 In a very important paper, Gwinn et al showed that activation of AMPK leads to 
phosphorylation of TSC2 at Ser1387 and of Raptor at Ser792 leading to inhibition of mTORC1 
kinase activity (D. M. Gwinn et al., 2008).  Although Ser792 phosphorylation is important for 
the regulation of mTORC1, it is not the only modification of Raptor.  Using tandem mass 
spectrometry, Raptor was found to be is phosphorylated at six different phosphorylation sites 
mainly in two clusters (cluster1, Ser696/Thr706 and cluster 2 Ser855/Ser859/Ser 863/Ser877). 
This observation was confirmed with site-specific antibodies for these sites. This raises the 
question of whether AMPK activators, which can strongly phosphorylate Raptor at Ser792, may 
inhibit mTORC1.  The 3rd chapter of this dissertation will be discussing whether, PTX, which 
activates AMPK and robustly phosphorylate Raptor at Ser 792 leads to inhibition of mTORC1.   
2.1.11 p53 mutations and cancer  
p53 is mutated in approximately 50% of human cancers, making it the most commonly mutated 
 105 
gene in human malignancies (B. Vogelstein, 1990).  As described above, p53 is capable of 
triggering apoptosis or growth arrest, both of which aid in maintaining genome stability. Due to 
the involvement of p53 in these pathways which protect the cell from transformation, extensive 
research has been done to understand the impact of the presence of mutant p53 in the genome. 
The majority of p53 mutations in human cancers disrupt the ability of p53 to bind to DNA (Kato 
et al., 2003).  In a study including 280 tumors containing p53 with somatic base substitution 
mutations, 98% of the mutations fell within a 600 base pair region of p53 encompassing exons 5 
through 8 (amino acids 110-307).  Out of the 280 analyzed, 227 were from solid tumors.  Colon, 
esophagus, breast and non-small cell lung cancer contained the highest number of mutations 
(Hollstein et al., 1991). In heterozygous cells, a mutant p53 allele can alter the function of the 
wild-type p53 allele, either by having a dominant negative effect on wild-type p53, or by 
resulting in gaining new oncogenic properties, independent of the wild-type p53 allele (Baker et 
al., 1989).  Analysis of tumors containing allelic deletions in the short arm of chromosome 17, 
the region encoding p53, showed that the remaining allele contained point mutations indicative 
of loss of heterozygosity (Baker et al., 1989).  Upon co-translation of mutant p53 and wild-type 
p53, mutant p53 was found to oligomerize with wild-type p53, driving it to a mutant phenotype 
characteristic of a dominant negative effect (Milner & Medcalf, 1991).  Transfection of mutant 
p53 into p53 null tumors resulted in lethal tumors, demonstrating that mutant p53 may gain 
oncogenic properties (D. Wolf, Harris, & Rotter, 1984). 
2.1.12 Interplay between p53-TSC2-Sestrin2 and mTORC1 
Feng et al. showed that upon DNA damage induced by etoposide, p53 competent cells show 
activation of AMPK followed by inhibition of mTORC1.  They suggested that, under genotoxic 
stress, p53 negatively regulates mTORC1 via p53 dependent activation of AMPK (Feng, Zhang, 
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Levine, & Jin, 2005).  It was not known, before this thesis, whether un-stimulated endogenous 
levels of p53 have any effects on mTORC1 regulation.  Later it was reported that activation of 
p53 by DNA damaging agent leads to increase in TSC2 (Feng et al., 2007) and sestrin2 (A. V. 
Budanov et al., 2002) mRNA and protein levels in p53 competent cells. Budanov et al showed 
that upon overexpression of exogenous Sestrin2, AMPK mediated phosphorylation of TSC2 
increases, leading to decrease in mTORC1 activity.   These investigators suggested that 
Serstrin1/2 was an essential participant in the interaction of TSC2 and AMPK for TSC2 
phosphorylation and activation (A. V. Budanov & Karin, 2008a). 
 All these studies cumulatively suggest that the involvement of p53 in mTORC1 pathway could 
be multimodal and dependent on the type of stress stimulant.  Most of these studies are done 
either by activation of p53 using DNA damaging drugs or by introducing ectopic TSC2, 
sestrin1/2 or AMPK.  
 
2.2 FOCUS OF THIS CHAPTER 
In this chapter, we focus on understanding the differences in control of mTORC1 activity in the 
presence and absence of p53 and followed those observations onto the effect of mutant p53 on 
control of mTORC1.   
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2.3 RESULTS 
2.3.1 mTORC1 activity is suppressed by basal p53 function in an AMPK independent 
manner. 
Feng et al (Feng et al., 2005) established a connection between p53 and mTORC1 when they 
showed that stabilization of p53 by the DNA damaging agent VP16 (etoposide) suppressed the 
phosphorylation of the mTORC1 target S6K1 in MEFs and that this effect does not occur in 
MEFs lacking p53. We observed the same phenomena for HCT116 colon carcinoma cells 
isogenic for p53 deletion, ie, S6K1 becomes hypophosphorylated in wt HCT116 cells treated 
with VP16 but not in the HCT116 cell line devoid of p53 (p53 -/-) treated with VP16 (Fig. 2-
4A). However, a second very significant effect was evident: untreated p53 (-/-) HCT116 cells 
displayed a robust hyperphosphorylation of S6K1 at T389 over that in HCT116 with p53 
function (Fig. 2-4A).  The effect of DNA damage on mTORC1 activity was shown by Feng et al. 
(Feng et al., 2005) to be mediated by AMPK activation; however, the stimulation of mTORC1 
with loss of p53 in untreated cells was not due to differences in the activation of AMPK, as the 
phosphorylation of AMPK at S172 was independent of p53 (Fig. 2-4B). 
There was a substantial decrease in the 4EBP1 detected in 7mGTP pulldowns in HCT116 p53 -/- 
cells (Fig. 2-5A), an index of unphosphorylated 4EBP1 capable of binding to capped mRNA; the 
level of elF4E on these beads was identical in p53 +/+ and -/- cells. Others have shown that 
4EBP1 is phosphorylated at as many as four residues by mTORC1 and that electrophosesis in 
high percentage acrylamide gels can resolve several 4EBP1 species as indicated in the lysate 
section of Fig. 2-5A (Gingras, Raught, & Sonenberg, 2001; Herbert, Tee, & Proud, 2002; M. K. 
Holz, Ballif, Gygi, & Blenis, 2005a; Ma & Blenis, 2009). The lowest band in western blot from 
lysates (Fig. 2-5A) represents unphosphorylated 4EBP1 and the higher bands (α, β, and γ) 
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represent species with progressively higher phosphorylation states; the phosphorylated forms are 
shunted to the proteasome and degraded (Ma & Blenis, 2009). 
The diminution of the unphosphorylated form of 4EBP1 was also observed as lower levels of the 
fastest migrating band detected in immunoblots of lysates from p53 -/- HCT 116 compared with 
wt p53 HCT116 (Fig. 2-5A). These data suggest that the basal level of p53 in HCT116 cells has 
a substantial suppressive effect on mTORC1 activity, and that deletion of p53 releases mTORC1 
from this control.  
In order to understand whether this difference in total levels of 4EBP1 in p53 +/+ and -/- cells is 
completely due to increased phosphorylation and decreased stability of the protein or its is 
partially due to transcriptional differences as, p53 is a transcription factor, we analyzed mRNA 
levels of 4EBP1.  p53 +/+ and p53-/- HCT116 cells were grown in RPMI media + 10% dFBS 
and were harvested 24 hrs later cells in Trizol; mRNA was extracted followed by cDNA 
synthesis.  Real Time qPCR analysis showed that 4EBP1 transcript levels were 3-4 fold lower in 
the absence of p53 suggesting that p53 was directly or indirectly involved in the transcriptional 
regulation of 4EBP1 (Fig. 2-5B). Therefore, we hypothesized that p53 regulates 4EBP1 
transcription and would be binding to the 4EBP1 promoter.  In order to test our hypothesis, we 
did in-silico analysis to find probable p53 binding site on 4EBP1 promoter.  We found that 
almost 1000 bp upstream of promoter there is a probable p53 binding half site. Thus we 
performed chromatin immunoprecipitation (ChIP) using anti-p53 antibody followed by DNA 
precipitation and Q-PCR, however, we did not find any increase in the binding of p53 at the 
4EBP1 promoter compared to IgG control for nonspecific binding (data not shown). This 
suggested that p53 indirectly but positively regulates 4EBP1 mRNA transcription without 
binding to 4EBP1 promoter. 
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Figure 2-4. mTORC1 activity is suppressed by p53 in an AMPK independent 
manner.  
A) HCT116 cells isogenic for p53 were treated with DMSO or VP16. 24 hrs later 
whole cell lysates were analyzed for P-T389 S6K1, as an indicator of mTORC1 
activity using immunobloting.   Levels of p53 and actin were checked as well. B) 
Levels of activated AMPK measured by P-ser172 AMPK, are unaffected by the status 
of p53.  
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Figure 2-5. Difference in 4EBP1 transcript and protein levels in p53 WT and null 
HCT116 cells.  
 A)Translation repressor species of 4EBP1 is diminished upon loss of p53; HCT116 p53 
wt and null cells were grown in RPMI for 24 hrs followed by 7m-GTP pull down. B) 
4EBP1 transcript levels are 3 fold higher in the presence of p53; HCT116 WT and null 
cells were grown as above followed by RNA extraction, cDNA synthesis and real time 
qPCR. Shown in B is combined data from three individual experiments 
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2.3.2 Negative regulation of mTORC1 by p53 is also seen in other carcinoma cell lines.  
To determine whether this effect of endogenous p53 on mTORC1 was peculiar to HCT116 or 
was more general, we tested other carcinoma cell lines.  H1299 lung carcinoma cells with 
ponesteron-A inducible wt p53, when induced with ponesteron for 24 hrs, showed remarkable 
decrease in phosphorylation of S6K1 (Fig. 2-6A). The hypophosphorylated species of 4EBP1 
was also increased in cells induced with ponesteron-A, in comparision to uninduced cells, seen 
as the shift of the band towards down and increase in the intensity of lowest band (Fig. 2-6).  We 
examined the activity of mTORC1 in other carcinoma cell lines with wt p53 after transfection of 
siRNA pools directed against p53. In the NSCLC lines H460 and A549 and in HCT116 (Fig. 2-
6B), the endogenous wt p53 levels were largely eliminated by siRNA treatment and, 
concomitantly, p-T389 S6K1 was enhanced and the level of unphosphorylated 4EBP1 was 
reduced, indicating a higher mTORC1 kinase activity upon loss of p53. We concluded that the 
endogenous level of p53 in several carcinoma cell lines was exerting a marked controlling effect 
on mTORC1. 
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Figure 2-6. Negative regulation of mTORC1 by p53 is more of a generality 
amongst various cancer cells.  
 A) Lung cancer cells H1299, consists of ponasteron inducible p53 vector, were 
induced with ponetsron for 24 hrs followed by immunoblotting to analyze P-T389 
S6K1 and 4EBP1 levels as an indicator of mTORC1 activity. B) p53 was knocked 
out using siRNA inference in HCT116, H460 and A549 cells. Cells were harvest and 
lysed 48 hours after p53-siRNA transfection. As an indicator of mTORC1 activity P-
T389 S6K1 and 4EBP1 migration was analyzed by using specific antibodies by 
immunobloting 
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2.3.3 Mutation of p53 also causes hyperactivity of mTORC1. 
Human tumors lose p53 function most commonly due to mutation in one allele followed by loss 
of the other from the genome.  Hence, we tested whether hyperactivity of mTORC1 was 
observed in carcinoma cells with a single allele of mutant p53 in the same genetic background.  
For this, p53-/- HCT116 colon carcinoma cells were stably transfected with three mutant p53 
species commonly seen in clinical samples, namely R175H, R248W, and R273H (Fig. 2-7). 
These same mutant p53 species and also V143A were stably transfected into H1299 small cell 
lung carcinoma cells and were compared with H1299 cells bearing a ponasterone-A-inducible wt 
p53 gene (Fig. 2-9).  In HCT116 (Fig 2-7A), mTORC1 targets S6K1 and 4EBP1 were as 
hyperphosphorylated in cells bearing any of these p53 mutant forms as they were in p53 null 
cells.  Likewise, the binding of 4EBP1 to m7GTP beads in lysates of the mutant p53-bearing 
carcinoma cells was minimal and comparably decreased from that seem in p53 wt cells as that in 
p53-null cells (Fig. 2-7B).   The effect of loss or mutation of p53 on 4EBP1 levels was also 
observed at the transcriptional level as the level of 4EBP1 mRNA was interestingly quite low in 
p53-/- and mutant p53 expressing cells in comparison to wt p53-bearing isogenic HCT116 (Fig. 
2-8) 
Ponasterone-A induced wt p53 in H1299 reduces mTORC1 activity as seen by the decreased 
phosphorylation of S6K1 and 4EBP1, and increased levels of unphosphorylated 4EBP1 (Fig. 2-
9A).  Like p53 null H1299, mutant p53 bearing H1299 also showed minimal binding of 4EBP1 
to m7GTP beads in lysates in compassion to isogenic cells expressing inducible wt p53 (Fig. 2-
9B). Like HCT116, loss or mutation of p53 lead to decreased levels of 4EBP1 mRNA levels in 
H1299 cells (Fig. 2-10). 
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We concluded that several mutant p53 could not reinstate the control of mTORC1.  Despite the 
high levels of p53 expression typical of p53 mutant tumors, hyperactivity of mTORC1 was 
equivalent to that in p53 null cells.  Hence, one of the functions of wild-type p53 is to exert a 
control on mTORC1 that is missing in the mutants. 
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Figure 2-7. Mutations in the DNA binding domain of p53 enhance mTORC1 activity 
equivalently to loss of p53.   
 Expression and phosphorylation of S6K1 and 4EBP1 were determined by immunoblotting 
of HCT116 p53-/- cells stably transfected with hot spot mutants of p53 (A), The binding of 
4EBP1 to m7GTP bound beads is severely depressed in HCT116 cells stably transfected 
with p53 mutants in comparison to HCT116 with WT p53 (B). 
 116 
 
 
 
 
 
  
 
0&
0.2&
0.4&
0.6&
0.8&
1&
1.2&
HCT&+/+& HCT'/'& HCT&175& HCT&248& HCT&273&
m
RN
A&
re
la
tv
e&
to
&a
c<
n&
4EBP1&
0&
1&
2&
3&
4&
5&
6&
H1299
&Ind.&
H1299
&Unind
.&
H1299
&143&
H1299
&175&
H1299
&248&
H1299
&273&
m
RN
A&
re
la
tv
e&
to
&a
c<
n&
4EBP1&
Figure 2-8. Mutations in the DNA binding domain of p53 decreases 4EBP1 mRNA 
expression to the level comparable to loss of p53.  
 HCT116 cells were grown in the same conditions (RPMI + 10%dFBS) for 24 hours to allow 
the 60% confluency followed by RNA extraction, cDNA synthesis and RT-qPCR analysis to 
determine the levels of 4EBP1. The expression of 4EBP1 in cells stably transfected with 
mutant p53 was compared with p53+/+ and p53-/- cells. mRNA levels are normalized to actin. 
(plotted as ±sd, n= ). Data suggested that mutant p53 overexpression does not compensate for 
loss of wt p53 function and the mRNA levels of 4EBP1 in mutant p53 is as low as in p53-/- 
cells. 
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Figure 2-9. Mutations in the DNA binding domain of p53 enhance mTORC1 
activity equivalently to loss of p53.  
The expression and phosphorylation of S6K1 and 4EBP1 were determined by 
immunoblotting of H1299 cells stably transfected with hot spot mutants of p53 and 
compared H1299 transfected with an inducible p53 construct (A), The binding of 
4EBP1 to m7GTP bound beads is severely depressed in H1299 cells stably transfected 
with p53 mutants in comparison to H1299 expressing Ponasteron-A inducible WT p53 
(B). 
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Figure 2-10. Mutations in the DNA binding domain of p53 in H1299, 
decreases 4EBP1 mRNA expression, comparable to loss of p53.  
 H1299 cells were grown in the same conditions (RPMI + 10%dFBS) for 24 
hours to allow the 60% confluency followed by RNA extraction, cDNA 
synthesis and RT-qPCR analysis to determine the levels of 4EBP1. The 
expression of 4EBP1 in H1299 stably transfected with mutant p53 was 
compared with H1299 expressing ponasteron-A inducible WT p53 and 
parental H1299. mRNA levels are normalized to actin. (plotted as ±sd, n=3). 
Induction of WT p53 increases the levels of 4EBP1 mRNA in comparison to 
mutant p53 expressing cells as well as p53 null cells. 
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2.3.4 In-vitro kinase assay of mTORC1 immunoprecipitated from p53 null cells showed 
higher mTORC1 kinase activity. 
When we saw the higher cellular mTORC1 activity in p53 null cells than that in p53 competent 
cells, we tested if this difference could be seen in-vitro. In order to address this question we 
performed in vitro kinase assays. We immunoprecipitated mTORC1 from p53 +/+ and -/- 
HCT116 cells under low salt condition (Y. Sancak et al., 2007) using Raptor antibodies.  Here, 
low salt condition refers to 100mM NaCl in wash buffer used for washing the bead-antibody-
mTORC1 complex.  This condition was used in order remove nonspecific protein sticking to 
beads, yet preserving the weak and transient but specific mTORC1 interacting proteins in the 
complex.  The kinase assays were performed using Rheb-GTPγS as an essential cofactor and 
recombinant 4EBP1 as substrate (described in methods and materials) (Fig. 2-11A). The levels 
of P-T37/46 4EBP1 were analysed by immunoblotting using phosphospecific antibodies for this 
modified residue of 4EBP1.  We found that mTORC1 immunoprecipitated from p53 -/- cells was 
catalytically more active and able to phosphorylate 4EBP1 to significantly higher levels than was 
mTORC1 from p53+/+ cells (Fig. 2-11A).  Three independent experiments were performed and 
immunoblots were quantified using Licore imaging and quantitation.  Data complied from all 
three experiments is represented as a bar graph with standard deviations representing the 
variation among replicate biological repeats (Fig. 2-11B).  
In vitro kinase assays on mTORC1 complexes immunoprecipitated with antibody against 
Raptor indicated that the mTORC1 isolated from p53 -/- HCT116 cells was more catalytically 
active than that from p53 +/+ cells (Fig 2-11A,B). Hence, the differences responsible for the 
enhanced kinase activity of mTORC1 from p53 -/- cells in either the components of this complex 
or the post-translational modifications of these components were at least partially stable to 
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immunoprecipitation.  The composition of the isolated IPs was investigated.  The level of Raptor 
and of the AMPK-dependent phosphorylation of Raptor at S792 were equivalent in Raptor IPs 
from p53 wt and null cells (Fig 2-12A, B left panels). Although the level of mTOR seen in 
lysates was unchanged (Fig 2-12A, right panel), the amount of total mTOR associated with 
Raptor was enhanced in p53 deficient cells (Fig 2-12A,B left panels). The Raptor-bound mTOR 
had higher p-S2448, a modification catalyzed by S6K1, but this appears to reflect the higher 
levels of mTOR bound to Raptor (Fig 2-12A, left panel).  Although the levels of PRAS40 and of 
p-T246 PRAS40 were unchanged in lysates of p53 null cells, the binding of total and p-T246 
PRAS40 to anti- raptor IPs was lower in p53 null cells (Fig. 2-12A, left panels and B right 
panel).  Contrary to the levels of the other components, the levels of TSC2 were substantially 
decreased in lysates of p53-null cells (Fig. 2-9A, right panel,), as they also were in lysates of all 
of the mutant p53s studied (Fig. 2-7A).  Apparently as a result of these lower expression levels 
of TSC2, the level of TSC2 in the IPs from p53 null cells was decreased compared to that in p53 
wt cells (Fig. 2-12A, left panels, B right panel). Overall, there were higher levels of mTOR in 
mTORC1 complexes in p53 null HCT116 cells and a lower content of PRAS40 and TSC2 bound 
to mTORC1, factors that would each promote higher mTORC1 kinase activity. 
In order to confirm that these differences are mTORC1 specific, immunoprecipitation under 
same conditions and buffer was performed using anti-Rictor antibodies and the component of 
mTORC2 complex were observed using immunoblotting (Fig. 2-13). The levels of Rictor in 
lysates as well as in IPs were the same in both p53+/+ and -/- cells (Fig 2-13 left and right 
panels). The levels of mTOR and S-2448 mTOR were also equivalent in both lysates and IPs 
from both cell lines (Fig 2-13 left and right panel). Interestingly, we found more phosphorylation 
of AKT at Ser473 and T308 in the lysates of p53 competent cells (Fig. 2-13, right panel). 
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Figure 2-11. In vitro kinase assay shows higher kinase activity in mTORC1, 
immunoprecipitated from p53 null cells.  
 A) The mTORC1 complex from p53-/- cells has enhanced kinase activity in vitro. 
mTORC1 was immunoprecipitated with an anti- Raptor antibody under low salt (100 
mM) conditions and in vitro kinase assays were performed using 4EBP1 as a substrate; p-
T37/46 4EBP1 generated was determined by immunoblot. (B) Licor densitometry data 
from three independent in vitro kinase assays (mean ±sd). 
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Figure 2-12. The enhanced kinase activity of the mTORC1 complex is retained 
during immunoprecipitation in cells lacking p53.  
 (A) The components of the mTORC1 complex differ between p53+/+ and p53-/- 
cells. Anti-Raptor immuneprecipitates from isogenic HCT116 cells were probed 
with antibodies against the indicated proteins; lysates were probed in parallel. (D) 
The level of Raptor, PRAS40, and TSC2 in p53-null HCT116 cells was measured by 
densitometry from 3 independent experiments and expressed (±sd) relative to the 
level in p53 wt control cultures.**p=0.0045 for mTOR, *p=0.0117 for PRAS40, 
*p=0.040 for TSC2. 
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Figure 2-13. The differences in mTORC1 components are specific to it and not 
seen in mTORC2.  
mTORC2 was immunoprecipitated in the same way as mTORC1 using anti-Rictor 
antibody. Immunoblotting was performed on immunoprecipitate and levels of 
Rictor, P-S2448 mTOR and mTOR were analyzed (left panel). Lysates from which 
IP was performed, were probed to analyze the levels of various components of 
mTORC2 (right panel) 
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2.3.5 Higher Rheb bound to mTORC1, immunoprecipitated from p53 null cells under 
low salt conditions 
In our immunoprecipitation studies, we found higher Rheb bound to the mTORC1, 
immunoprecipitated from p53 null cells (see below).  Others have not successfully detected 
endogenous Rheb in mTORC1 immunoprecipitates.  Therefore, when we detected the band at 
the size corresponding to Rheb (21 KD) we set out to confirm whether the band detected in our 
studies is indeed Rheb or it is a non-specific band.  We tested this by performing a competitive-
peptide blocking experiment.  The principle behind this experiment is that, in the presence of 
excess Ab-specific peptide (against which antibody has been raised), antibody will not be able to 
bind to the corresponding protein band on the immunoblot due to competitive binding of peptide 
with the antibody.  Thus, the blot incubated with antibody (-competitive peptide) will show 
signal at the correct size, suggesting the presence of the corresponding protein, while the blot 
incubated with antibody (+ competitive peptide) will not.  In this experiment we probed the 
lysates of p53 null and competent cells with either anti-Rheb antibody alone or Ab + peptide 
solution (i,e. anti-Rheb antibody pre-incubated for 30 minutes with 100ng or 1µg of Rheb-
epitope peptide).  The blot incubated with anti-Rheb antibody in the absence of peptide showed 
the presence of band at 21kD, however the blot incubated with anti-Rheb antibody, pre-
incubated with Ab + 1µg peptide solution, showed the absence of this band (Fig. 2-14). This 
indicated that the peptide competed with the Rheb present in the lysates and that the 21 KDa 
band was indeed Rheb.  We concluded that the antibody we used for the detection of Rheb is 
indeed specifically binding to Rheb.  
mTORC1 complexes, immunoprecipitated from p53 -/- and +/+ cells were equally 
divided and loaded in duplicate on SDS-PAGE gels followed by transfer onto the PVDF 
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membranes.  One blot (representing 1 set of protein samples) was incubated overnight with 
Rheb-antibody alone and other blot (representing a second identical set of the protein samples) 
was incubated with Rheb-antibody with 1µg of competitive peptide (Ab+ peptide solution).  
After incubation with the secondary antibody followed by detection on a Licore, we found that 
the blot incubated with anti-Rheb antibody in the absence of competitive peptide, showed the 
Rheb band at 21 Kd, in immunoprecipitate from p53-/- cells, however this band was not present 
on the blot incubated with Ab + peptide (Fig. 2-15). This indicated that higher Rheb is bound to 
the immunoprecipitate from p53 null cells than to that from p53 competent cells.  
In our studies, the mTORC1 immunoprecipitation was done using wash buffer with 100 
mM NaCl concentration.  We hypothesized that the probable cause of unsucessful attempts of 
detecting Rheb in mTORC1 immunoprecipitates by others, was the use of wash buffers with salt 
concentartions too high to allow survival of these complexes.  We also hypothesized that Rheb 
interacts with mTORC1 transiently so that with the use of high salt concentrations (150 mM to 
500mM)  as previously used by others would be immunoprecipitaion conditions too stringent to 
catch loosely bound interactions.  Therefore, we preformed mTORC1 immunoprecipitation from 
lysates of p53 -/- and +/+ cells, using increasing concentration of NaCl (from 50 to500 mM) in 
the wash buffer. Rheb was detectable in the mTORC1 complex, immunoprecipitated at 50mM 
and 100mM salt-wash buffer, but, with the increase of the salt concentration in the wash buffer, 
binding of Rheb with mTORC1 complex was decreased and completely vanished at 500mM salt. 
To confirm the mTORC1 specific binding of Rheb, nonspecific mouse IgGs (same species as of 
α-Raptor antibody) were used for immunoprecipitation as a negative control.  We saw that Rheb 
was immunoprecipitated only under low salt conditions and only in IPs done with anti-Raptor 
antibody (Fig. 2-16). This suggests that Rheb loosely interacts with the mTORC1 complex and 
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this interaction is higher in p53-/- cells. This could be due to higher Rheb levels in lysosomal 
membranes of p53 null cells, as suggested by Catherine Bell’s experiments (data not shown). 
The mRNA and protein levels of Rheb are equivalent in p53 null and competent cells (Fig. 2-17, 
2-14 respectively).  As expected, under 500 mM salt condition, PRAS40 binding was remarkably 
decreased as previously shown by Sancak et al. (Y. Sancak et al., 2007) (Fig 2-17). 
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Figure 2-14. Rheb peptide block shows the specificity of the α-Rheb 
antibody. 
 p53 null and wt HCT116 cells were seeded and harvested fater 24 hrs. 25 µg of 
cell lysates from p53 +/+ and -/- cells were loaded in triplicate. Proteins were 
transferred on the PVDF membrane. Membrane was blocked using start block and 
cut into three strips, A, B, C. A) Incubated with α-Rheb antibody ; B) α-Rheb 
antibody + 100ng peptide; C) α-Rheb antibody + 1ug peptide . All three 
membranes were simultaneously incubated with secondry antibody and signal was 
detected by Licor. 
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Figure 2-15. Higher Rheb is bound to mTORC1 complex immunoprecipitated 
from p53 null cells.  
Immunoprecipitation was performed using lysates from p53 +/+ and -/- HCT116 
cells. Immunoprecipitates were divided equally and ran on SDS-PAGE gels in 
duplicate followed by transfer on PVDF memebranes A) Left blot was incubated 
with α-Rheb antibody + 1ug peptide solutaion, overnigh at 4 degree. B) This was 
incubated only with α-Rheb antibody (-peptide) overnight at 4 degree. Secondry 
antibody incubation and detection by licore was done simulationously. The red 
arrow indicates the Rheb band at the size of 21 kD. 
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Figure 2-16. At 100mM or low salt condition of wash buffer, Rheb is detectable 
and higher in the immunoprecipitates of p53 null cells.  
 p53 null and wt HCT116 cells were seeded and harvested fater 24 hrs. 
Immunoprecipitaion was perfroemd using α-Raptor antibody and wash buffers with salt 
concentration as indicated. Immunoblotting was performed to analyze Raptor, p-S792 
Raptor, mTOR, p-S2448 mTOR, PRAS40, p-T246PRAS40 and Rheb using 
corresponding antibodies and signal was detected by Licor. 
 
 130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S2: 
Rh
eb
 m
RN
A 
le
ve
ls
 
re
la
tiv
e 
to
 a
ct
in
 
Figure 2-17. Steady state mRNA levels in p53 null and competent cells.  
 HCT116  p53-/- and +/+ cells were grown in triplicates in the same conditions 
(RPMI + 10%dFBS) for 24 hours to allow the 60% confluency followed by 
RNA extraction, cDNA synthesis and RT-qPCR analysis to determine the levels 
of Rheb. Data is plotted after normalization to actin (plotted as ±sd, n=3).  
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2.3.6 The transcript and protein levels of TSC2 and Sestrin 2 are lower in p53 null 
HCT116 cells. 
We found that the levels of TSC2 bound to the mTORC1 complex are lower in p53 null cells 
than to that in p53 competent cells.  It was not known whether the uninduced, basal level of p53 
can regulate these two genes. Therefore, we asked if the total levels of TSC2 and sestrin2 would 
be decreased upon loss or mutation of p53.  Steady state mRNA levels of TSC2 and Sestrin2 
were measured by RT-qPCR.  mRNA was extracted from HCT116 p53 competent or null cells 
followed by cDNA synthesis. Real time q-PCR analysis showed that levels of TSC2 are 
approximately 2 fold lower in p53 -/- cells than in p53 +/+ cells (Fig. 2-18, left panel).  This 
apparent transcriptional effect was even larger in the case of Sestrin2 where p53+/+ cells express 
almost 5 fold higher levels of Sestrin2 mRNA than p53-/- cells (Fig 2-18, right panel).  Previous 
reports have also indicated an effect of p53 on levels of TSC2 mRNA (Feng et al., 2007) and 
DNA-damaging drugs were reported to increase Sestrin2 mRNA (A. V. Budanov et al., 2002).  
We further investigated if this difference was translated into protein levels. Indeed, we saw 
significantly lower levels of TSC2 and Sestrin2 protein levels in p53 -/- HCT116 cells (Fig. 2-
19). 
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Figure 2-18. Steady state mRNA levels of TSC2 and Sestrin2 are lower in the 
absence of p53.  
 p53 +/+ and p53-/- HCT116 cells were grown in the same conditions (RPMI + 
10%dFBS) for 24 hours to allow the 60% confluency followed by RNA 
extraction , cDNA synthesis and RT-qPCR analysis to determine the levels of 
TSC2 (left panel) and sestrin2 (right panel). mRNA levels are normalized to 
actin. 
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Figure 2-19. Protein levels of TSC2 and Setsrin2 are reduced to great extent 
upon loss of p53.  
p53 +/+ and p53-/- HCT116 cells were grown in the same conditions (RPMI + 
10%dFBS) for 24 hours to allow the 60% confluency. Cells were harvested and 
lysed. Immunoblotting was performed in order to analyze the levels of TSC2, 
Sestrin 2 and p53. Actin is shown as a control for equal protein loading across 
the samples. Data represents three individual biological repeats, run on the SDS 
page and immunoblotted at the same time. 
 134 
2.3.7 The levels of TSC2 mRNA and protein increased upon activation of p53 by DNA 
damaging drug etoposide suggesting p53 transcriptional regulation of these two 
genes.   
In order to confirm if the levels of TSC2 were regulated by p53, we treated HCT116 p53+/+ 
cells with etoposide, a conventional method of inducing DNA damage leading to activation of 
p53 and its transcription activity.  HCT116 p53+/+ and p53-/- cells were treated with DMSO or 
etoposide (VP16, 20µM) for 24 hrs. Cells were harvested and processed further for 
immunoblotting or RNA extraction.  Upon RT-qPCR analysis we found that the levels of TSC2 
mRNA were increased by almost 2 fold in cells treated with VP16 in p53 wt cells but not in cells 
treated with VP16 genetically null for p53 (Fig. 2-20A).  The protein levels of TSC2 were also 
increased after VP16 treatment only in p53 +/+ cells but not in p53-/-cells (Fig. 2-20B).   Hence, 
we show here that activation of AMPK can lead to increase in the levels of AMPK dependent 
phosphorylation of TSC2 at S1387 (Fig. 2-20B). We conclude that upon activation of p53 after 
VP16 treatment, the increased levels of TSC2 and Sestrin2 allow the interaction of activated 
AMPK and TSC2 and the phosphorylation of TSC2 at Ser1387.  
2.3.8 Carcinoma cells that are p53 null or that express only mutant p53 have decreased 
levels of TSC2 and Sestrin2 
HCT116 and H1299 cells expressing mutant p53 were studied to compare their TSC2 and 
Sestrin2 mRNA and protein levels with their isogenic p53 null and wt p53 cells. The steady-state 
levels of TSC2 and Sestrin2 mRNA were determined by RT-qPCR.  Both mRNA populations for 
TSC2 and for sestrin2 were decreased with loss or mutation of p53 (Fig. 2-21).  The protein 
levels of TSC2 were also diminished in both HCT116 and H1299 cells without p53, or with 
mutant p53 (Fig. 2-22).  
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Figure 2-20. Levels of TSC2 mRNA and protein increased upon 
activation of p53 after etoposide treatment.  
 HCT116 p53+/+ and -/- cells were treated with either DMSO or VP16 (20µM) 
for 24 hours. (A) Cells were harvested to extract RNA followed by RT-qPCR 
to determine steady state levels of TSC2 mRNA.  mRNA levels are normalized 
to actin  mRNA levels. (B) Cells were harvested and lysed followed by 
immunoblotting to analyze the levels of P-T1387 TSC2 , TSC2 and p53. Actin 
is used a marker for equal protein loading.   
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Figure 2-21. Carcinoma cells that are p53 null or that express only mutant 
p53 have decreased levels of TSC2 and Sestrin2 mRNA.  
 Cells were grown in the same conditions (RPMI + 10%dFBS) for 24 hours to 
allow the 60% confluency followed by RNA extraction , cDNA synthesis and 
RT-qPCR analysis to determine the levels of TSC2 (left panel) and sestrin2 
(right panel). mRNA levels are normalized to actin (plotted as ±sd, n=3). Data 
suggests that either loss or mutation of p53 leads to decreased levels of these 
two mRNA species in both colon carcinoma cells HCT116 cells as well as in 
lung carcinoma cells H1299. 
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Figure 2-22. Protein levels of TSC2 and Setsrin2 are reduced to great extent 
upon mutation in p53 and is comparable to loss of p53.  
Cells were grown in the same conditions (RPMI + 10%dFBS) for 24 hours to allow 
the 60% confluency. Cells were harvested and lysed. Immunoblotting was 
performed in order to analyze the levels of TSC2. Actin is shown as a control for 
equal protein loading across the samples.  Cells expressing mutant p53 or p53-/- 
cells have remarkable decrease in TSC2 level (A) HCT116 cells, (B) H1299 cells. 
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2.3.9 Complementation of the control of the mTORC1 pathway in p53 null cells by TSC2 
and Sestrin2.  
Because of the centrality of TSC2 to the control of mTORC1 kinase activity and to the role of 
Sestrins in the activation of TSC2 by AMPK (A. V. Budanov & Karin, 2008a), we questioned 
whether the hyperactivity of mTORC1 seen in p53 -/- HCT116 cells was due to the lower levels 
of TSC2 and Sestrin2.  When FLAG-tagged Sestrin 2 or HA-TSC2 were individually transfected 
into p53 -/- HCT116, the phosphorylation of S6K1 was reduced almost to the levels seen in wt 
HCT116; when both constructs were co-transfected, the level of p-T389 S6K1 was identical to 
that in wt HCT116 (Fig. 2-23A).  Likewise, transfection of TSC2 or Sestrin2 or of both 
constructs into p53 -/- HCT116 returned the level of 4EBP1 seen in 7mGTP pulldowns back to 
that seen in p53 +/+ HCT116 (Fig 2-23B). We concluded that the enhanced mTORC1 activity 
seen in p53 null cells was due to diminished function of TSC2 due to lower levels of TSC2 itself 
and of lower levels of Sestrin2.  
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Figure 2-23. Complementation of the control of the mTORC1 pathway in p53 
null cells by TSC2 and Sestrin2.  
 Increasing the levels of TSC2 and Sestrin2 in p53 null cells reverses the elevated 
mTORC1 activity in p53 null cells. (A) FLAG-tagged Sestrin2, HA-TSC2, or an 
empty vector were transfected into p53-/- HCT116 cells and p-T389 S6K1 was 
determined by immunoblotting. (B) Exogenous TSC2 and Sestrin2 restores 7mGTP 
cap binding in p53 null cells. 7mGTP pulldown assays were performed on p53-/- 
HCT116 cells following transfection as in (A); bound 4EBP1 and eIF4E were 
detected by immunoblot 
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Figure 2-24. Proposed model depecting the mechanism of p53 mediated 
regulation of mTORC1.  
 A) p53 wt cells have more TSC2, more PRAS40, less Rheb and less mTORC1 
complex present at lysosomal membrane. Due to higher TSC2 levels Rheb 
mediated activation of mTORC1 will decline, causing lower mTORC1 activity 
in p53 wt cells. B) In the absence of p53, TSC2 levels are low, PRAS40 levels 
bound to mTORC1 are low and levels of Rheb on the lysosomal membrane is 
high, leading to higher mTORC1 activity. 
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2.3.10 Discussion 
The single most frequent genetic change in human tumors is mutation of the p53 gene at 
positions that alter the transcriptional activity of the protein. Typically, mutation in one allele is 
followed by a loss of the other allele, with major changes in levels of transcriptional targets of 
the wt protein.  As a less frequent event, some tumors have lost both alleles of this gene.  We 
show here that either mutations of p53 that modify its transcriptional function or complete loss of 
the gene upregulates mTORC1 activity.  The intermediate step that mediates this upregulation 
appears to be lower expression of TSC2, a previously suggested transcriptional target of p53 
(Feng et al., 2007) and Fig.20, 21, 22).  The fact that replacement of TSC2 levels by transfection 
reverses the effect of p53 loss on mTORC1 activity argues for this causal relationship.  These 
observations are supported by the studies done by my colleague Catherine Bell.  In her studies of 
subcellular fractionation and confocal microscopy, she showed that p53 null cells have lower 
levels of TSC2 and increased levels of Rheb localized in the lysosomal membrane, the site of 
mTORC1 activity (data not shown).  This observation suggested that the decreased levels of 
TSC2 in p53 null cells resulted in a lower distribution of TSC2 to lysosomal membranes and that 
this effect is, surprisingly, associated with an enhanced level of Rheb in fractions containing both 
mTOR and Raptor, presumably representing the active mTORC1 complex (Fig.  2-24). These 
differences in lysosomal localization of TSC2 and Rheb are more obvious in cells completely 
lacking TSC2 expression, i.e., TSC2-null MEFs (Experiments done by Ms. Bell and data not 
shown). The current literature suggests that redistribution of TSC2 to lysosomal membranes 
plays an intrinsic role in control of mTORC1 activity.  Interestingly, by causing a primary 
decrease in TSC2 levels at the lysosomal membrane, we also observed the redistribution of Rheb 
(experiment of Catherine Bell, data not shown).  Two recent papers suggest the involvement of 
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another p53 target, the Sestrins, in mTORC1 localization at lysosomal membranes (Parmigiani et 
al., 2014).  We observed the reinstatement of control of mTORC1 following exogenous 
expression of Sestrin2 in p53 null cells, apparently a reflection of the enhanced efficiency of the 
residual levels of TSC2 in p53-null cells in the presence of higher Sestrin2.   This interpretation 
reflects the current view of a dynamic equilibrium of the binding of TSC2 at the lysosomal 
membrane, affecting mTORC1 activity. 
We have used immunoprecipitation (this thesis), membrane fractionation (Catherine Bell) 
and confocal microscopy (Catherine Bell) to study effects of p53 on the distribution of 
components of mTORC1.   All three approaches indicated that the decrease in TSC2 levels in 
p53 null cells is followed by a decreased occupancy of TSC2 at the position of active mTORC1.  
The effect of p53 loss on enhanced Rheb colocalization with mTORC1 was indicated by 
membrane fractionation and confocal microscopy. This phenomenon was also captured in IPs 
done at low (100mM) NaCl concentration in wash buffer, but not at high salt-wash buffer, as 
would be expected for a transient interaction.  Decreases in PRAS40 were detectable in IPs, 
when these immunocomplexes were washed with lower levels of salt (Y. Sancak et al., 2007), as 
were higher distribution of mTOR into Raptor complexes; these redistributions were not obvious 
from membrane distribution studies or confocal microscopy, but reflected the changes in 
mTORC1 activity in p53 null cells. 
The enhancement of mTORC1 we observed in p53 null cells was also seen in carcinoma 
cells expressing mutant p53s at the very high levels of this protein usually found for such 
mutations, a fact that emphasizes the centrality of the p53-driven transcriptional program in 
control of mTORC1 activity. There have been prior indications that AMPK-mediated TSC2 
control of mTORC1 depends on p53 function and involves the p53 target Sestrin2.  Feng et al 
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showed that stabilization of p53 by DNA damaging agents caused phosphorylation and 
activation of AMPK, leading to mTORC1 inhibition; these effects were TSC2 dependent (Feng 
et al., 2005). A recent study (H. Wang et al., 2008) demonstrated that this DNA damage-initiated 
effect on AMPK involved ATM effects on p53 and p63, as well as DNA- PK; these effects of 
DNA damage are clearly distinct from those reported here. The effect isolated by our studies is 
clearly not one which involves activation of p53 by a DNA damage effect, seen by Feng et al., 
but rather an activity mediated by the low steady state levels of wt p53.  These effects, which are 
downstream of and not mediated by AMPK, represent distinctly different level of involvement of 
p53 in control of mTORC1 activity. Therefore, we concluded that loss or mutation of p53 
enhances mTORC1 activity by decreasing the TSC2 expression and its localization at lysosomal 
membrane as depicted in Fig. 2-24. 
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Chapter 3 
3 Involvement of p53 in pemetrexed-activated AMPK mediated inhibition of 
mTORC1 
3.1 INTRODUCTION 
In the previous chapter we determined the effects of p53 on mTORC1 regulation and concluded 
that p53 negatively regulates mTORC1 activity via regulating the expression of TSC2 and 
Sestrin2.  We also showed that there were differences in the components of the mTORC1 
complex in p53 +/+ and -/- cells, including more mTOR and less TSC2 and PRAS40 in p53-/- 
cell in comparison to p53 +/+ cells, which would contribute to the higher mTORC1 activity in 
p53 compromised cells. A very interesting finding by my colleague Catherine Bell, suggested 
that p53 competent cells have decreased Rheb and increased levels of TSC2 at the lysosomal 
membranes, apparently leading to decreased mTORC1 activity in these cells.  It is clear from 
these data that, upon loss of p53, negative regulation of mTORC1 is relieved leading to an 
increase in cell growth and proliferation.  This correlation of p53 and mTORC1 is evident in 
most cancers where function of WT p53 is diminished or lost and mTORC1 activity is high.  As 
most cancers show hyperactive mTORC1, mTORC1 inhibition offers a very attractive and 
promising approach for targeted chemotherapy.  
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This chapter is focused to understand the molecular mechanism of an AMPK activator 
pemetrexed (PTX), which inhibits mTORC1.  Our lab has shown that PTX inhibits AICARFT, a 
second folate dependent enzyme in de novo purine synthesis which when inhibited, causes robust 
buildup of its substrate ZMP (Racanelli, Rothbart, Heyer, & Moran, 2009; Rothbart, Racanelli, 
& Moran, 2010). ZMP is an AMP mimetic and thus can activate the central energy sensor of the 
cell, AMPK. Our lab also showed that this activation of AMPK by PTX inhibits mTORC1 in an 
LKB1 independent manner (Racanelli et al., 2009; Rothbart et al., 2010).  Whereas the majority 
of lung cancers have a p53 null or p53 mutant phenotype, our studies in chapter two suggests that 
mTORC1 activity increases to a significant level upon loss or mutation of p53.  Because PTX is 
active against lung cancers and also can inhibit mTORC1, we wanted to understand if PTX 
mediated inhibition of mTORC1 is modulated by p53 status.  Therefore the focus of this chapter 
is to understand the role of p53 in PTX-mediated activation of AMPK and inhibition of 
mTORC1.  In the pursuit of an understanding of how activation of AMPK by pemetrexed PTX 
would behave in the presence and absence of p53 function, we compared it with another AMPK 
activator, AICAR.  This chapter also shines light upon the mechanism whereby two AMPK 
activators that initially activate AMPK via ZMP accumulation, can lead to two different 
downstream effects based on their ability to activate p53. Therefore, this chapter builds a bridge 
between our findings from chapter 2 and a long-standing question of how PTX is so effective 
against lung cancers. This chapter also lays a platform for understanding the effects of PTX on 
gain-of-function mutant p53 in chapter 4. 
3.1.1 Accumulation and Stabilization of p53 by Post Translational Modifications (PTMs) 
Normally, p53 is maintained at very low concentration due to its relative short half-life of 
approximately 20 minutes, much less than that of mut p53 (Strano et al., 2007).  p53 is rapidly 
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turned over in unstressed cells through its interaction with MDM2, a RING family type E3 
ligase, which promotes poly-ubiquitination and proteasomal degradation (Honda, Tanaka, & 
Yasuda, 1997). Therefore, after a genotoxic stress or a variety of other cellular insults, levels of 
p53 immediately increase by stabilization of the p53 protein. Kastan et al. showed that, after the 
genotoxic stress of IR-induced DNA damage, protein levels of p53 increased, apparently due to 
by a post-translational mechanism (Kastan, Onyekwere, Sidransky, Vogelstein, & Craig, 1991).  
Human p53 harbors an array of serine (S)/ threonine (T) phosphorylation sites that span the 
entire protein, but these sites are highly concentrated in the N terminal transactivation and C-
terminal regulatory domains (Fig. 3-1).  It has been shown that the phosphorylation of p53 at 
Ser15 and possibly at ser20 causes p53 accumulation by blocking the interaction between 
MDM2 and p53 thereby inhibiting its degradation (Shieh, Ikeda, Taya, & Prives, 1997; Siliciano 
et al., 1997; Toledo & Wahl, 2006).  PTMs of p53 have been extensively investigated; 
modifications can include phosphorylation, acetylation, methylation, ubiquitination, adenylation 
and/or sumoylation (Reviewed in (Toledo & Wahl, 2006). After different cellular stresses, 
several of these PTMs are thought to act as a barcode dictating the multiple cellular functions of 
p53.   p53 phosphorylation at the N terminus has been reported to have significant redundancy; a 
single residue can be phosphorylated by several kinases and one kinase can phosphorylate 
several residues (J. P. Kruse & Gu, 2009). This section will address the literature on those 
phosphorylation sites that are investigated in this chapter.  Fig. 3-1 summarizes the known PTMs 
of p53. This chapter also compares the effects of two AMPK activators and a DNA damaging 
agent on the phosphorylation levels of several key p53 residues and what is known about the 
consequences of these phosphorylation events on p53 stability and transactivation is summarized 
below.  
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Figure 2-2. Post-translational modifications of p53.  A map of the post translational 
modifications of p53 where each residue known to be modified is shown. Phosphorylation (P) 
sites are indicated in yellow, acetylations (A) in pink, ubiquitination (U) in grey, methylation 
(M) in as blue and neddylation (N) in green.  
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Fi e 3-1. Post-tr nsl tional m difications of p53.  
A map of the post translational modifications of p53 where each residue 
known to be modified is shown. Phosphorylation (P) sites are indicated in 
yellow, acetylations (A) in pink, ubiquitination (U) in grey, methylation (M) 
in as blue and neddylation (N) in green. Red circles indicate the 
phosphorylation sites and green circles indicate acetylation sites, analyzed in 
the studies of this chapter. 
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Figure 3-2 Schema of mTORC1 pathway.  
 This is a schematic representation of AKT-mTORC1-AMPK pathway. 
Black arrows show activating phosphorylation events and red arrows show 
inhibitory events. 
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3.1.1.1 Serine 15 and serine 20 
The most studied post-translational modifications of p53 are serine 15 and serine 20 
phosphorylation. These phosphorylation sites have had the attention of the p53 community not 
only because the biology of these phosphorylation sites is complex but also because they are 
believed to be crucial in manipulating the stability and trans-activation of p53 (Siliciano et al., 
1997; Toledo & Wahl, 2006). The E3 ligase, MDM2, interacts with amino acids 18-23 of p53, 
and phosphorylation at serine 15 is thought to block this interaction and promotes the 
accumulation of p53 (Shieh et al., 1997). However, there is a diverse and contradictory literature 
about the importance of ser15 phosphorylation in the transactivation of p53.  Fuschs et al 
suggested that phosphorylation of serine 15 is not required for p53 accumulation or 
transcriptional activation but rather that S15 phosphorylation enhances subsequent 
phosphorylations on neighboring residues (Fuchs, O'Connor, Fallis, Scheidtmann, & Lu, 1995). 
Serine 15 lies within a nuclear export signal and phosphorylation of S15 results in nuclear 
retention of p53 (Zhang & Xiong, 2001).  Lambert et al. showed that after IR, phosphorylation of 
serine 15 increases which in turn increases the ability of p53 to recruit and associate with the 
transcriptional co-activator proteins CBP and p300 (Lambert, Kashanchi, Radonovich, 
Shiekhattar, & Brady, 1998). The acetyltransferase activity of p300 recognizes the C- terminal 
domain of p53 as a substrate resulting in acetylation at lysines 373 and 382 enhancing the 
sequence-specificity of p53 binding to DNA (Gu & Roeder, 1997a). Several kinases have been 
linked to the phosphorylation of serine 15, including ATM, ATR, AMPK, DNA-PK, ERK, p38 
and CDK9 (Reviewed in (Toledo & Wahl, 2006).  Phosphorylation of serine 20 also aids in p53 
accumulation and nuclear retention in a similar fashion as was described for serine 15 
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phosphorylation, as both residues lies within the nuclear export sequence region. However, it has 
been reported that S20 phosphorylation also is not required for p53 stabilization and activation 
(Chehab, Malikzay, Stavridi, & Halazonetis, 1999). Chk1, among several other kinases, have 
been identified to be capable of phosphorylating serine 20 and, rather surprisingly, other than 
facilitating p53 stabilization, no further functions of this modification have been elucidated 
(Shieh, Ahn, Tamai, Taya, & Prives, 2000a). Studies with mice containing serine to alanine 
mutations in p53 at ser15 or ser 20 or both showed the redundancy in the functional requirement 
of the phosphorylation of these two residues. Individual mutations in gene knock-in experimental 
mice only showed a marginal difference in the stability and transactivation activity of p53. 
However, mice bearing both ser15/20 mutations of showed a more severe phenotype, including 
tissue specific reduced apoptotic capacity, compromised replicative senescence and a latent 
development of a spectrum of tumors (Chao, Herr, Chun, & Xu, 2006; Toledo & Wahl, 2006). 
3.1.1.2 Serine 37  
Dohoney et al showed that, following DNA damage by UV- or γ-irradiation, p53 is stabilized 
and phosphorylated at a number of residues, including serines 15 and 37. Phosphorylation at 
serine 37 appears to be important in p53-dependent transcription after UV and IR treatment. 
Mutating this serine residue to an alanine significantly impairs the transactivating ability of p53 
in a MDM2-luciferase reporter assay (Dohoney et al., 2004). A previous study in which the N-
terminal domain of p53 was fused to the DNA-binding domain of the yeast GAL4 protein, 
showed that phosphorylation of S15, but not S37, is critical for p53-dependent transactivation 
(Dumaz & Meek, 1999) 
Sequence-specific DNA binding of p53 is also enhanced when serine 37 is phosphorylated. 
Serine 37 phosphorylation has been reported to be important for the transactivation and pro-
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apoptotic activities of p53 (Li et al., 2006).  The phosphorylation of serine 37 was shown to 
stimulate the interaction between p53 and the transcriptional coactivators p300 and PCAF which 
acetylate p53 at lysine 382 and lysine 320, respectively, activating the sequence-specific DNA-
binding of p53 (K. Sakaguchi et al., 1998).  
3.1.1.3 Serine 46  
Phosphorylation of serine 46 has been implicated in p53-dependent apoptosis.  A study in which 
knock-in mice expressing the human p53 gene with a S46A mutation were compared with mice 
expressing the wild-type human p53 gene. These mice were generated by homologous 
recombination and LoxP/Cre-mediated deletion to introduce a Ser46 to Ala missense mutation 
into the human p53 knock-in allele in mice (p53hki(S46A)).  This study suggested a modest 
reduction in p53 mediated transcription activation of some pro-apoptotic targets and 
compromised apoptosis in MEFs and embryonic stem cells from these mice (L. Feng, Hollstein, 
& Xu, 2006).  When p53 S46 is mutated to an alanine, mouse embryonic fibroblasts (MEFs) and 
mouse e mbryonic stem cells had a reduced ability to induce apoptosis after UV treatment when 
compared to cells containing wild-type p53.  Mayo et al. showed that during mild VP16-induced 
DNA damage, serine 46 is not phosphorylated and p53 thereby activates the transcription of 
MDM2 inducing the autoregulatory feedback loop.  After extensive VP16-induced DNA 
damage, serine 46 is phosphorylated and the transcriptional activation by p53 becomes more 
extensive, for instance, PTEN transcription is activated and increased apoptosis was observed. 
These results were confirmed by genetic manipulation studies.  A nonphosphorylatable serine 46 
to alanine p53 mutant (S46A) targeted the MDM2 promoter in preference to that for PTEN.  A 
serine 46 to aspartate mutant (S46D, a phosphorylation mimic) targeted PTEN in preference to 
MDM2.  Thus this study concluded that phosphorylation of S46 is essential and sufficient for 
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choosing PTEN as a target gene over MDM2.  This must be in order to overcome the induction 
of MDM2 and the formation of the autoregulatory feedback loop of MDM2-p53 (Mayo et al., 
2005).  
3.1.1.4 Serine 392  
Studies done by Sakguchi et al suggested that phosphorylation of serine 392 significantly 
enhanced tetramer stability, possibly through hydrogen bonds between the phosphorylated 
residue and the N-terminal region of p53 (K. Sakaguchi et al., 1997). DNA binding and 
transcription activation of p53 is also enhanced after phosphorylation of serine 392 during UV 
treatment (Keller, Zeng, Wang, Zhang et al., 2001a).  Phosphorylation of the C-terminal S392 
following UV-radiation activates specific DNA binding through stabilizion of the p53 tetramer 
(Matsumoto, Furihata, & Ohtsuki, 2006).  For a long time it was believed that S392 
phosphorylation is a response to DNA damage induced by UV radiation but a group recently 
showed that phosphorylation of Ser392 can also occur during the induction of p53 by a range of 
stimuli including treatment of cells with the MDM2 inhibitor, Nutlin 3a. (Cox & Meek, 2010). 
Phosphorylation of serine 392 appears to be important for the anti-proliferative activity of p53. 
When SV3T3 mouse cells were transfected with p53 containing an alanine at this residue, this 
mutant p53 was unable to suppress colony formation as compared to cells transfected with wild-
type p53 (Milne, Palmer, & Meek, 1992).  
3.1.1.5 Acetylation 
Lysine acetylation is a powerful mechanism for activating function.  It has been said to work at 
three levels in the case of p53: 1) it promotes p53 stabilization by blocking ubiquitination; 2) it 
inhibits the formation of the HDM2/HDMX repressive complex at the promoter of target genes 
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and thus alleviates promoter inhibition; 3) it assists in the recruitment of transcription cofactors 
at the promoter for p53 transcriptional activity.  Of the nine acetylation sites have been identified 
for p53, six are lysine residues (K370. K372, K373,K381, K382 and K386) in the C- terminal 
regulatory domain. These sites are shown to be acetylated by CBP/p300 and ubiquitinated by 
HDM2 (J. Kruse & Gu, 2008; Nakamura, Roth, & Mukhopadhyay, 2000). Histone acetyl 
transferases which are responsble for these modifications include the structurally related p300, 
CBP, p300/CBP associated factors (PCAF) and the MYST (named for the members MOZ, 
Ybf2/Sas3, Sas2 and Tip60) family of HATs, Tat-interactive Protein of 60 kDa (TIP60) and 
human Males absent On the First (hMOF) (J. Kruse & Gu, 2008; Sykes et al., 2006; Sykes, 
Stanek, Frank, Murphy, & McMahon, 2009). It has been shown that p53 can be modified by 
acetylation both in vivo and in vitro and the site of p53 that is acetylated by its co-activator, 
p300, resides in a C-terminal domain known to be critical for the regulation of p53 DNA 
binding.  Therefore, the acetylation of p53 at this region can dramatically stimulate its sequence-
specific DNA-binding activity, possibly due to an acetylation-induced conformational change 
(Gu & Roeder, 1997a; Luo et al., 2004).  
 A seventh lysine residue, K320, in the tetramerization domain is acetylated by PCAF (J. 
Kruse & Gu, 2008). Acetylation of this residue promotes p53-mediated activation of Cyclin-
Dependent Kinase inhibitor 1A (CDKN1A), commonly known as p21, results in cell cycle arrest 
and thus favors cell survival (Knights et al., 2006).  More recent studies have discovered two 
new additional sites of acetylation, K120 and K164 which are in the DNA binding domain and 
are acetylated by TIP60/hMOF (Sykes et al., 2006) and CBP/p300 (Tang, Zhao, Chen, Zhao, & 
Gu, 2008) respectively.  Nevertheless, despite all the studies suggested that acetylation of the C-
terminal domain plays a critical role in p53 mediated processes, mice expressing acetylation-
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deficient p53 generally did not exhibit any major depression in cell cycle control, apoptosis or 
tumor suppression (L. Feng, Lin, Uranishi, Gu, & Xu, 2005). This observation is in accordance 
with the fact that only rarely do human cancers have mutations in the C-terminal domain of p53 
(http://p53/free.fr/). 
3.1.2 Transcriptional Regulation by p53  
As described in the previous section, p53 contains a DNA binding domain which specifically 
binds the p53 response element (p53RE) within promoter regions of its genes, and a C-terminal 
domain which has been shown to non-specifically bind DNA and then coordinate the linear 
search of DNA for p53REs (el-Deiry, Kern, Pietenpol, Kinzler, & Vogelstein, 1992; McKinney, 
Mattia, Gottifredi, & Prives, 2004).  This section will briefly describe the mechanisms whereby 
p53 regulates gene transcription.  
3.1.2.1 p53 Response Element  
The p53RE contains two copies of the 10 bp motif 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ separated 
by 10-13 bps where Pu is a purine base and Py is a pyrimidine base (el-Deiry et al., 1992; Miner 
& Kulesz-Martin, 1997). It has been shown that tetrameric p53 is able to recognize, bind and 
transactivate genes from noncanonical consensus sequences containing only half of the 
consensus sequence (Jordan et al., 2008).  Overall, the literature suggests that different p53RE 
have different binding affinities for p53. A study using a red-white p53 reporter system in 
Saccharomyces cerevisiae measured the ability of p53 to transactivate a reporter gene from 
various p53REs. It was shown that there is as much as a 1000-fold difference between the 
transactivation from weaker p53RE to stronger p53RE.  The p21 promoter has two p53Res 
located 1.2 and 2.4 kb upstream of the transcriptional start site.  The sequence of the upstream 
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p21 p53RE has the highest affinity for p53, while the p53RE within the BAX promoter has the 
weakest affinity (Inga, Storici, Darden, & Resnick, 2002). The promoters of three other p53-
regulated cell cycle genes, cyclin G, 14-3-3 and GADD45 also have quite high binding affinities, 
compared with that of the proapoptotic genes PUMA, BAX and p53AIP (Weinberg, Veprintsev, 
Bycroft, & Fersht, 2005).  Posttranslational modifications of p53 and p53 binding partners also 
contribute to the diversity of the transcriptional response.  For instance, the phosphorylation of 
serine 46 discussed above has been shown to selectively induce p53 to transactivate the pro-
apoptotic gene p53-regulated Apoptosis Inducing Protein1 (p53AIP).  In the latter study, the 
authors selected the p53 binding sequences from the human genome using in-silico analysis and 
cloned and found a novel mitochondrial protein designated as p53AIP.  They showed that the 
expression of p53AIP can be induced by wt p53 after DNA damage in MCF-7 cells.  The 
induction of p53AIP led to enhanced apoptosis and this phenomenon was dependent on the 
phosphorylation of p53 at Ser46 (Oda et al., 2000).  
3.1.2.2 Transcriptional Initiation  
For successful transcriptional initiation, the chromatin around a promoter must be modified to 
form an open chromatin structure (euchromatin) that allows the general transcriptional initiation 
machinery to bind to the DNA. The role of p53 in this process is critical. After p53 has bound to 
the p53RE, histone acetyltransferases (HATs) are recruited to acetylate the histones surrounding 
p53 (Lill, Grossman, Ginsberg, DeCaprio, & Livingston, 1997). P300/CBP are recruited to the 
promoter following the interaction of CBP with the transactivation domain of p53.  p300/CBP 
acetylates the histones bound to DNA in the vicinity of p53, as well as the C terminal domain of 
p53, increasing the activation of gene transcription (Gu & Roeder, 1997b). After the opening of 
regional chromatin, the general transcription machinery can be recruited to form the preinitiation 
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complex (PIC). p53 is known to act with several components of the PIC to initiate transcription. 
The assembly of a complex containing p53, TBP, the TBP associating factors (TAF), TAFII60, 
TAFII40 and TAFII250 appears sufficient to activate transcription.  
 The composition of the PIC required for transcriptional activation differs between genes 
as well as between stress stimuli promoting transcription of a particular gene. Two examples of 
this are the p21 and FAS promoters. Espinosa et. al showed that prior to any cellular stress, p53 
is poised at the p21 promoter along with components of the PIC, TBP and paused RNA 
polymerase (Espinosa, Verdun, & Emerson, 2003). After UV stress, levels of p53 bound to the 
promoter increase,leading to completion of the transactivation process by p53-dependent 
recruitment of TAFII250. This stimulates the phosphorylation of serine 2 in the C terminal 
domain (CTD) of the paused RNA polymerase, converting it to the elongation form. In contrast 
to p21, the FAS promoter does not contain a TATA box.  Prior to any stress, p53 is also poised 
on the FAS promoter, but the levels of paused RNA polymerase are significantly lower than 
found at the p21 promoter (Espinosa et al., 2003). After UV treatment, p53 levels increase, 
recruiting HATs and TAFII250 to the promoter.  There is no net loss of paused RNA polymerase 
at the promoter after the appearance of the elongation form, suggesting that the initiation and 
elongation rates were similar.  The difference between these two promoters demonstrate a 
strategic placement of p53 on the gene promoters depending on their role in cellular 
mechanisms.  Cell cycle genes, such as p21, are poised for rapid transcriptional activation after 
cellular stress while the transcriptional activation of the proapoptotic gene Fas is slower due to 
the lower levels of RNA polymerase poised at the promoter (Espinosa et al., 2003).  
3.1.2.3 Transcriptional Elongation 
After RNA polymerase is cleared from the promoter, other elongation factors are recruited to the 
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promoter vicinity, some of which interact with p53. The phosphorylation of serine 392 of p53 is 
often implicated in complexes with elongation factors and, as described above, this 
phosphorylation promotes oligomerization of p53 and subsequent DNA binding (Hupp, Meek, 
Midgley, & Lane, 1992; K. Sakaguchi et al., 1997). During the discovery that casein kinase 2 
(CK2) is able to phosphorylate serine 392 of p53 after UV treatment, p53 was found to be in a 
complex with subunits from the FACT (facilitated chromatin transcription) complex, a known 
elongation factor (Keller, Zeng, Wang, Zhang et al., 2001b). It is also shown that the human p-
TEF (positive transcription elongation factor) is responsible for converting the paused RNA 
polymerase to elongating polymerase through phosphorylation at serine 2 in the carboxy terminal 
domain (Marshall, Peng, Xie, & Price, 1996). The Cdk9 kinase is the component of p-TEF 
responsible for phosphorylating serine 5 of the CTD of RNA polymerase (Ramanathan et al., 
2001; Zhu et al., 1997). Cdk9 is known to interact with p53 and phosphorylate it at serine 392; 
the stabilized p53 then promotes transcription of Cdk9, thereby promoting transcriptional 
elongation in a feed-forward system (Claudio et al., 2006). 
3.1.2.4 Transcriptional Repression  
A less studied role of p53 is transcriptional repression. After binding to some promoters, p53 
interacts with mSin3a recruiting HDAC1 (histone deacetylase), which removes the acetyl 
moieties from the chromatin causing the chromatin to close around the promoter and repressing 
transcription (Murphy et al., 1999). The physical binding of p53 to promoters may restrict the 
binding of other transcription factors required for transcriptional activation. This is observed 
during hypoxic stress: under these conditions p53 binds to the alpha-fetoprotein promoter, 
inhibiting the binding of the transcriptional activator HNF3 and, hence, repressing transcription 
(Y. I. Lee et al., 2000). Although the mechanism of transcriptional repression is not understood 
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yet, the binding of p53 to the Rad51 promoter, repressing transcription of this gene, is critical to 
homologous recombination during DNA damage (Arias-Lopez et al., 2006).  
3.1.3 p53 Dependent Apoptosis    
Yonish et al. demostrated the importance of p53 in the mechanism of apoptosis when they  
showed that tumor cells null for p53 underwent spontaneous cell death after the introduction of a 
wild-type p53 by transfection, suggesting that p53 was involved in the apoptosis pathway 
(Yonish-Rouach et al., 1991). Bax was found to be a direct transcriptional target of p53 and the 
first example of a proapoptotic gene directly regulated by p53 (Miyashita & Reed, 1995). The 
restoration of p53 in murine leukemia cells caused an increase of Bax mRNA and protein levels 
(Selvakumaran et al., 1994). Since then several other pro-apoptotic genes have been identified 
that are regulated by p53, including p53AIP1, APAF1, Caspases 1, 6 and 10, FAS, PUMA, DR4 
and DR5. Upon binding to the promoters of these genes, p53 activates transcription, thereby 
promoting increased levels of the downstream components of the apoptosis cascade (Reviewed 
in (Riley, Sontag, Chen, & Levine, 2008). Evidence for a role of p53 in the regulation of 
apoptosis that was independent of transcription was first hypothesized after transcriptionally 
inactive mutants of p53 were found to induce cell death (Haupt, Rowan, Shaulian, Vousden, & 
Oren, 1995).  
 
3.1.4 p53 senses cellular stresses induced by chemotherapeutic agents  
Understanding of p53 as a cellular stress response protein, it was of interest to know how p53 
responds to stresses induced by chemotherapeutic agents.  Most cellular responses by p53 have 
been studied after IR or UV exposure.  Ionizing radiation, camptothecin and bleomycin directly 
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and rapidly induce DNA strand breaks, promoting the accumulation of significant levels of p53 
within one hour of treatment.  Cells electroporated with DNaseI or the restriction enzyme AluI 
also accumulated p53, leading to the conclusion that DNA strand breaks initiate p53-dependent 
signaling pathways (Nelson & Kastan, 1994). Further analyses showed that as little as one DNA 
strand break per cell was sufficient to induce a p53 dependent growth arrest (Huang, Clarkin, & 
Wahl, 1996). 
  Much less is known about the p53 response to nucleotide pool deprivation.  Linke 
et al, for the first time proposed the concept that p53 could sense nucleotide levels and then 
would become stabilized (Linke, Clarkin, Di, Tsou, & Wahl, 1996). In their experiments, WS1 
embryonic skin cells containing wild-type p53, treated with antimetabolites inhibiting different 
parts of de novo pyrimidine and purine synthesis resulted in a G1 cell cycle arrest.  However, 
p53 null cells slipped into early S-phase and then arrested. Interestingly, dNTP biosynthesis 
inhibitors caused arrest in early S-phase regardless of p53 status. In the studies of Linke and 
colleagues, the G1 arrest was reversed upon the addition of the limiting nucleotides and no 
apparent DNA damage was detected by metaphase chromosome analysis, therefore, the p53 
dependent nucleotide deficiency arrest was not caused by DNA damage (Linke et al., 1996). 
Feng et. al have shown that DNA damage induced activation of p53 leads to phosphorylation and 
activation of AMPK in a p53 dependent manner (Z. Feng, Zhang, Levine, & Jin, 2005). Whereas 
finding of Jones et. al have suggested that upon metabolic stress, i.e upon glucose deprivation, 
AMPK activation leads to phosphorylation of p53 at ser15. This ser15 phosphorylation of p53 is 
required to induce AMPK mediated metabolic checkpoint and cell growth arrest (R. G. Jones et 
al., 2005a). These two studies suggest that connection of p53 and AMPK but with different 
theories. Former suggests that p53 mediated effects on mTORC1 are AMPK activation 
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dependent and later suggest that AMPK mediated effects on cell growth are p53 and p53 
phsophorylation at ser15, dependent. Cleraly these differences in the observation by two groups 
could be due to different type of cell stresses used in the studies. A section of this dessertaion is 
dedicated to understand the response of p53 under the treatment of DNA damaging agent VP16 
and two AMPK activators, PTX and AICAR.  
3.1.5 ATM/ATR regulation of p53 
To protect the genome from genetic assault caused by environmental factors like radiation, 
reactive oxygen species, ultraviolet light, and other environmental mutagens, cells have evolved 
complex mechanisms, collectively referred to the DNA damage response.  This pathway acts to 
rectify DNA damage to allow the minimization of genetic infidelity. The cellular response to 
DNA damage involves both repair mechanisms and checkpoint responses. Checkpoint responses 
are thought to have evolved to delay the cell cycle progression in order to prevent error prone 
DNA replication. Many of the published studies on the involvement of p53 in the DNA damage 
response were done using radiation or DNA damaging agent such as etoposide (VP16). 
Etoposide is a topoisomerase inhibitor, which forms a ternary complex with DNA and the 
topoisomerase II. Topoisomerase II is a helicase, which unwinds the DNA during replication.  
Thus binding of VP16 with topoisomerase stabilizes DNA and topoisomerase II complex, 
prevents re-ligation of the DNA strands, and causes DNA double strand break.  
ATM-Chk2 and ATR-Chk1 pathways play key roles in the DNA damage response (Sancar, 
Lindsey-Boltz, Unsal-Kacmaz, & Linn, 2004). ATM and ATR are large kinases with sequence 
similarity to the phosphatidylinositol-3-kinase (PI3K) family. Each of them phosphorylates 
multiple protein substrates (Abraham, 2001). The two key, well-studied substrates are Chk1 and 
Chk2 which are selectively phosphorylated by ATR and ATM, respectively.  Chk1 and Chk2 are 
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serine-threonine checkpoint effectors, that is, they are themselves phosphorylated early in the 
checkpoint response, but then have activities as kinases, essential to the imposition of the G1/S, 
or G2/M phase blocks in cell-cycle traverse (Bartek & Lukas, 2003) dependent on the intensity 
and type of DNA stress. 
The ATM–Chk2 and ATR–Chk1 pathways respond to different types of damaged DNA 
structures (Fig.3-3).  ATM is recruited to and activated primarily at DNA double-strand breaks 
(DSBs) in conjunction with the MRE11:RAD50: NBS1 (MRN) sensor complex (J. H. Lee & 
Paull, 2005; Paull & Lee, 2005; Suzuki, Kodama, & Watanabe, 2005) whereas ATR is activated 
via recruitment to single-stranded DNA (ssDNA) upon single strand break in association with its 
partner protein, ATRIP (Dart, Adams, Akerman, & Lakin, 2004; Lupardus, Byun, Yee, Hekmat-
Nejad, & Cimprich, 2002; Zou & Elledge, 2003). ATM and Chk2 are activated potently by 
radiation and genotoxins that induce DSBs, but only weakly, if at all, by agents that block DNA 
replication without inducing damage (Matsuoka et al., 2007). This piece of information is 
important for the understanding and explanation of the later section of this chapter. In response 
to DSBs, inactive subunits of ATM homodimerize, then  autophosphorylate each other and 
dissociate to form partially active monomers (Bakkenist & Kastan, 2003; Kastan & Bartek, 
2004). ATM autophosphorylated at S1981 is often taken as an indicator of its activation. 
Modification of this residue has been shown to be involved or at least linked to ATM activation 
under most circumstances (Bakkenist & Kastan, 2003; Kastan & Bartek, 2004). However, this 
residue is not essential for ATM function, at least in mice (Pellegrini et al., 2006).  ATM 
monomers are then recruited to the DSBs site with the MRN sensor complex where they can 
locally act on multiple substrates.  Of the several substrates for ATM, the two most important, or 
at least the most studied, are H2AX (Fernandez-Capetillo, Lee, Nussenzweig, & Nussenzweig, 
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2004) and ChK2 (Lukas, Falck, Bartkova, Bartek, & Lukas, 2003).    
 
 
 
 
 
 
 
 
  
Figure 3-3. Schematic representation of activation of ATM-Chk2 and ATR-Chk1 
pathway following genotoxic stress. 
The ATM-Chk2 and ATR-Chk1 pathways are activated selectively by DSBs and by 
tracts of ssDNA, respectively. Here, for clarity and simplicity multiple proteins 
involved in the DNA repair mechanism are represented as DRPC = DNA repair 
protein complex. Studies in later part of this chapter suggest that AICAR or VP16 
treatments lead to DNA damage activating p53 and its transcriptional activity, 
however, PTX might cause replication halt leaving p53 transcriptionally inactive. 
This concept is presented here in the form of question marks in red color 
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ATM phosphorylates Chk2 on T68, a residue located within an N-terminal 
serine/threonine (SQ/TQ) rich motif (Ahn, Li, Davis, & Canman, 2002).  Once the SQ/TQ motif 
of one Chk2 molecule is phosphorylated, it interacts with the phosphopeptide-binding Fork-head 
associated (FHA) domain of another, homodimerize transiently;  autophosphorylation ensues  
and ATM achieves a fully activated state (Ahn et al., 2002; Cai, Chehab, & Pavletich, 2009; 
Oliver et al., 2006). It has been suggested that these activated Chk2 monomers dissociate from 
the site of damage and disperse through out the nucleus to act on several substrates involved in 
the response to DNA damage, which includes proteins involved in cell cycle progression, gene 
transcription, and apoptosis  (Lukas et al., 2003).  One of the most studies substrates of Chk2 
kinase is the p53 protein, which was shown to be phosphorylated at ser15 by Chk2 (Chehab, 
Malikzay, Appel, & Halazonetis, 2000; Oliver et al., 2006; Shieh, Ahn, Tamai, Taya, & Prives, 
2000b). ATM has been thought to activate p53 by directly phosphorylating it upon DNA 
damage.  ATM also phosphorylates MDM2 and MDMX, which regulate the stability of p53, and 
thus is thought of as responsible for the stabilization of p53 upon DNA damage (Chen, Gilkes, 
Pan, Lane, & Chen, 2005; Lavin & Kozlov, 2007).  There is also increasing evidence that 
supports the concept that ATM may have substrates and function in the cytoplasm (Lavin, 2008). 
 ATR–Chk1 signaling is also thought to be activated upon blockage of DNA replication.   
Replication fork stalling generates ssDNA directly; however, this structure can also arise through 
the action of nucleotide excision repair (NER) or at dysfunctional telomeres. As a result of 
nucleotide depletion or DNA damage lesions caused by ultraviolet light, blockage of DNA 
replication can occur, which causes the uncoupling of DNA polymerase from the replication 
helicase, generating ssDNA tracts (Byun, Pacek, Yee, Walter, & Cimprich, 2005).  These ssDNA 
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tracts are rapidly coated by trimeric ssDNA binding protein complex and replication protein A 
(RPA) and Chk1 are recruited at these tracts with ATR-interacting proteins (ATRIP) (Zou & 
Elledge, 0626). However, it is important to remember that the ATR-ChK1 pathway is also 
activated in response to DSBs after which nucleolytic strand resection exposes ssDNA. Serine 15 
of p53 is phosphorylated by ATR after IR, UV or HU treatment.  Kinase inactive mutants of 
ATR interfere with phosphorylation of p53 in late S-phase during IR treatment and completely 
suppress p53 phosphorylation after UV treatment, suggesting an important role of ATR in the S-
phase checkpoint (Tibbetts et al., 1999). DNA breaks induced by camptothecin induce ATR 
which in turn phosphorylates H2AX, an event required to recruit DNA repair proteins Mre11, 
Rad50 and NSB1 (MRN) (Furuta et al., 2003). As the DSB response can be generated by 
replication of damaged DNA, when leading strand DNA polymerase encounters single strand 
nicks, it leads to activation of both ATM-Chk2 and ATR-Chk1 pathway. Thus, the effects of 
ATM and of ATR are not mutually exclusive, especially when cells are exposed to genotoxic 
stress, inducing ionizing radiation and most of the cytotoxic chemotherapy agents. 
 DNA damage induces cell cycle delays or arrest at the G1/S and G2/M transitions (the G1 
and G2 checkpoints), and also causes a transient decrease in the rate of DNA synthesis (the intra-
S checkpoint). All these cell cycle delays are dependent on and carried out by different proteins 
including p53, although it has been suggested that ATM and ATR have overlapping targets. 
 
3.2 FOCUS OF THIS CHAPTER 
In this chapter, I investigate the differential dependence of two AMPK activators on p53 in the 
mechanisms whereby they inhibit mTORC1.  Surprisingly, while comparing these AMPK 
activators, AICAR and PTX, we found that even after the similar initiation mechanism of AMPK 
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activation (ZMP accumulation), some of the downstream signaling differs between the two 
compounds, while some remains the same. We showed that whereas PTX-activated AMPK is a 
p53 and thus TSC2-independent inhibitor of mTORC1, AICAR-activated AMPK leads to the 
activation of TSC2 and thus suggests the involvement of TSC2 in the AICAR mediated 
inhibition of mTORC1.  It is also shown that this difference is due to the differences in p53 
transcriptional activity following treatment with these drugs.  AICAR causes an increase in the 
levels of transcriptionally active p53, thus, allowing the p53 dependent increase of TSC2 and 
sestrin2 levels, followed by AMPK-mediated (Sestrin2 is required for AMPK mediated 
phosphorylation of TSC2 at Ser1387 (Gwinn et al., 2008; R. J. Shaw et al., 2004) activation and 
phosphorylation of TSC2. On the other hand, p53 accumulating after PTX is transcriptionally 
compromised.  Even under the conditions of limited TSC2 function and hyperactive mTORC1, 
PTX is effective and sufficient for inhibition of mTORC1 activity.  This is due to the p53-
independent, AMPK-mediated phosphorylation of S792 Raptor by PTX, which is shown to be 
necessary and sufficient for mTORC1 inhibition. 
 In order to understand the underlying mechanism of differential behavior of p53 under 
these two AMPK activators, we compared these effects of these AMPK activators with those 
coming on after treatment with the control DNA damaging agent, etoposide (VP16). We found 
very interesting differences and similarities in the posttranslational modifications of p53 under 
these treatments. We also observed the differences of the ATM/ATR mediated Chk2/ Chk1 
activation which may explain the differences in the p53 transcriptional activity under these drug 
treatments. 
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3.3 RESULTS 
3.3.1 Overactive mTORC1 in p53 null cells is suppressed by PTX.  
HCT116 p53 +/+ and p53-/- cells were treated with PTX in the presence of TdR in order to 
circumvent the effect of PTX on thymidylate synthase and restrict its effects to AMPK activation 
and downstream mTORC1 signaling. Phosphorylation of the downstream targets of mTORC1 
was suppressed in both HCT116 cells and their isogenic p53-null derivative after PTX treatment, 
in response to activation of AMPK (Fig. 3-4). PTX activates AMPK to the same extent in both 
p53+/+ and p53-/- HCT116 cells as determined by assessing phosphorylation using p-
Thr172AMPK antibodies (Fig 3-6). The phosphorylation of T389 on S6K1 was diminished by 
PTX treatment in both HCT116 p53 (+/+) and (-/-) cell lines  (Fig. 3-4). An immunoblot with 
phosphospecific antibody against 4EBP1 phosphoT70 indicates equivalent levels of suppression 
of mTORC1 activity following PTX treatment of HCT 1116 cells with and without p53 function 
(Fig 3-4).  4EBP1 detected with a pan-antibody showed multiple and much lighter bands in 
untreated p53 null cells in comparison to wt p53 cells (Chapter 2-Fig. 2-5, Fig. 3-4) and (Holz, 
Ballif, Gygi, & Blenis, 2005) and these bands shifted towards lower phosphorylation state after 
PTX treatment in both p53 -/- and p53 +/+ cells. Using RT-qPCR, it was also noted that the level 
of 4-EBP1 mRNA was significantly lower in cells null for p53 than in wild-type cells (Fig. 2-
5B).  Overall, it appears that PTX can inhibit mTORC1 activity independent of p53 status at the 
level of both of its substrates, S6K1 and 4EBP1(Fig. 3-4).   The effect of PTX on 4EBP1 binding 
to capped mRNAs was assessed using the 7mGTP bead pull down assay; the results of these 
experiments suggested that the levels of 4EBP1 bound to 7mGTP beads are increased 
substantially after PTX treatment, independent of p53 status (Fig. 3-5), but that the amount of 4-
EBP1 accumulating in p53 null cells on capped RNA is decreased when p53 is lost.   
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Nevertheless, treatment with PTX inhibits mTORC1 in a p53-independent manner, preserving 
levels of hypophosphorylated 4EBP1 and prolonging the integrity of 4EBP1-elF4E complexes. 
As hypophosphorylated species are the active inhibitor of cap-dependent translation initiation 
and are not targeted by the proteasome, the binding of this species of 4EBP1 increased on 
7mGTP beads, which mimic the 7mGTP cap of mRNA (Fig 3-5).  Once again, the levels of 
4EBP1 bound to beads in lysates from TdR-treated p53 WT cells is quite a bit higher than that 
from TdR-treated p53 null cells, as shown previously in untreated p53 isogenic HCT 116 
(Chapter 2-Fig. 2-5A). Overall, the effects of PTX on S6K1 phosphorylation are strong but the 
effects on 4EBP1 seemed to be more extensive and are probably a greater contributing factor for 
inhibition of mTORC1 signaling to cap-dependent protein synthesis initiation, in agreement with 
experiments previously performed by Scott Rothbart in this laboratory (Rothbart et al., 2010) . 
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Figure 3-4 Overactive mTORC1 in p53 null cells is suppressed by PTX.  
PTX activates AMPK in p53 null cells and can reduce mTORC1 activity 
in these cells. 
p53+/+ and p53-/- HCT116 cells were treated with 1 µM PTX + TdR for 24 
hrs. AMPK activation and phosphorylation of S6K1 and 4EBP1 were 
assessed by immunoblotting 
 169 
 
 
 
 
 
 
 
 
 
4EBP1 
eIF4E 
p53 +/+#############+/+#########$/$#########$/$#
P-T389-S6K1 
S6K1 
4EBP1 
P-T-704EBP1 
Actin 
7m
GT
P#
pu
ll 
do
w
n 
Ly
sa
te
 
4EBP1 
eIF4E 
p53 +/+#############+/+#########$/$#########$/$#
P-T389-S6K1 
S6K1 
4EBP1 
P-T-704EBP1 
Actin 
7m
GT
P"
pu
lld
ow
n"
Ly
sa
te
"
Figure 3-2. PTX mediated increase in the 4EBP1 binding to 
7mGTP beads is p53 status independent.   
 HCT116 wt and p53 null cells were treated with 1 µM PTX + TdR 
for 24 hrs. m7GTP pull down was performed using sepharose beads 
bound to m7GTP mimicking mRNA. Pulldowns were 
immunoblotted to analyze the levels of bound 4EBP1 to the beads. 
Lysates were probed to analyze the phosphorylation of S6K1 and 
4EBP1. 
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3.3.2 Unlike AICAR, PTX treatment does not lead to activation of TSC2 by 
phosphorylation at Ser1387  
AMPK is thought to negatively affect mTORC1 by two signals: activation of TSC2 GAP activity 
following phosphorylation of TSC2 S1387 (Garami et al., 2003; Sato, Nakashima, Guo, & 
Tamanoi, 2009; Tee, Manning, Roux, Cantley, & Blenis, 2003) and direct inhibition of 
mTORC1 kinase by phosphorylation of Raptor at S792 (Gwinn et al., 2008). These events were 
monitored after PTX-  or AICAR treatment of HCT116 cells.  The phosphorylation of AMPK at 
T172 in either p53 WT or null HCT116 cells was equivalent after either PTX or AICAR and was 
not p53-dependent (Fig 3-6). The AMPK-dependent phosphorylation of TSC2 at S1387 was seen 
in HCT116 cells with WT p53 after AICAR treatment (Fig. 3-7A), but not after PTX plus 
thymidine (Fig. 3-7B). In fact, the phosphorylation of S1387 of TSC2 was diminished in PTX-
treated wt HCT116 cells, and the p-S1387 immunoblot had to be exposed longer to detect any 
signal. The level of p-S1387 TSC2 in treated cells was clearly dependent on p53 function: 
neither TSC2 nor p-S1387 TSC2 was easily detected in AICAR- or PTX-treated p53 -/- HCT116 
(Fig. 3-7A,B).  There was an increased expression of TSC2 in AICAR-treated p53-wt cells (Fig. 
3-7A), which was not seen in p53 wt cells treated with PTX (Fig. 3-7B); this effect proved to be 
due to differences in p53 transactivation after these drugs (discussed below). We drew the 
conclusion that there was a defect in AMPK signaling to TSC2 in p53-null cells and PTX treated 
cells due to a deficiency of TSC2.  In contrast, robust inhibitory phosphorylation of Raptor was 
observed after either AICAR or PTX and was unaffected by deletion of p53 in HCT116 cells 
(Fig. 3-7). We observed some interesting effects in these experiments, which raised some 
intriguing questions; 1) why does PTX-activated AMPK not phosphorylate TSC2, 2) why does 
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PTX not cause an increase in TSC2 protein levels when TSC2 is clearly a target of p53 (Fig. 2-
18 to 22, and Fig. 3-7B), and 3) How is PTX-mediated inhibition of mTORC1 independent of 
TSC2 activation? Our later studies suggested that the answers to questions 1 and 2 are related, as 
discussed below. 
3.3.3 p53 stabilized by PTX is transcriptionally compromised 
As shown previously (Z. Feng et al., 2007) Chapter 2, Fig 2-18 to 22), TSC2 is a transcription 
target of p53.  When we observed that the levels of TSC2 increased in wt p53 HCT116 cells after 
AICAR treatment but not after PTX treatment and that p53 null cells have lower levels of TSC2, 
the levels of p53 and its stabilization by AMPK activators were studied.  In order to understand 
the difference of effects of two AMPK activators on p53, the accumulation of p53 was examined 
in HCT116 cells exposed to either PTX in the presence of thymidine or AICAR and these levels 
were compared with those in cells treated with VP16, a widely used topoisomerase II inhibitor 
known to damage DNA.  PTX or AICAR caused the accumulation of p53 in HCT116 cells that 
was similar to that seen in VP16 (Fig 3-8), although the levels of p53 in PTX-treated cells were 
usually somewhat lower that in AICAR or VP16.  Likewise, AICAR caused a robust 
enhancement of the level of several proteins whose genes were known to be p53 transcriptional 
targets (Budanov et al., 0923; Z. Feng et al., 2007; Riley et al., 2008), namely p21, sestrin 2, 
human mdm-2, and Bax (Fig. 3-8), and TSC2 (Fig. 3-7A), in a pattern identical to that seen after 
DNA damage. Very surprisingly, the level of these proteins did not change in cells treated with 
PTX (Figs 3-8, 3-7B respectively).  RT-qPCR studies indicated that the steady-state levels of 
mRNA for these genes reflected the protein levels seen after each drug; i.e., VP16 and AICAR 
augmented the levels of p21, Sestrin 2, and TSC2.  The steady state levels of human MDM2, 
PUMA, PIG3, BAX, well known transcriptional targets of p53 mRNAs also showed a modest to 
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substantial increase after VP16 and AICAR but there was no change in the mRNA for these p53 
target genes after PTX (Fig 3-9).  Thus, the transcriptional response of the p53 that accumulated 
in PTX-treated cells, was severely compromised.  Budanov et. al have shown that Sestrin2 
promotes the AMPK-mediated activation and phosphorylation of TSC2 at Ser1387.  Because 
PTX-activated AMPK does not phosphorylate TSC2 at Ser1387 , it seemed that levels of TSC2 
and Sestrin2 were not sufficient for AMPK-mediated phosphorylation of TSC2. 
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Figure 3-3. PTX and AICAR mediated AMPK activation is p53 
status independent.   
PTX and AICAR both activate AMPK in cells with and without p53 to the 
same extent. p53+/+ and p53-/- HCT116 cells were treated with 1 µM PTX 
+ TdR for 24 hrs or with 250 µM AICAR . AMPK activation was assessed 
by immunoblotting using antibody against P-ser172 AMPK, where ND= no 
drug treatment. 
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Figure 3-4. PTX and AICAR mediated AMPK leads to differential signaling 
downstream of AMPK.   
 PTX and AICAR both activate AMPK in cells with and without p53 to the same extent.  
p53+/+ and p53-/- HCT116 cells were treated with (A)1 µM PTX + TdR (B) 250 µM 
AICAR for 24 hrs. AMPK mediated phosphorylation of TSC2 and Raptor was detected 
by using anti- P-ser1387 TSC2 and P-ser792 Raptor antibodies by immunoblotting. 
Total TSC2 and Raptor were also detected. 
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Figure 3-5. PTX causes accumulation of p53 but does not activate p53-
dependent transcription. 
 Wild-type HCT116 cells were treated with VP16, DMSO, or TdR, or 
PTX + TdR, or AICAR (500 µM) for 24 hrs. Cell lysates were probed 
for p53 and its transcriptional targets p21, Sestrin2, HDM2, and BAX by 
immunoblot. PTX causes accumulation of p53 but does not activate p53-
dependent transcription. 
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Figure 3-6. PTX stabilized p53 does not activate transcription of its target 
genes.  
 Wild-type HCT116 cells were treated with VP16, DMSO, or TdR, or PTX + 
TdR, or AICAR (500 µM) for 24 hrs. Total cell RNA was harvested followed by 
cDNA synthesis and q-RT PCR to analyze steady state levels of mRNAs of p53 
transcription targets; p21, HDM2, PUMA, PIG3, BAX, TSC2 and Sestrin2. 
Three independent biological repeats combined and expressed (±sd) and P 
values <.0001.   
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3.3.4 PTX effects on mTORC1 are TSC2 and Sestrin2 independent.   
TSC2 and Sestrin2 are two genes involved in the negative regulation of mTORC1 that are p53 
transcription targets (Budanov et al., 0923; Z. Feng et al., 2007) chapter 2). As shown in Fig. 3-
7B, after PTX treatment p53 transcriptional activity is compromised, an effect that mutes TSC2-
mediated inhibition of mTORC1.   We addressed if PTX effects were dependent on TSC2 and 
sestrin2 levels.  First,  p53-/- MEFs and p53-/-, TSC2 -/- MEFs were treated with PTX and 
mTORC1 signaling was observed at the level of pThr389 S6K in order to assess the effect of 
deletion of TSC2.  mTORC1 activity was equally inhibited after PTX treatment in MEFs 
whether or not they expressed TSC2, in spite of the fact that TSC2-/- MEFs showed higher 
mTORC1 activity than TSC2 WT MEFs (Fig. 3-10A).   In related experiments, the effects of 
PTX were compared in MEFs from WT or Sestrin 2 -/- mice; PTX mediated inhibition of 
mTORC1 was unaffected by the genetic loss of Sestrin2 (Fig. 3-10B), again, in spite of the fact 
that mTORC1 activity was higher in cells that had lost Sestrin 2 function.  Because genetic 
deletion of TSC2 is a lethal event unless done in a background of p53-/- mice, the above 
experiments only allowed test of the effects of loss of TSC2 in a p53 null background.  Hence, 
we depleted TSC2 in p53 wild type HCT116 cells with pools of siRNA to isolate the effect of 
TSC2 loss itself from the loss of p53.   Untreated HCT116 cells in which TSC2 was depleted 
with siRNA had a substantial increment in mTORC1 activity as seen from the increased 
phosphorylation of S6K1 and 4EBP1 (Fig. 3-11).  Nevertheless, the hyperactive mTORC1 in p53 
wt HCT116 cells with siRNA-depleted TSC2 was suppressed by PTX (Fig. 3-11), as was also 
seen in p53-null HCT116 cells (Fig 3-4), TSC2 null MEFs in a p53 null background (Fig. 3-
10A,), and Sestrin2-null MEFs (Fig. 3-10B).  We concluded that enhanced activity of mTORC1 
in p53 null cells is caused by the p53 dependence of transcription of TSC2 and Sestrin2 (Chapter 
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2), but that PTX controlled mTORC1 even in cells null for TSC2, Sestrin 2 or p53 function.  
3.3.5 PTX effects on cell growth are not affected by p53 or TSC2 loss, AICAR effects are. 
WT HCT116 cells and their p53-null derivative were treated with PTX in the presence of 
thymidine to determine whether p53 loss altered growth suppression by activated AMPK.  These 
experiments were also done in the absence of thymidine to determine the effect of p53 on PTX 
activity against thymidylate synthase and activation of AMPK, conditions germane for clinical 
use of this drug. There was no difference in the response to PTX between the p53 wild type and -
/- HCT116 cell lines under either condition (Fig. 3-12A), although a decrease in sensitivity in the 
presence of thymidine was observed, as expected from previous experiments in this laboratory 
(Rothbart et al., 2010). This would concur with the observation that PTX treatment in the 
presence (Fig 3-8) or absence of thymidine (see below) did not activate the transcriptional 
program of p53.  In contrast, HCT116 cells wt for p53 function were more sensitive to AICAR 
than HCT116 null for p53 (Fig. 3-12B), in accord with the fact that p53 increased leves of TSC2 
in AICAR-treated cells, while PTX did not (Fig. 3-7).  Nearly identical results were found using 
MEFs with and without p53 and TSC2 function (Fig. 3-12 C,D). These observations suggested 
that PTX mediated inhibition of mTORC1 was independent of p53 and TSC2 function, and this 
fact was evident even at the level of cell growth. We concluded that suppression of growth by 
AICAR in carcinoma cells would be muted by loss of p53, but that the loss of p53 or TCS2 
would be without effect on therapeutics with PTX. 
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Figure 3-7. Overactive mTORC1 in p53 null cells is suppressed by PTX, 
independent of TSC2 and Sestrin2. 
PTX decreases mTORC1 signaling in cells lacking p53 and TSC2, as well 
as in cells lacking Sestrin2. TSC2+/+ and -/- MEFs, and Sestrin2+/+ and -
/- MEFs were treated with PTX + TdR for 24 hrs and p-T389 S6K1 
evaluated by immunoblot.  
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Figure 3-8. PTX inhibits enhanced mTORC1 activity after TSC2 
transient knock down. 
 PTX controls mTORC1 activity in cells after TSC2 silencing. WT HCT116 
cells were transfected with siRNA against TSC2 for 36 hrs, then were 
treated with PTX + TdR for 24 hrs; p-T389 S6K1 and p-T70 4EBP1 were 
determined by immunoblot. 
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Figure 3-9. Growth inhibition by PTX was not affected by loss of p53 or TSC2. 
(A) The presence of p53 does not influence cell proliferation after PTX 
treatment. 
Wt HCT116 (filled symbols) and p53-/- (open symbols) cells were treated with 
PTX alone (circles) or PTX + TdR (inverted triangles) for 72 hrs before cells were 
harvested and counted using a Coulter counter. (B) HCT116 cells with wt p53 
show higher sensitivity to AICAR than HCT116 cells null for p53. HCT116 
p53+/+ and p53-/- cells were treated with AICAR for 72 hrs and final cell numbers 
were determined as in (A). In (A) and (B), each symbol is the mean ± sd of three 
experiments, each of which was performed in duplicate.  (C) PTX attenuates the 
growth of wt MEFs and MEFs lacking p53 and/or TSC2 equally. The growth of 
MEFs null for p53 (open circles) or null for both p53 and TSC2 (filled inverted 
triangles) were compared with that of wild type MEFs (filled circles) after 72 hrs 
exposure to increasing concentrations of PTX with thymidine. (D) MEFs lacking 
TSC2 and/or p53 are less sensitive to AICAR. MEFS were treated with increasing 
concentrations AICAR for 72 hr as in (C).  The studies on growth inhibition in 
HCT116 cells were performed by Richard Moran. 
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3.3.6 Phosphorylation of Raptor is necessary and sufficient for suppression of mTORC1 
in PTX-treated HCT116 cells.   
Shaw and his colleagues have previously demonstrated that AMPK can regulate mTORC1 by the 
phosphorylation of Raptor as well as the control by phosphorylation of TSC2 that was 
discovered earlier (R. J. Shaw & Cantley, 2006; R. J. Shaw et al., 2004).  Our data suggest that 
PTX activated AMPK mediated inhibition of mTORC1 is TSC2 independent, which suggested 
that phosphorylation of Raptor at Ser 792 by AMPK might be the affecting factor. To test 
whether the phosphorylation of Raptor by AMPK was involved in and sufficient to suppress 
mTORC1 kinase activity in the absence of TSC2 function, p53-/- TSC2 -/- MEFs were 
transfected with a vector encoding wild type human Raptor or a construct for Raptor in which the 
two serines phosphorylated by AMPK were mutated to alanines (AA Raptor, (R. J. Shaw et al., 
2004).  The vectors carrying WT or AA Raptor resulted in expression of recombinant Raptor in 
substantial excess over endogenous Raptor (Fig. 3-13).  Raptor was phosphorylated at S792 in 
vector transfected cells after PTX and even more so in PTX-treated cells transfected with WT 
Raptor, but cells transfected with AA Raptor and treated with PTX showed a strong suppression 
of pS792 Raptor.  We drew the conclusion that the Raptor made from transfected Raptor vectors 
was competing with endogenous Raptor for binding to mTORC1 complexes.  Treatment of 
MEFs transfected with empty vector or WT Raptor with PTX resulted in suppression of 
mTORC1 kinase activity as seen by lower levels of phosphorylation of S6K1 at S389 and of 
4EBP1 by phosphorylation at T70.  However, neither of these phosphorylation events was 
suppressed in AA Raptor-transfected cells after treatment with PTX (Fig 3-13).  Similar 
dominance of Raptor phosphorylation was observed when p53 competent and p53 null HCT116 
cells were transiently transfected with either empty vector, or vector containing WT or AA raptor 
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(Fig 3-14).  Both cell types when transfected with AA raptor followed by PTX treatment showed 
no decrease in P-Thr398 S6K1 suggesting no inhibition of mTORC1 in the absence of raptor 
phosphorylation (Fig. 3-14). Hence, we concluded that, as in MEFs lacking TSC2, in HCT116 
cells the suppression of mTORC1 following PTX was mediated by phosphorylation of Raptor by 
AMPK and that, in cells in which endogenous Raptor in mTORC1 complexes was replaced by a 
mutant Raptor incapable of AMPK mediated phosphorylation, mTORC1 suppression after PTX 
treatment did not occur. 
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TSC2-/- p53-/- MEFs were transfected for 36 hrs with pBABE-Hygro containing WT or AA 
Raptor, then treated with PTX + TdR for 24 hrs. Phosphorylation of S6K1 and 4EBP1 were used 
as indices of mTORC1 activity 
 
 
 
 
 
 
Figure 3-13. Phosphorylation of Raptor is necessary and sufficient for suppression of mTORC1 in 
PTX treated cells. 
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 WT and p53 null HCT116 cells were transfected for 36 hrs with pBABE-Hygro containing WT 
or AA Raptor, then treated with PTX + TdR for 24 hrs. Phosphorylation of S6K1 and 4EBP1 
were used as indices of mTORC1 activity 
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Figure 3-14. Phosphorylation of Raptor is necessary and sufficient for suppression of 
mTORC1 in PTX treated HCT116 cells. 
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3.3.7 AICAR mediated inhibition of mTORC1 is TSC2 dependent 
AMPK activated by both AICAR and PTX leads to the phosphorylation of Raptor. As shown in 
Fig. 3-7A, phosphorylation of Raptor is necessary and sufficient for inhibition of mTORC1in 
HCT116 cells and in MEFs treated with PTX.  Hence, one would think that in TSC2 null cells, 
AICAR mediated phosphorylation of raptor might also be sufficient for the inhibition of cell 
growth.  Contrary to this idea, AICAR mediated inhibition of cell growth is decreased by the loss 
of p53 or of TSC2 and p53 (Fig. 3-12B,D).  Thus, we compared PTX- and AICAR-activated 
AMPK mediated phosphorylation of Raptor and TSC2.  WT HCT116 cells were treated with 
PTX in the presence of TdR or with AICAR (Fig. 3-15).  The levels of p-Thr172 AMPK were 
equivalent under both the treatments.  However, PTX-activated AMPK mediated 
phosphorylation of Raptor to a greater extent than did AICAR treatment at the doses used in 
these experiments (Fig. 3-15).  As previously seen (Fig 3-7A), the level of phosphorylated TSC2 
as well as total TSC2 increased under 250 µM AICAR treatment.  This suggest that when TSC2 
GAP activity is deficient in p53 null or TSC2 null cells, AICAR is less growth inhibitory due to 
a weaker phosphorylation of Raptor and its dependence on TSC2 mediated inhibition of 
mTORC1 (Fig. 3-12B,D) and equivalent growth inhibition may require a higher dose of AICAR 
in absence of p53.   In cells competent for p53 function, AICAR causes both Raptor 
phosphorylation and TSC2 phosphorylation, and growth inhibition was more intense.  On the 
other hand, PTX-activated AMPK only phosphorylates Raptor due to the deficit of TSC2 
subsequent to the inactivity of p53 transcription caused by PTX, so that there is no difference in 
potency in p53 WT or null cells (Fig. 3-12A,C).  In order to probe the degree to which inhibition 
of mTORC1 depends on activation of TSC2, the effect of deletion of TSC2 on the inhibition of 
mTORC1 by AICAR was studied in p53-/- TSC2-/- MEFs.  p53-/- TSC2+/+ MEFs showed 
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almost equivalent inhibition of mTORC1 by PTX as did p53 -/- TSC2 -/- MEFs, while AICAR 
was substantially less effective in p53-/- TSC2-/- MEFs (Fig. 3-16).  This supported the concept 
that AICAR-activated AMPK activates TSC2 GAP activity as well as directly inhibiting Raptor 
function to inhibit mTORC1 but PTX relies only on phosphorylation of Raptor.   
 Hence, while one would predict that AICAR would be more active against p53 WT 
tumors, it would substantially lose activity against p53 null tumors, and probably also tumors 
bearing DNA binding domain p53 mutations (Chapter 2) and would be substantially less active 
against tumors that had lost TSC2 function, such as tuberous sclerosis syndrome.  On the other 
hand, PTX would not be affected by loss of p53, nor by loss of TSC2 and should retain activity 
against tumors with these genotypes.  
 
3.3.8 Schema of differential signaling to mTORC1 by PTX- and AICAR-activated AMPK 
AICAR activates AMPK via ZMP while also causing the accumulation of a transcriptionally 
active p53, promoting the transcription of both Sestrin2 and TSC2. Consequently, AMPK-
catalyzed phosphorylation of Raptor and TSC2 occurs and mTORC1 is inhibited (Fig. 3-17, 
right). PTX, likewise, causes activation of AMPK via ZMP, but subsequent p53-dependent 
transcription is defective. As a result, Sestrin2 and TSC2 levels are diminished and AMPK 
cannot activate TSC2. Nevertheless, PTX-activated AMPK causes a robust phosphorylation of 
Raptor sufficient to inhibit mTORC1 kinase (Fig. 3-17, left).  
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p53+/+ HCT116 cells were treated with 1 µM PTX + TdR or 250 dRls wer for 24 hrs. AMPK 
activation assessed by immunoblotting using antibody against P-ser172 AMPK. Phosphorylation 
of Raptor and TSC2 was assessed by immunoblotting using antibodies against P-ser792 Raptor 
and P-Ser1387 TSC2 respectively.  
7 
  AMPK 
P-S792 Raptor 
 Raptor 
P-T172 AMPK 
5 a. 
7 
  AMPK 
P-S1387 TSC2 
P-
T389P70S6
K1 
P-S792 Raptor 
TSC2 
S6
K1 
 Raptor 
P-T172 AMPK 
5 a. 
7 
  AMPK 
P-S1387 TSC2 
P-
T389P70S6
K1 
P-S792 Raptor 
TSC2 
S6
K1 
 Raptor 
P-T172 AMPK 
5 a. 
 P-ser1387 TSC2 
 TSC2 
7 
  AMPK 
P-S792 Raptor 
 Raptor 
P-T172 AMPK 
5 a. 
7 
  AMPK 
P-S1387 TSC2 
P-
T389P70S6
K1 
P-S792 Raptor 
TSC2 
S6
K1 
 Raptor 
P-T172 AMPK 
5 a. 
7 
  AMPK 
P-S1387 TSC2 
P-
T389P70S6
K1 
P-S792 Raptor 
TSC2 
S6
K1 
 Raptor 
P-T172 AMPK 
5 a. 
 P-ser1387 TSC2 
 TSC2 
Figure 3-15. Differential effects of PTX and AICAR, downstream to activated AMPK 
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p53-/- TSC2+/+ and p53-/- TSC2-/- cells were treated with 1 C2-/-ptor AI or 250 ere trea for 24 
hrs. S6K phosphorylation was assessed by immunoblotting using antibody against P-T389 S6K1 
as an indicator of mTORC1 activation.   
P-T389 S6K1 
 S6K1 
P53-/- TSC2+/+ 
 MEFs 
P53-/- TSC2-/-  
MEFs 
 β-actin 
Figure 3-16 AICAR mediated inhibition of mTORC1 is TSC2 dependent 
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(right) AICAR activates AMPK via ZMP while also causing the accumulation of a 
.transcriptionally active p53, promoting the transcription of both Sestrin2 and TSC2. 
Consequently, AMPK-catalyzed phosphorylation of Raptor and TSC2 occurs and mTORC1 is 
inhibited. (left) PTX, likewise, causes activation of AMPK via ZMP, but subsequent p53-
dependent transcription is defective. As a result, Sestrin2 and TSC2 levels are diminished and 
AMPK cannot activate TSC2. Nevertheless, PTX-activated AMPK causes a robust 
phosphorylation of Raptor sufficient to inhibit mTORC1 kinase 
 
 
 
 
 
 
 
 
Fig.4"
B
Fig 5
Fig 6
Figure 3-17. Proposed model for the differential effects of PTX and AICAR 
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3.3.9 Post-translational modifications of p53 following AMPK activation 
Earlier sections of this thesis have shown that PTX stabilized p53 is transcriptionally inactive.   
In order to reveal the cause of this phenomenon, we studied the post translational modifications 
of the p53 under these treatments.  The post-translational modifications of the p53 accumulating 
in PTX-treated HCT116 cells were compared to those after AICAR or VP16.  To assure that the 
PTM-specific blots in these experiments reflected the stoichiometry of modification rather than 
the level of p53, we first estimated the relative levels of p53 in control cells and cells after each 
drug treatment, then loaded different volumes of lysates onto a gel to achieve equivalent loading 
of p53.  There were striking differences in the post-translational modification profiles of p53 
after treatment with VP16 or either of the two AMPK-activating drugs (Fig. 3-18A):  after VP16 
treatment, p53 was modified at a number of residues that reflect the molecular events of the 
DNA-damage response (Appella & Anderson, 2001; Siliciano et al., 1997), including N-terminal 
acetylation at K373 and K382, and C-terminal phosphorylation at S20, S37, and S46.  None of 
these post-translational modifications was observed with either activator of AMPK, PTX or 
AICAR.  Like VP16, both AICAR and PTX induced phosphorylation of p53 at S392.  The sole 
modification observed that distinguished the transcriptionally inactive p53 in PTX-treated cells 
from the transcriptionally active p53 in AICAR (and VP16) was phospho-S15, a modification 
previously found essential for transcriptional response to p53 (Fig. 3-18A) (R. G. Jones et al., 
2005b; Siliciano et al., 1997).   
3.3.10 Differential activation of Chk1 and Chk2 by AMPK activators 
In order to understand the cause of the differences in the posttranslational modifications of p53 
observed after, VP16, AICAR or PTX treatment, we studied the activation of the central effector 
kinases ATM/ATR by studying the phosphorylation of their downstream targets Chk2 and Chk1, 
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respectively.  The phosphorylation of Chk1 did not occur after either AMPK activators, AICAR 
or PTX, but was robust after DNA damage induced by VP16 (Fig. 3-18B). This difference in 
phosphorylation of Chk1 might be the underlying explanation of the differences in the 
posttranslational modifications of p53 between AICAR and VP16 such as Ser S20, S37, and S46 
and acetylation at K373 and K382.  However, phosphorylation of Chk2 was observed in both 
treatments associated with p53 transcriptional activation, DNA damage by VP16 and AMPK 
activation by AICAR, but not following PTX (with thymidine)(Fig 3-18B). Hence, it would 
appear that the p53-dependent transcription following activation of AMPK by AICAR is 
associated with phosphorylation of Chk2 and subsequent phosphorylation of p53 serine 15, 
probably by Chk2  (Chehab et al., 2000; Oliver et al., 2006; Shieh, Ahn, Tamai, Taya, & Prives, 
2000b) while PTX neither activates phosphorylation of Chk2 and p53 serine 15 nor p53-
dependent transcription.  This in turn would suggest that ATM is activated by AICAR treatment 
of HCT116 cells, as well as treatment with VP16.   
3.3.11 Stabilization and phosphorylation of p53 at ser15 are ATM mediated.  
p53 wt HCT116 cells, when pretreated with a specific inhibitor of ATM, Ku-60019, for 2 hrs 
followed by treatment with either VP16, PTX + TdR, PTX, or AICAR showed decreases in the 
p53 levels stabilized by these drugs; the levels of ser-15 phosphorylation of p53 was remarkably 
decreased (Fig. 3-19), strongly implying that ATM was essential for S15 phosphorylation of p53. 
Decrease in the levels of P-T68 Chk2 was also seen, an indicator of ATM inhibition by Ku-
60019.  This suggested that although there are several perplexing differences in the effects of 
these drugs on p53 and p53 activating pathway, they all directly or indirectly activate ATM and 
leading to ATM mediated stabilization of p53. As PTX in the presence of thymidine stabilizes 
p53 but does not show increases in the levels of p53 pS15, this suggested that although PTX 
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stabilizes p53 in an ATM dependent manner, the cause of activation of ATM might be different 
and thus leading to a different signaling than seen with VP16 or AICAR, as noted by the absence 
of pS15 p53, pser345 Chk2, pT68 Chk2 and pS139 H2A.X.  This suggests that in the absence of 
DNA damage, p53 is transcriptionally inactive. 
However, PTX in the absence of thymidine, causes DNA damage, leads to ATM dependent 
increase in the levels of p53, pSer15 p53, pser345 Chk1 but it does not phosphorylate Chk2 at 
Thr68.  This indicates that although PTX causes DNA damage and activates ATM, but 
presumably due to some mechanistic differences in activation of ATM is leading to a differential 
signaling downstream from ATM to p53 transcriptional activation and leaving p53 
transcriptionally compromised. We propose that this mechanistic difference in actvation of ATM 
could be due to difference in type and extent of genotoxic stress or DNA damage like DSBs vs 
SSBs or replication halt. 
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Figure 3-18. Differential p53 post translation modification and Chk1 and Chk2 
phosphorylation following AMPK activation. 
P53 +/+ HCT116 cells were left untreated or treated with 20 µ5 VP16, or 1 µV PTX + TdR 
or 500 µP AICAR for 24 hrs. (A) Cells were harvested and lysates were probed to assess the 
levels of p53 under each treatment followed by densitometry to find p53 levels to calculate 
the amount of protein need to be loaded to get equal levels of p53 loading. After loading 
protein so that levels of p53 are equal, blots were probed for different posttranslational 
modifications commonly known and correlated with p53 activation. (B) Equal amount of 
protein loaded to assess the levels of phosphorylation of Chk1 and Chk2 by using antibodies 
against P-ser345 Chk1 and P-T68 Chk2 
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Figure 3-19. Pretreatment with ATM inhibitor Ku-60019 decreases levels of p53, P-serp53 
and P-Thr68 Chk2 in all treatments. 
p53 competent HCT116 cells were treated  with Ku-60019 for 2hrs or left untreated followed by 
treatment either with VP16, AICAR or PTX with or without TdR. Lysates were probed for the 
assessment of p53, P-ser15 p53, PThr68 Chk2 and Chk2 using corresponding antibodies. 
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3.3.12 Binding of p53 and presence of Acetyl Histone 4 at p21 promoter is equivalent after 
PTX or AICAR treatment 
As p53 accumulated after PTX treatment was not activating the transcription of its target genes, 
we decided to analyze whether this p53 was binding to the promoter of p21. We performed 
Chromatin Immunoprecipitation (ChIP) studies using α-p53 antibody to measure the relative  
occupancy of p53 at p21 promoter.  We found that the levels of p53 bound to p21 promoter after 
VP16 treatment increased several fold.  Although the levels of p53 bound to the p21 promoter 
after PTX treatment were lower than after VP16, they were equivalant to that after AICAR 
treatment, which were sufficient to transcriptionally activate p21 (Fig. 3-20, blue bars).  The 
presence of p53 at the p21 promoter without transactivating transcription.   It led us to question 
the next step required for promoter accessibility by the transcriptional machenary, namely the 
recruitment of histone acetylases (HATs) to histones in the vicinity of the promoter, creating a 
euchromatin structure.  We performed ChIP using acetyl-histone H4 to analyze the presence of  
acetylated hostones at the promoter region of the p21 gene, an indicator of euchromatin form of 
gene.  The levels of acetylated histone 4 occupancy at p21 were increased after VP16, PTX and 
AICAR treatment (Fig. 3-20, green bars).  As expected this increase was higher under VP16 
treatment in comparision to that after AICAR and PTX treatment, which were equivalent (Fig. 3-
20, green bars).  This suggested that binding of p53 or recruitment of HATs at p21 promoter 
were not the limitng factors for p53 transcriptional activity under PTX treatment (Fig. 3-20) and 
that, hence, the deficit in PTX was further downstream in the transcriptional response. 
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3.3.13 AICAR leads to a delayed DNA damage but PTX (with TdR) does not 
Because it seemed that AICAR and VP16 both activated ATM, but PTX did not, it was of 
interest to determine the generic question of whether the activation of AMPK resulted in DNA 
damage.   The initiation of DNA damage after AMPK activation was followed by observation of 
phosphorylation of histone H2A.X and comparison with the time course of DNA damage with 
VP16.  H2A.X phosphorylation was robustly induced by as little as 3 hours exposure to VP16 
and was maintained for at least 24 hr (Fig 3-21A).   This time course coincided with the 
occurrence of robust Chk2 phosphorylation and equally robust and sustained phosphorylation of 
p53 ser15, while Chk1 phosphorylation was more delayed in onset as was the accumulation of 
p21 after treatment with VP16.  Unlike the rapid time course of p53 S15 phosphorylation in 
VP16-treated cells, the phosphorylation of p53 S15 was a delayed event in AICAR-treated cells.   
Interestingly, and quite surprisingly, H2A.X phosphorylation was detected after AICAR 
treatment on a time scale coincident with Chk2 and p53 ser15 phosphorylation, and p21 
transcription (Fig 3-21A).  Notably, the phosphorylation of H2A.X, of Ser15 and of Chk2 were 
less pronounced after AICAR than after VP16, but they were easily measurable and appeared to 
explain the transcription of p21 in AICAR.  The time course of these events in cells treated with 
PTX and thymidine indicated no H2A.X phosphorylation, no Chk1/ Chk2 activation, no p53 ser 
15 phosphorylation and no p53-dependent transcription of the p21 gene at any time point studied 
(Fig. 3-21B).  We concluded that the difference between AICAR and PTX activation of AMPK 
reflected a relatively weak and late-occuring but quite noticeable DNA damage response 
coincident with Chk2 phosphorylation induced by AICAR, whereas this did not occur with PTX. 
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3.3.14 PTX-activation of AMPK does not result in the DNA damage response, but PTX 
inhibition of thymidylate synthase does.   
The transcriptional response of the p53 target gene p21 coincided in time with increased levels of 
pH2A.X, a common marker of DNA damage and/or replication halt, in AICAR-treated cells, 
while PTX (in the presence of TdR) mediated activation of AMPK did not lead to DNA damage.  
The primary target of PTX is thymidylate synthase, but the biochemical consequences of TS 
inhibition on growth are prevented by thymidine (Taylor et al., 1992). Thus in the absence of 
TdR, we can study the effect of PTX mediated thymidylate synthase inhibition as well as effects 
on AMPK activation.  We fully expected that the effects of PTX on thymidylate synthase would 
induce DNA damage leading to stabilization of a transcriptionally competent p53 and set up 
experiments to test whether this was the case.  Under these conditions, a robust phosphorylation 
of H2A.X was seen in HCT116 cells, indicating severe genotoxic stress (Fig 3-22).  
Interestingly, the DNA damage or replication arrest induced by PTX led to phosphorylation of 
Chk1 but Chk2 was not phosphorylated and, remarkably, p21 transcription still did not occur. 
This was completely unexpected, but suggested that phosphorylation of Chk2 is necessary for 
p53-mediated transcriptional activation of p21. Interestingly, an appreciable level of 
phosphorylation of p53 S15 was seen, but this did not translate to transcriptional activation of 
p21.  
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Figure 3-20 Chromatin immunoprecipitaion suggest equivalent binding of p53 and 
presence of acetylated histone 4 at p21 promoter after AICAR and PTX treatment. 
p53 +/+ HCT116 cells were left untreated or treated with 20µM VP16, or 1 µM PTX + 
TdR or 500 µM AICAR for 24 hrs. Cells were harvested and lysed followed by chromatin 
immunoprecipiattion using α-p53 or α-Acetyl-histone4 antibody. Precipiated DNA was 
used for realtime qPCR analysis to see the binding of p53 and acetylated-histone4, 
respectively. 
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Figure 3-21. AICAR leads to a delayed DNA damage but PTX (with TdR) does not. 
WT HCT116 cells were treated with VP16 (20 μM) AICAR (500AR  or PTX (1 μm + 
Tdr (5.6 μm)  for given time durations. Cells were harvested and lysates (A) from 
VP16 and AICAR (B) VP16 and PTX + Tdr, treated cells were probed for P-Ser345 
Chk1, Chk1, P-T68 Chk2, Chk2, P-S139 H2A.X, H2A.X, P-ser15p53 and p21 using 
corresponding antibodies 
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Fig. 3-22. PTX-activation of AMPK does not result in the DNA damage response, but PTX 
inhibition of thymidylate synthase does.  
Cells were either treated with VP16, PTX +/- TdR, AICAR or in combination of VP16 and PTX 
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+/- TdR or VP16 and PTX . Cells were harvested and lysates were probed for the assessment of 
p53, P-ser15 p53, p21, P-Ser139 H2A.X, H2A.X, P-Ser345 Chk1, P-T68 Chk2 using antibodies 
against corresponding residues. 
 
 
3.3.15 Blocking VP16 effects by pre-treatment with PTX.  
The initial phases of phosphorylation of H2A.X were seen after six hr exposure to VP16 and this 
exposure resulted in enhanced p21 transcription (Fig 3-23B).  When HCT116 cells were 
pretreated for 20 hours with PTX plus thymidine prior to exposure to VP16 (Experimental 
scheme Fig. 3-23A), remarkably, the DNA damage caused by VP16 was blocked, as was the 
phosphorylation of Chk1 and the transcription of p21 (Fig. 3-23B).  Chk2 phosphorylation was 
not blocked by pretreatment with PTX and thymidine, conditions that activate AMPK but do not 
inhibit thymidylate synthase.  Hence, activation of AMPK even with phosphorylation of Chk2 
and of S15 p53, was not sufficient for p53-dependent transactivation of p21 without DNA 
damage. 
  When thymidine was not added to PTX in the medium, so that the genotoxic stress 
subsequent to inhibition of thymidylate synthase occurred as well as activation of AMPK, 
extensive H2A.X phosphorylation was seen, Chk1 phosphorylation was observed, and Chk2 was 
not, but p21 transcription was not stimulated (Fig. 3-23B) as also seen before (Fig. 3-22).  When 
VP16 was added to cells pretreated for 20hrs with PTX alone, Chk1, Chk2 and ser15 p53 
phosphorylation was seen and but there was still no p21 transcription was observed. 
Interestingly, pretreatment with PTX (+ Tdr) blocks VP16 mediated DNA damage, suggesting 
that PTX mediated activation of AMPK blocks cells from undergoing the events needed for the 
development of DNA strand breaks after stabilization of Topoisomerase cleavable complexes 
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with VP-16 (see Discussion).  As PTX in the absence of thymidine, itself causes phosphorylation 
of H2A.X, it was not clear from this data that whether PTX blocks VP16 mediated DNA 
damage. Steady state levels of mRNA of p53 transcription target genes P21, MDM2, PUMA, 
PIG3, BAX showed no increase upon VP16 treatment in cells pre treated with PTX (+/- TdR) for 
20 hrs (Fig. 3-23C).  However, cells treated with VP16 alone for 6hr or AICAR alone for 24 hrs 
showed remarkable increase in the steady state levels of these above mentioned mRNA (Fig. 3-
23C) 
 These data suggested that DNA damage and Chk2 phosphorylation were required for p21 
transcriptional activation, that AMPK activation by PTX in the presence of thymidine was 
insufficient for p53 transcriptional activation, that DNA damage by itself could be segregated 
from p53-dependent transcriptional activation by whether or not Chk2 was activated and p53 
S15 was phosphorylated.  Overall, the effects of PTX (+/- TdR) interfered with those of VP16 , 
blocking the transcription activity of p53 induced by VP16. 
3.3.16 PTX can block DNA damage effects even after prolonged exposure of VP16 
PTX (+ TdR) can block DNA damage induced by 6 hr exposure of VP16, concomitant with the 
block of p21 transcription induction. We asked whether PTX would be able to hold its blocking 
effects under the prolonged exposure of VP16. P53 competent HCT116 cells were treated with 
PTX (+ TdR) for 20 hrs followed by addition of VP16 at 6, 12 and 24 hrs before harvestation.  
As expected, VP16 caused stabilization of p53 and induces the DNA damage by 6 hrs with an 
increase by 12 and 24 hrs. This DNA damage was harmonized with the increase in p21 protein 
levels (Fig. 3-24). Interstingly, we found that the PTX (+ TdR) can block the DNA damage 
induced by VP16 for 12 hrs, however, by 24 hrs the effects of VP16 seems to start dominating 
over PTX + TdR, indicated by some induction of p-S139 H2A.X at 24 hr VP16 treatment in cells 
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pretreated with PTX+ TdR. This induction of p-S139 H2A.X was concur with increase in p21 
levels suggesting that DNA damage is essential for VP16 mediated activation of p21 
transcription by p53 (Fig. 3-24). 
3.3.17 Blocking AICAR effects by PTX.  
In order to understand if PTX, an AMPK activator can block the effects of another AMPK 
activator, AICAR, that appeared to initiate a DNA damage response, we co-treated cells with 
AICAR and PTX with both drugs added at the same time (experimental scheme, Fig. 3-25A).  
As with VP16, PTX in the presence of thymidine blocked AICAR mediated DNA damage 
indicated by phosphorylation of H2A.X, phosphorylation of ser15 p53 and Chk2, p21 
transcription.  In the absence of thymidine, PTX itself causes DNA damage thus it cannot be 
interpreted from this data whether PTX blocks AICAR mediated DNA damage.  Phosphorylation 
of p53 S15 was observed with both PTX alone and PTX with AICAR treatment (fig. 3-25B). 
AICAR mediated phosphorylation of Chk2 is blocked by PTX concomitant with block in 
transcription of p21.  Steady state levels of mRNA of p53 transcription target genes; P21, 
MDM2, PUMA, PIG3, BAX shows no increase upon AICAR treatment when combined with 
PTX (+/- TdR) (Fig. 3-25C).  
We conclude that in the presence of the thymidine, PTX-activated AMPK neither cause DNA 
damage nor allowed the DNA damage mediated by VP16 or AICAR, yet it blocks the p21 
transcriptional response.  Hence, in the absence of thymidine, PTX blocks thymidylate synthase 
as well as activates AMPK and causes DNA damage or replication stress but still does not 
activate transcriptional activity of p53.  Surprisingly, the effects of PTX without thymidine 
(AMPK and inhibition of thymidylate synthase) also block the effects of VP16 and AICAR on 
p53 transcriptional activation.  We concluded that the activation of p53 transcriptional activity 
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depends on the type of genotoxic stress and DNA damage as well as the phase of cell cycle arrest 
induced (see Discussion). 
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p53 
p21 
p-S139 H2A.X 
p-Ser345 Chk1 
 H2A.X 
Chk1 
Chk2 
p-T68 Chk2 
p-ser15 p53 
A 
B 
C 
Fig. 3-23. PTX blocks VP16 mediated transcriptional activation of wt p53 :  p53 competent 
HCT116 cells were treated alone either with VP16, PTX , AICAR with or without TdR or  
VP16 was added to media in  PTX (+/- TdR) after 20hrs as shown in (A) . Cells were harvested 
6 hrs later for (B) protein analysis by immunoblotting, (C) steady state mRNA analysis using 
RT-qPCR. Experiment is replicated twice showing similar patterns of changes in mRNA levels.  
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p53 wt HCT116 cells were treated with PTX + TdR for 24 hrs or left untreated followed by 
addition of VP16 (20µM) for indicated time points. Cells were harvested and lysed for immuno- 
blotting to analyze p-S139 H2A.X, an indiator of DNA damage and p21. 
 
 
 
 
 
 
 
 
 
9/5/13 
p21 
p53 
p-S139 H2A.X 
H2A.X 
Figure 3-24. PTX (+TdR) blocks DNA damage and p21 trasncription even after 
prolonged exposure to VP16.  
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p53 competent HCT116 cells were treated alone either with VP16, AICAR or PTX with or 
without TdR or  with combination of AICAR and PTX (+/- TdR) for 24 hrs as described in (A) 
followed by protein analysis by immunoblotting (B) , steady state mRNA analysis by RT-
qPCR(C). 
 
Figure 3-25. PTX limits AICAR mediated transcriptional activation of wt p53 
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3.3.18 The effects of PTX plus TdR are caused by the PTX, not by thymidine. 
PTX in the presence of thymidine blocks VP16 and AICAR mediated DNA damage, indicated 
by decreased levels of p-S139 H2A.X in cells pretreated with PTX + TdR followed by VP16 or 
AICAR treatment (Fig. 3-23,24,25). However, in the absence of thymidine, PTX itself causes 
genotoxic stress, shown by increased levels of p-S139 H2A.X (Fig. 3-23,24,25). Thus, we asked 
the question whether the DNA damage block seen by PTX + TdR, is due to PTX mediated 
effects or is an effect of TdR present in the media, originaly added to circumvent the effects of 
PTX on thymidylate synthase inhibition. p53 competent HCT116 cells were pretreated with PTX 
(+ TdR) or TdR for 20 hrs followed by addition of VP16 6hr prior to cell harvest or were 
cotreated with AICAR and PTX (+ TdR) or TdR. As expected, VP16 and AICAR mediated 
induction of DNA damage and p21 protein levels were blocked only in cells pretreated with PTX 
(+TdR) and not with TdR only (Fig. 3-26). This suggested that PTX mediated activation of 
AMPK leads to some interesting yet unclear signaling events, which do not allow the DNA 
damage to take place, presumably due to cell cycle arrest at G1 phase.  
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p53 wt HCT116 cells were treated with PTX+TdR, TdR or AICAR alone. For comination 
treatment, cells were pretread with PTX + TdR or TdR for 20 hr followed by VP16 treatment 6 
hrs before harvesting the cells. For AICAR combination studies with PTX + TdR or TdR, 
indicated drugs were added simulatnously for 26 hrs. Cells were harvested and immunoblotting 
performed to analyze p53, p-H2A.X and p21. β-actin was used as loading control. 
 
  
9/5/13 
p21 
p53 
p-S139 H2A.X 
H2A.X 
β-actin 
Figure 3-26. VP16 and AICAR induced DNA damage and p21 transcription is blocked 
by PTX, not TdR. 
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3.4 DISCUSSION 
The studies in this chapter were started with a fairly simple but important question of how p53 
status affected PTX mediated effects on mTORC1?  Very early in the studies we found that PTX 
activated AMPK could still inhibit mTORC1 in cells which have lost p53 function, inspite of the 
fact that the mTORC1 is hyper-activated in these cells.  This led us to question why PTX effects 
on mTORC1 are p53 independent.   In order to understand that, PTX effects were compared with 
those of AICAR, a moderately well studied AMPK activator.  We found that the effects of PTX 
and AICAR were the same on AMPK activation but different downstream to that.  PTX-
activated AMPK only phosphorylates Raptor and thereby blocks mTORC1 kinase activity, 
whereas AICAR-activated AMPK phosphorylates both TSC2 and Raptor. Thus, AICAR 
activated both controlling arms whereby AMPK inhibits mTORC1, whereas PTX could only 
activate one of these arms.  
 
Involvement of p53.   The difference in the effects of PTX and AICAR proved to be due to 
differential transcriptional activity of p53; p53 stabilized by AICAR was transcriptionally active 
and caused the transcription of TSC2 and sestrin2, two molecules involved in and required for 
AMPK mediated phosphorylation and activation of TSC2, whereas PTX stabilized p53 is 
transcriptionally inactive, unable to promote the transcription of the TSC2 and sestrin2 genes.  In 
the presence of low levels of these proteins, AMPK does not phosphorylate TSC2 and thus TSC2 
GAP activity is not enhanced. This answered the question why PTX effects on mTORC1 are p53 
independent; it does not activate p53 regulated TSC2 arm of pathway.  Thus p53 function it does 
not make a difference in the inhibition of mTORC1 by PTX.   We further found that the effects 
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of PTX on mTORC1 are indeed TSC2 and sestrin2 independent.  
 
PTX-mediated AMPK signaling  This raised the hypothesis that, if PTX does not exploit TSC2 
GAP activity, then raptor phosphorylation has to be taking the whole burden of inhibition of 
mTORC1.  In order to test this hypothesis we transfected TSC2-/-p53-/- MEFs with WT and 
double mutant Raptor (AA: S792A and S772A) that cannot be phosphorylated by AMPK. We 
found that upon PTX treatment, cells which have WT raptor, show inhibition of mTORC1 but 
not those with AA raptor.  In the absence of TSC2, WT raptor when phosphorylated by AMPK 
led to inhibition of mTORC1 in these cells suggested that AMPK mediated phosphorylation of 
Raptor is dominant, necessary and sufficient for inhibition of mTORC1.  This was reflected in 
the cell growth assays that PTX mediated inhibition of cell growth was p53 and TSC2 
independent while loss of p53 or TSC2 was diminishing the growth inhibitory effects of AICAR. 
This is a critical and an important observation, as this property of PTX can be harnessed in the 
cancers that have lost p53 or TSC2 function and have enhanced activity of mTORC1.  
 
AICAR-mediated AMPK signaling.  Given that the effects of PTX-activated AMPK on 
mTORC1 suppression was independent of TSC2 function, it was of interest to determine if 
AICAR mediated suppression of mTORC1 requires TSC2 function or whether the 
phosphorylation of Raptor by AICAR is sufficient. Treatment of MEFs null for TSC2 with 
AICAR showed that AICAR could inhibited mTORC1 only in TSC2 competent MEFs and not in 
MEFs null of TSC2.  This suggested that at the dose of AICAR used in this experiment, is 
dependent on both TSC2 and Raptor phosphorylation.   Presumably, at higher doses of AICAR, 
Raptor phosphorylation could also become sufficient to mTORC1 inhibition. 
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P53 PTMs   PTX stabilized p53 was transcriptionally crippled and thus does not increase the 
levels of TSC2 and Sestrin2.  We set off to understand the reason for this phenomenon. We used 
DNA damaging agent VP16 as a control, which is well studied and known to activate the 
transcriptional activity of p53.  We saw very interesting differences and similarities between 
AICAR and VP16 or AICAR and PTX.  Whereas AICAR and VP16 both stabilize and activate 
p53 transcriptional activity, they had very clear and surprising differences in the posttranslational 
modifications of p53.  VP16 activated p53 was post transnationally modified at all the residues 
analyzed in this study, but AICAR activated p53 was only phosphorylated at Ser15 and Ser392.  
Interestingly, PTX stabilized p53 was only phosphorylated at Ser392, a residue thought to be 
responsible for tetramer formation of p53.  Therefore the only difference at the level of 
posttranslational modification evident between AICAR and PTX, was p-S15. This suggested that 
absence of p-S15 of p53 might be the causative factor for transcriptional inactivity of p53 in PTX 
treatment. We also analyzed the binding of p53 and occupancy of acetylated histone 4 at p21 
promoter, and found that occurence of both the events were equivalent in AICAR and PTX 
(+TdR) treatments, eliminating the possibility of these events to be a limiting factor for p53 
transcriptional inactivity under PTX treatment.  Phosphorylation of p53 at ser15 and ser20 
stabilizes p53 by inhibiting its interaction with  MDM2, an E3-ubiqitin protein ligase.  
 
Signaling upstream of p53   As ATM and ATR are the kinases known to phosphorylate Chk2 
and Chk1, respectively, upon DNA damage which then phosphorylate p53 at S15, we studied the 
activation of these proteins and their target protein H2AX, as an indicator of DNA damage.  We 
found that Chk1 was phosphorylated only under VP16 treatment, known to cause DSBs, but not 
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under AICAR treatment, in spite of the fact that AICAR also caused H2A.X phosphorylation. 
While both AICAR and VP16 treated cells show p-S15 p53 and increased p21 levels, ATR-
mediated Chk1 phosphorylation was absent in AICAR as it was in PTX-treated cells. This 
suggested that phosphorylation of Chk1 is not required for the transcriptional activation of p53. 
Interestingly, unlike PTX (+TdR), both VP16 and AICAR treated cells showed increased levels 
of ATM-mediated phosphorylation of Chk2.  Therefore, the absence of phosphorylation of Chk2 
and p53 at S15 were the only differences noted between AICAR and PTX. It was clear by the 
time course studies that phosphorylation of; p53 at S15 and Chk2 at T68 was coinciding with the 
induction of H2A.X, an indicator of DNA damage after VP16 or AICAR treatment.  None of the 
events; p-S345Chk1, p-T68Chk2, p-S15 p53 were present in PTX (+ TdR) nor was the DNA 
damage indicator p-S139H2A.X.  This suggested that in the absence of DNA damage, ATM 
does not get activated, which, in turn, does not phosphorylate and activate Chk2, leaving ser15 
p53 un-phosphorylated and p53 transcriptionally inactive .   
We decided to check if DNA damage is required for the transcriptional activation of p53.  
PTX in the absence of TdR inhibits thymidylate synthase and can cause genotoxic stress.  We 
decided to test if PTX in the absence of the thymidine can activate DNA damage followed by 
transcriptional activation of p53.  When cells were treated with PTX alone, it caused a 
remarkable increase in the levels of p53, p-S15 p53, p-S345Chk1 and p-S139 H2A.X with no 
increase of p21 protein levels.  This suggests that even after genotoxic stress, p53 stabilized by 
PTX is not transcriptionally active.  This showed that the genomic stress caused by PTX-
mediated inhibition of thymidylate synthase is not sufficient to activate p53 transcriptional 
activity.  Interestingly, the genomic stress caused by PTX could cause activation of ATR 
mediated activation of Chk1 without causing an increase in p21 levels. The only difference 
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between the signaling after treatments stabilizing transcriptionally active p53 (VP16 and 
AICAR) versus treatment stabilizing transcriptionally inactive p53 (PTX + TdR and PTX alone), 
was pT68 Chk2.  This suggested that in the absence of Chk2 activation, and therefore activation 
of ATM, p53 is transcriptionally compromised.   
 
PTX interfered with the DNA damage response.  Interestingly, when we pretreated cells with 
PTX (+ TdR), followed by exposure to VP16, we saw that the DNA damage induced by VP16 
was blocked, concomitant with a failure to promote transcription of p21.  Similar observations 
were made with the co-treatment of PTX + thymidine and AICAR: PTX + TdR blocked the 
AICAR-mediated DNA damage and hence, p53 could not transcribe p21.  
We know by the data generated by Scott Rothbart, a former graduate student of our lab, that PTX 
in the presence of thymidine blocks cells at the G1/S border and PTX without thymidine inhibits 
thymidylate synthase and causes S phase cell-cycle block. From this information, we inferred 
that the pretreatment of cells with PTX in the presence of thymidine blocks cells at G1 phase of 
cell cycle and does not allow the induction of DNA damage by VP16 or AICAR.   This was a 
surprise, since topoisomerase poisons were thought to act at several parts of the cell cycle. 
When cells are treated with PTX (-TdR), it causes a S phase cell cycle block and increases in p-
S139 H2A.X but it does not transactivate p53.  Cells pretreated with PTX followed by VP16, 
apparently had all signaling events caused by ATM activation (p-ser15 p53, p-ser345Chk1, p-
T68Chk2, p-ser139 H2A.X) induced but there was still no increase in the p21 levels.  A possible 
explanation could be that upon PTX treatment, due to thymidine insufficiency, DNA replication 
is halted but it does not allow the double stranded DNA damage caused by VP16 and thus is not 
capable of transactivation of p53.  Similar effects were seen when cells were treated with PTX 
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and AICAR together.  In addition we found that PTX decreased the level of p-T68 Chk2 
activated by AICAR in the cells pretreated with PTX.  Perhaps the transcriptional inactivation of 
p53 caused by PTX does not allow the production of a protein essential to the DNA damage 
response, e.g. 53BP1. 
This chapter raises many important questions and unleashes some very interesting phenomenon 
taking place under unique pharmacological stimuli.  This study clearly challeneges the corealtion 
of signaling events like p-S15p53, p-S345Chk1, p-T68Chk2 and p-S139H2A.X and p53 
transcriptional activity.   
3.5 CONCLUSIONS 
Studies in this chapter lead to the conclusion that PTX effects on the mTORC1 pathway are 
independent of p53 and TSC2 function, which makes it a suitable drug for cancers with 
hyperactive mTORC1 due to loss or mutation of these genes.  We also uncovered the mechanism 
of this independence by showing that p53 accumulated under PTX treatment, is transcriptionally 
compromised and thus does not allow the activation of TSC2 transcription and its GAP activity 
leaving the mTORC1 inhibition by PTX, TSC2 function independent.  PTX mediated effects on 
mTORC1 inhibition are due to robust phosphorylation of Raptor by AMPK and this effect is 
necessary and sufficient to inhibit mTORC1, even in cells with enhanced mTORC1 activity. 
Later we went on to address the reason of p53 transcriptional incompetence under PTX treatment 
and we show some very interesting effects of this drug on the ATM/Chk2-ATR/Chk1-P53 
pathway.  We believe that, in the presence of thymidine, the G1 cell cycle arrest blocked the 
DNA damaging effects of VP16 and AICAR and allow the accumulation of a transcriptionally 
inactive p53.  On the other hand, in the absence of thymidine PTX inhibits thymidylate synthesis 
and arrest cells at S phase of cell cycle, which probably leads to a replication halt, which neither 
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activates p21 transcription itself nor allows VP16 or AICAR mediated activation of p21 
transcription.  
3.6 SURPRISES FROM THIS STUDY 
These surprises are discussed in more detail in the future directions section of this thesis 
(Chapter 5). 
Ø PTX (+ TdR) stabilizes p53 without causing phosphorylation of p53 at ser15.  
Ø Chk1 activation has been reported to inhibit transcriptional activity of p53. In my studies, 
etoposide activates Chk1 and AICAR does not, but both activate p53 transcriptional 
activity. 
Ø PTX (+TdR) can block the DNA damage mediated by VP16 or AICAR and blocks p21 
transcription.  This provides strong evidence that DNA damage is required for VP16 or 
AICAR activation of p53. 
Ø PTX-activated AMPK, does not cause DNA damage and does not activate p21 
transcription. Hence, AMPK activation per se does not activate p53 
Ø We found that although both AICAR and VP16 lead to transcriptional activation of p53, 
AICAR treatment does not lead to increase in pS345Chk1 but levels of pS15p53 and 
pT68Chk2 are increased. On the contrary, VP16 treatment led to increase in the 
phosphorylation of all these three proteins; pS345Chk1, pS15p53 and pT68Chk2. This 
challenges the correlation between activation of Chk1, Chk2, phosphorylation of p53 at 
ser15 and trans-activation of p53. 
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Chapter 4 
4 Interference of PTX with transcriptional activity of mutant p53 may help 
to explain its effects against lung cancers 
4.1 ABSTRACT 
The role of p53 as a tumor suppressor gene is very well studied and p53 has been established as 
one of the most frequently mutated genes in human cancers.  Until a decade or two ago, it was 
believed that the mutation of p53 most often led to a nonfunctional protein.  However, 
substantial evidence has accumulated that supports the concept that DNA binding domain 
mutations of p53, can also confer properties that intensify its oncogenic activity.  Such mutant 
p53 proteins with neomorphic activities are referred to as Gain-of-Function (GOF) mutant p53s. 
Different missense mutations confer different and unique activities and the literature on this field 
is quite extensive.   This chapter addresses a very unique phenomenon observed under PTX 
treatment that PTX not only prevents transcriptional activation by wild type p53, but also 
interfers with GOF mutant p53 transcription.   Most human lung cancers have GOF mutp53s that 
often lead to transcriptional activation of growth and chemoresistance promoting genes not 
induced by wt p53.   The previous chapter of this dissertation determined that PTX increases the 
levels of WT p53 but blocks its transcriptional activity.  Therefore, we hypothesized that PTX 
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might also block the transcriptional activity of mutp53s.   This proved to be the case.   
 
4.2 DISCOVERY OF MUTANT P53 AND ITS ROLE IN CANCER 
The p53 protein was first identified in a complex with the simian virus 40 large T- antigen (Lane 
& Crawford, 1979).  It was demonstrated that many tumors expressed abundant levels of this 
protein, and that the levels of the p53 protein positively correlated with the progression of cancer 
(DeLeo et al., 1979); thus, p53 was initially though to be an oncogene.  This concept was 
reinforced when ectopic expression of the newly cloned p53 cDNA was shown to cooperate with 
oncogenic Ras to transform primary cells in culture (Eliyahu, Raz, Gruss, Givol, & Oren, 1984). 
Later, when several groups compared the sequence of their cloned p53 cDNAs, the striking 
results was that each clone differed in sequence (Levine & Oren, 2009).  It was later recognized 
that these early experiments demonstrating that p53 overexpression could transform cells and 
promote in vivo tumor growth were actually performed with mutant version of p53 that has been 
isolated from tumor cells (Hinds, Finlay, & Levine, 1989; Levine & Oren, 2009). Thus, the 
concept of gain-of-function of mutant p53 came to be recognized.  Mutation in p53 gene can lead 
to three possible outcomes (Fig.4-1). 
 A) Loss of function  
 B) Dominant Negative behavior  
 C) Gain of function  
4.2.1 Loss of function of p53  
More than 85% of mutations found in the p53 gene are single point mutations that result in 
missense proteins.  Mutations, which lead to complete loss of p53 tumor suppresser function, 
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would severely compromise the ability of the cells to respond to genotoxic stress. Mutations of 
p53 can occur by deletion, insertion, truncation or point mutation and tumors with a mutant p53 
allele very frequently subsequently undergo loss of heterozygosity with loss of the wild type 
allele of p53 resulting in complete loss of p53 or p53 function.  Some of these point mutations 
lead to formation of protein which is functionally inactive (Fig.4-1) (Hollstein et al., 1994). 
4.2.2 Dominant Negative Behavior 
Point mutation in one allele results in a missense protein with loss of function of one allele.  
Some of these mutations, especially when expressed in higher amount, can exert a dominant 
negative effect on protein coded by the remaining wild-type allele. This results in an abrogation 
of the ability of wt p53 to inhibit cellular transformation (Fig. 4-1)  (Brosh & Rotter, 2009; Oren 
& Rotter, 2010). This dominant negative behavior is either due to formation of mutant/wild type 
co-tetramers (Chan, Siu, Lau, & Poon, 2004) or the incorporation of  wild type p53 into mutant 
p53 super-tetrameric aggregates (Xu et al., 2011). This is rare in human cancers as the wild type 
allele is usually lost by deletion or gene conversion. 
4.2.3 Gain of function (GOF) mutants of p53 
Unlike most of the tumor suppressor genes, which have one allele inactivated by mutations or 
truncations followed by silencing of the second wild type allele (Weinberg, 1997), the vast 
majority of cancer-associated mutations in p53 are missense mutation with substitution of one 
base pair, which lead to translation of a different amino acid in that position and can give rise to 
a protein with an unique functionality. The great majority of these mutations are clustered in the 
central-most region of the p53 known as the DNA binding domain (Fig. 4-2).  Of the several 
mutations known and mentioned in the literature, some occur at higher frequency and are known 
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as “hot spot” mutations (Harris & Hollstein, 1994). The wild type p53 is a very short-lived 
protein expressed at low steady state levels in normal conditions, but is stabilizes during any kind 
of genotoxic or cellular stress.  However, missense mutations lead to expression of altered full 
length proteins with a substantially increased half life (Fig. 4-3)(Strano et al., 2007).  Each 
mutation leads to a very different and unique protein and protein function, and generalizations 
about p53 across mutations can be misleading.  The selection of inactivating mutations in p53 
during tumor progression might be preserving their activity as dominant negative inhibitors of 
wild type p53, but the extensive prior literature on this point provides enough evidence to say 
that some missense mutation give an additional survival advantage; these mutant p53s are known 
as Gain of Function mutants (GOF) (Fig.4-1, 2,3).  
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Figure 4-1 Schematic representing differnces in the mutant forms of p53 at the 
level of their transcriptional specificity 
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Top) WT p53, Bottom) GOF p53, where read lines in the DNA binding domain represent the 
mutations present in the cells lines used in this study. 
 
 
 
 
 
 
 
 
 
  GOF mutants most commonly consist of DBD 
mutations 
WT p53 
7 
DBD 
(102-292) 
GOF p53 
mutant 
R158L R267P R273P 
Figure 4-2 Structure of wt and Gain-of-function mutant p53.  
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Figure 4-3. Schematic representation of difference in half-life and effects on 
downstream cell processes after DNA damage.  
A. Wild type p53, B. Gain-of-function mutp53. 
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One of the clearest pieces of evidence for GOF effects derives from experiments in which the 
expression of tumor derived mutant p53s in non-transformed, otherwise p53 null cells are 
inoculated into mice; such constructed cell lines greatly increased their tumor forming ability in 
nude mice compared with cells transfected with wt p53.  Wolf et al. showed that L12, an Ab-
MuLV-transformed, p53 null cells, when transfected with a tumor derived p53 gene, gave rise to 
a L12 derived cell with mutant p53 which efficiently transcribed p53 mRNA and synthesized the 
p53 protein. When injected into syngeneic mice, L12 derived cells expressing this mutant p53 
protein showed much more tumorogenicity than parental L12 cells. Tumors formed by parental 
L12 later regressed but tumors formed by L12 derived clones with mutp53 made lethal tumors, 
suggested an advantage of survival gained by mutant p53 over loss of p53 function (Wolf, 
Harris, & Rotter, 1984).  Dittmer et al. reported that the expression of human or murine mutant 
p53 in p53 null cells exerted a new and additional phenotype to these cells. They showed that 
expression of mutant p53 in p53 null cells increases their tumorigenic potential in nude mice or 
enhances plating efficiency in agar cell culture.  Introduction of mutant p53 in p53 null cells 
increased the expression of the gene regulated by the multidrug resistant enhancer promoter 
element suggesting that other then loss of function, mutations can also lead to “Gain of 
function”(Dittmer et al., 1993) which is oncogenic.  
These pioneering studies were done either in cell culture or by injecting cells in nude mice. 
However, to understand and confirm this phenomenon, mouse models were required to 
demonstrate that mutation of p53 is not equivalent to loss of p53 function. Almost a decade after 
the p53 knock out mouse was generated, two “knock- in” mouse of Li-Fraumeni Syndrome 
(LFS) were generated (Lang et al., 2004; Olive et al., 2004).  In an attempt to better recapitulate 
the human disease, these groups created tumor derived mutp53 expressing, genetically 
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engineered mice, by inserting a tumor derived p53 cDNA into the endogenous TP53 locus, using 
homologous recombination. Two hot spot mutations were used; structural mutant p53 R172H 
and the contact mutant p53R270H, which are murine equivalent of human p53 codon 175 and 
273, respectively. Also, p53R172H/- and p53R270H/- mice developed biologically different 
tumors compared to p53-/- mice, including a variety of carcinomas and more frequent 
endothelial tumors. They showed that p53R172H/+ and p53R270H/+ mice developed allele-
specific tumor behavior, which is quite distinct from that of p53+/- mice. This suggested that 
there was a difference in tumor behavior upon loss of one allele versus mutation in one allele. 
These results clearly suggested that mutation in p53 generated a genetically altered tumor along 
with a more metastatic capability, supporting the hypothesis of GOF mutant p53 (Lang et al., 
2004; Olive et al., 2004). Similarly, in an analysis of a LFS patient, a germ line missense 
mutation in TP53 have been shown to be associated with an earlier age (approximately 9 yrs) 
onset of tumor when compared to germ line deletion in TP53, suggesting a gain of function 
effect of missense p53 mutants in human tumors (Bougeard et al., 2008). Also, several studies 
have shown that the presence and level of expression of mutant p53 has a strong co-relation with 
poor prognosis of several types of human tumors, including breast cancer (Elledge et al., 1993; 
Olivier et al., 2006). 
4.3 VARIOUS ASPECTS OF CELLULAR PROGRAMMING MODULATED BY 
MUTANT P53:  
In addition to knockout mice and human epidemiology data, cell based assays also have 
implicated that mutant p53 affects different aspects of tumorigenesis by targeting different 
modes of cellular programming. Some of them are discussed below (Fig.4-4): 
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4.3.1 RNA synthesis and proliferation 
Bossi et al showed that inhibition of mutant p53 by RNA interference reduces cell proliferation 
in vitro, and in vivo it increases tumorigenicity and resistance to cancer drugs.  Overall they 
demonstrated that knock down of mutant p53 weakens the aggressiveness of human cancer cells 
and provides evidence of the GOF hypothesis (Bossi et al., 2006).  A mutant form of p53 protein 
interacted with the NF-Y transcription factor and, after DNA damage, this interaction causes a 
p53/NF-Y dependent increase in RNA synthesis. They showed that mutant p53 binds NF-Y 
target promoters and, upon DNA damage, recruits p300, leading to histone acetylation. The 
recruitment of mutant p53 to the CCAAT sites was severely impaired upon abrogation of NF-Y 
expression.  Endogenous NF-Y, mutant p53, and p300 proteins formed a triplex complex upon 
DNA damage. This study suggested that aberrant transcriptional regulation might explain the 
ability of mutant p53 proteins to act as an oncogenic factor (Di Agostino et al., 2006) 
4.3.2 Cell Survival 
Various experiments done for the purpose of differentiating loss of function of p53 and from the 
effects of expression of a mutant p53 suggested that mutant p53 showed an advantage of survival 
over loss of p53.  Stambolsky et al. showed that mutant p53 can be recruited to the vitamin D-
receptor (VDR) regulated genes and modulates their expression. Mutant p53 can increase the 
accumulation of VDR in the nucleus. It can augment the transactivation of some genes and 
relieve the repression of others. Overall, mutant p53 can convert vitamin D into an anti-apoptotic 
agent that promotes cell growth and survival of tumor cells (Stambolsky et al., 2010).  
4.3.3 Chemoresistance 
Several studies have compared the properties of the cells with and without p53 mutations within 
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the same cell population. These experiments were usually done by introducing human tumor 
derived mutant p53 species into p53-null H1299 cells. Clonogenic survival assays performed on 
these cells suggested that cells overexpressing the His175 p53 mutant, but not the His273 
mutant, recover preferentially from etoposide treatment. Moreover, etoposide-induced apoptosis 
were substantially reduced in the presence of p53His175 or p53His179, whereas p53His273 and 
p53Trp248 did not have much protective effect. In contrast, both p53His175 and p53His273 
showed increased resistance against low concentrations of cisplatin, but resistance reduced with 
higher concentration and showed no protection at all against high concentrations. This suggested 
that particular p53 mutants might offer a selective survival advantage to tumor cells during 
chemotherapy. These findings define a new type of mutant p53 selective gain of function which 
may compromise the efficacy of cancer chemotherapy (Fig.4-3,4) (Blandino, Levine, & Oren, 
2002). 
4.3.4 Abnormal centrosome and spindle checkpoints  
Fibroblasts from Li-Fraumeni syndrome heterozygotes expressing mutant p53s, when exposed to 
a spindle depolymerizing agent, generates polyploid cells more frequently than p53 null 
fibroblasts from LFS heterozygotes. This study also showed that, this class of dominant gain of 
function mutants (p53-RSC (relaxed spindle checkpoint allele)) does not need any new 
transcriptional activity of mutant p53 to exert this behavior. This suggested that one of the ways 
by which mutant gain of function p53 can help tumor survival and progression can be a direct 
promotion of genetic instability (Gualberto, Aldape, Kozakiewicz, & Tlsty, 1998).  
4.3.5 Gene amplification  
Albor et al. showed that mutant p53 proteins can interact and activate topoisomerase I, and that 
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this could be a mechanism for induction of genomic instability by mutant p53 proteins (Albor, 
Kaku, & Kulesz-Martin, 1988). Later, this group followed up with the study of the effects of 
exogenous mutant p53 protein expression in genomic stability in human p53-/- Saos-2 cells.  
They established the correlation between the presence of mutant p53 and an increased number of 
PALA (N-(phosphoacetyl)-L-apartate)-resistant colonies, a phenotype caused by gene 
amplification of the aspartate transcarbamylase gene. They showed by immunoprecipitation that 
mutant p53 interacts with topoisomerase I and upon continuous expression of mutant p53 for 
several generations, the number of PALA resistant colonies increases after subsequent exposure 
of PALA.  Furthermore, following exposure to camptothecin (which stabilizes topoisomerase I 
cleavage complexes and mediates non homologous recombination) the number of PALA 
resistant colonies increased.  When combining the expression of mutant p53 with exposure to 
camptothecin, an additive increase in the number of PALA resistant colonies was evident.  These 
studies suggested that mutant p53 mediated gene amplification processes independent of its 
capability to inactivate wild type p53 protein but dependent on interaction of mutant p53 with 
topoisomerase I (El-Hizawi, Lagowski, Kulesz-Martin, & Albor, 2002). 
4.3.6 Somatic cell reprogramming and stem cell characteristics 
A well-known hallmark of some of the most aggressive and deadly cancers is a poorly 
differentiated phenotype thought to result from the presence of stem-like cancer cells.  (Ben-
Porath et al., 2008). The increased expression of a set of embryonic stem cell (ESC) genes and a 
decreases expression of genes that are targets for polycomb identifies a poorly differentiated lung 
adenocarcinoma.   This gene expression signature was the marker of poor prognosis and worse 
overall survival in lung adenocarcinomas but not all poorly differentiated non-small cell lung 
cancers exhibit such a gene expression profile (Hassan, Chen, Kalemkerian, Wicha, & Beer, 
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2009) Human cancers are known to consist of a heterogenous set of diseases which are  
from one another by pathologic presentation and molecular signature. 
Breast cancer in one of the best fitting example of this phenomenon and each breast cancer 
subtype on the basis of pathological presentation is also heterogenous when viewed on a 
molecular basis. Mizuno et al. studied if a p53 mutation could allow cells within a tumor to 
acquire a stem cell-like state by coordinating expression of stem cell identified genes.  Using 
microarray and database studies, they demonstrated that breast and lung cancers with p53 
mutations exhibit a stem cell-like transcriptional pattern. These data suggest the model that loss 
of p53 function enables acquisition of stem cell properties, which are positively selected during 
tumor progression (Mizuno, Spike, Wahl, & Levine, 2010). 
4.3.7 Disruption of tissue architecture  
Breast cancer is thought to arise from mammary epithelial cells found in acini, which 
collectively form terminal ductal lobular units.  Each acinus consists of a single layer of 
polarized luminal epithelial cells surrounding a hollow lumen (Bissell, Radisky, Rizki, Weaver, 
& Petersen, 2002). Freed-Pastor et al. used 3D culture system to understand the involvement of 
mutant p53 in the distortion of tissue architecture. They showed that depletion of mutant p53 is 
sufficient to phenotypically revert breast cancer cells to more acinar-like morphology (Freed-
Pastor et al., 2012) 
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Figure 4-4 Schematic representation of mechanism of mutp53 mediated induction 
of chemo-resistance in cancer cells 
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4.3.8 Angiogenesis 
Angiogenesis is one of the requirements for tumor growth and progression because unlimited 
growth of cells demands high supply of nutrient and thus blood supply. There are some studies, 
which suggest that mutant p53 transcriptional programming includes some genes like ID4, which 
are directly involved in angiogenesis. ID4 (inhibitor of DNA binding 4) is a member of a family 
of proteins that function as dominant-negative regulators of basic helix-loop-helix transcription 
factors. The ID4 protein binds to and stabilizes mRNAs encoding pro-angiogenic factors IL8 and 
GRO-alpha. This results in the increase of the angiogenic potential of cancer cells expressing 
mutant p53 (Fontemaggi et al., 2009) 
4.3.9 Migration, invasion and metastasis 
One of the biggest challenges faced cancer therapeutics is migration, invasion and metastasis of 
cancer cells. There is some evidence that suggests that mutant p53 might play a role of an 
oncogene by helping and promoting cell migration, invasion, and metastasis. When immune 
deficient SCID mice are transplanted with human T cell acute lymphoblastic leukemia (T-ALL), 
only those cells which either possessed a mutant p53 gene or lacked the wild type allele 
infiltrated and induced the lethal hematopoietic disease. The mutant p53 genes exert a distinct 
pattern in vivo and in vitro: mutants which showed greatest cell proliferation of T-ALL lines in 
vitro and colony formation in methylcellulose cultures, also showed greatest tissue invasiveness 
of T-ALL cells in vivo (Hsiao et al., 1994).  It was clear that mutant p53 gave an additional 
advantage for survival and invasion in vivo and in vitro over lack of wild type p53 function. 
Some specific hot spot mutants of p53 play a role in the generation of lymphohematopoietic 
metastatic potential and tissue invasiveness as assayed in SCID mice, whereas the expression of 
wild-type p53 is capable of keeping this metastatic potential in check (Hsiao et al., 1994). 
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4.4  MOLECULAR MECHANISM OF TUMOR PROMOTING ACTIVITY OF GOF 
MUTANT P53  
All known mutants of p53 are either loss of function or gain of function proteins. A huge focus 
of researchers in the p53 field is to understand and elucidate the underlying molecular 
mechanism of the GOF behavior.  A significant amount of research has been done to address this 
question and there are several molecular mechanisms that have been proposed to explain the gain 
of function of mutant p53.  These are discussed below. 
 
4.4.1 Interaction and Inhibition of the activity of other p53 family proteins 
Mutant p53 has been suggested to interact, sequester and interfere with the activity of proteins 
involved in the antitumor protective mechanisms of cells.  The p63 and p73 proteins, which are 
not targets of WT p53, have been shown to interact with gain-of-function mutant p53 (Fig.4-3) 
(Di Como, Gaiddon, & Prives, 1999; Marin et al., 2000).  The p63 and p73 genes each encode 
several isoforms derived by combination of multiple transcription start sites and alternative 
splicing.  Some of those isoforms share or mimic WT p53 function.  Upon expression or 
accumulation of mutant p53, p63 and p73 bind to mutant p53 and thus cannot perform their 
transcriptional activity, leading to deregulation of p63 and p73 target genes.  p63 and p73 target 
genes are mainly involved in apoptosis and cell proliferation regulation. Thus, the binding of 
mutant p53 to p63 and p73 severely diminishes their transcriptional activity and diminishes 
apoptosis (Irwin et al., 2003; Strano et al., 2000). The core domain of the mutant p53 is sufficient 
for the binding to p63 and p73 (Gaiddon, Lokshin, Ahn, Zhang, & Prives, 2001; Strano et al., 
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2002; Strano & Blandino, 2003) Thus, this region of mut p53 might serve as a protein-protein 
interaction module which contributes to gain of function activity. Keeping the complexity of the 
proteins involved in the interaction network of the WT p53 in mind, it would not be unexpected 
to find additional new interacting partners of GOF mutant p53 in the future. 
4.4.2 Mutant p53 as a bona-fide transcription factor 
 Almost a decade of research has investigated this aspect of gain of function p53.  Levin's group 
reported that a p53 mutant with mutation at two critical residues at the N-terminus loses its gain 
of function activity (Lin, FAU, & Levine, 1995). A genome-wide approach has shown that 
mutant p53 modulates the levels of numerous transcripts.  Most of these genes are found to be 
involved in cell cycle, cell growth and cell proliferation, cell migration, angeiogenesis, and 
chemoresistance suggesting that regulation of  these genes by GOF mutant p53 could be 
pivotal in its function as a pro-oncogenic protein (S. Deb, Jackson, Subler, & Martin, 1992; M. 
W. Frazier et al., 1998a; Iwanaga & Jeang, 2003; Y. I. Lee et al., 2000; Ludes-Meyers et al., 
1996; Margulies & Sehgal, 1993; Mizuarai, Yamanaka, & Kotani, 2006; Scian et al., 1203; 
Subler, Martin, & Deb, 1994; Tsutsumi-Ishii, Tadokoro, Hanaoka, & Tsuchida, 1995). 
Consequently, gain-of-function mutant p53 might trigger other pathways by modulating the 
transcription of genes, which may represent the molecular basis of the broad-spectrum gain-of-
function activity.  Despite continuous efforts from the scientific community, the understanding of 
molecular details of the transcription activity of mutant p53 is still very scarce mainly due to 
different behavior of each mutant.  However, some of the possible mechanisms for this 
regulation of transcription by mutant p53 are as follows; 
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4.4.3 Interaction of gain-of-function mutant p53 with transcription factors leading to 
differential regulation of WT p53 targets.   
Wild type p53 has been shown to interact with a number of transcription factors (E2F1, SP1, NF-
Y, YY1, TBP, TAFs), giving rise to protein-protein-DNA complexes.  Mostly, these 
macromolecular complexes modulate the transcription of genes whose promoters lack wild type 
p53 binding sites. Often these promoters are inhibited by wt p53 in specific phases of the cell 
cycle after DNA damage (Farmer, Friedlander, Colgan, Manley, & Prives, 1996; Lu & Levine, 
1995; Manni et al., 2001; mbriano et al., 2005; St Clair et al., 2004). Some studies have shown 
interaction of wt p53 with NF-Y on CCAAT box-containing promoters, and upon DNA damage 
this complex recruits histone deacetylases (HDACs) and releases histone acetyl transferase 
(HATs), causing repression of the key cell cycle control genes like cyclin A, cyclin B1, cdk1, 
cdc25c and cdk1-associated kinase activity (mbriano et al., 2005). Interestingly, Di Agostino 
recently reported that mutant p53 interacts with NF-Y upon DNA damage and leads to response 
opposite  to that of wt p53.  This interaction provoked the expression of cyclin A, cyclin B1, 
cdk1, cdc25c and cdk1-associated kinase activity leading to mutp53/NF-Y complex-dependent 
increase in DNA synthesis.  Upon DNA damage, mutant p53 binds NF-Y target promoters and 
recruits p300, leading to histone acetylation and promoting the initiation of transcription of those 
genes. They further showed that even in normal conditions, NF-Y and mutant p53 are present on 
NF-Y regulated gene promoters along with HDACs, independent of DNA damage.  This 
suggests that binding of mutant p53 with NF-Y is dependent on the presence of NF-Y and on the 
CCAAT box of the promoter; upon DNA damage this association increases. This leads to the 
recruitment of the p300 HATs in a mutant p53-dependent manner. The switch between p300 and 
HDACs is shifted towards increased acetylation and reduced methylation of neighboring 
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histones leading to the promotion of initiation of transcription from these promoters.  This 
observation opened up several interesting questions.  The foremost is: since both WT and mutant 
p53 can interact with both p300 or HDACs in complex containing NF-Y, then how are p300 or 
HDACs recruited in an opposed manner by Wt and mutant p53?   Second, as mutant p53 is 
present in a complex with NF-Y/HDACs in unstressed condition, what is the role of this complex 
under these conditions ? However, the overall conclusion of the study by Di Agostino et. al.  was 
that mutant p53 enhances transcription of  proliferative targets of NF-Y.  
In fact, mutp53 interacts with many other sequence specific transcription factors and shows 
differential regulation from that by wt p53.  One such factor is Sp-1 which regulates transcription 
by binding to Sp-1-response elements (Sp-1-REs) and interacts with both mut p53 as well as wt 
p53 (Chicas, Molina, & Bargonetti, 2000; Gualberto et al., 1998).  Transcription regulation 
outcomes by p53:Sp-1 interaction depends on the type of p53 protein.  While wt p53 leads to 
inhibition of Sp-1 dependent transcription activation, presumably by interfering with the DNA 
binding of Sp-1 (Bargonetti, Chicas, White, & Prives, 1997), mutp53 elicits co-operative effects 
on Sp-1 mediated transcription activation.  Similarly, wt p53 interaction with the proto-oncogene 
ETS-1 is inhibitory to its activity (E. Kim et al., 2003; Pastorcic & Das, 2000), whereas mutp53: 
ETS-1 interaction promotes ETS-1 mediation transcription activation (Sampath et al., 2001).  
This suggest that the macromolecular complex assemblies containing WT or mut p53 are 
functionally distinct.  
Interaction of gain-of-function mutant p53 with DNA.   
The question of whether mutp53 transactivation may require its direct binding with DNA has 
been a discussion of controversy for a long time. This is mainly due to a lack of evidence 
suggesting that mutp53 can bind to DNA with specificity.  This question has been approached 
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mainly by analysis of the ability of mutp53 proteins to bind at wt p53 recognition sequences, and 
the lack of binding was interpreted as an inability of mutp53 to bind DNA specifically.  
However, most of the promoters activated by mutp53 do not contain wt p53 binding consensus 
sequences nor show similarity to it, suggesting that mutp53 regulates these promoter by binding 
at response elements different than wt p53-Res (Dittmer et al., 1993; M. W. Frazier et al., 1998b; 
Gualberto et al., 1998; Tsutsumi-Ishii et al., 1995; Yang, Pater, & Tang, 1999).  However, from 
studies performed on mut p53-regulated promoters and not based on wt p53-REs , it was clear 
that mutp53 binds with DNA (Bargonetti et al., 1997; Chicas et al., 2000; Y. I. Lee et al., 0907; 
Zalcenstein et al., 2003). Chromatin immunoprecipitation studies reveled that mutp53 proteins 
do physically bind with their responsive promoters in vivo, suggesting that mutp53 targets DNA 
in a specific manner but independent of Wtp53 canonical binding sequence (Zalcenstein et al., 
2003). One of the biggest barriers in the determination of the putative binding site for mutp53 on 
DNA is that most of the promoters activated by mutp53 do not show any sequence homology of 
mut p53 binding site.  However, Kim and Deppert's lab has proposed the idea that mutp53 
binding with DNA is not sequence specific but it is largely determined by DNA structure. This 
idea was originated after the observation that mutp53, but not wt p53, interacts with Matrix 
Attachment Region (MAR) elements, which are regulatory DNA sequences shown to play a role 
in high order chromatin organization, and chromatin modification (E. Kim & Deppert, 2004).  
Weissker et al tested the interaction of the mutant p53 with DNA representing high complexity 
with regard to sequence and secondary structure. They showed a specific binding of the mutp53 
with lambda DNA and suggested the possibility that p53 might be able to interact with nuclear 
MAR DNA sequences (Weissker, Muller, Homfeld, & Deppert, 1992).   There are several 
studies which suggest that wt and mutp53 interact with promoters as macromolecular complexes 
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that show distinct functionality. On the other hand, it is shown that regulation of the MDR1 
promoter by wt p53 and mutp53 are from different promoter regions (Sampath et al., 2001). 
There have been several studies focusing on defining the new targets of mutp53 which are now 
categorized as neo-morphic genes.  
4.5 POTENTIAL TRANSCRIPTION TARGET GENES OF MUTANT P53   
The mechanism for oncogenicity of mutp53 which has been studied the most, is transcriptional 
regulation of mutp53.  Mutp53 have been reported to modulate the transcription of various genes 
(Table 4.1) that are briefly discussed below.  These genes are:  MDR1, NfkB2, Axl, PCNA, 
hTERT,, hsp70 and EGFR, all of which have been functionally implicated in increased 
aggressive behavior of tumors.  The characteristics of each of these neomorphic p53 targets are 
briefly summarized, below. 
4.5.1 Multidrug resistant gene 1 (MDR1)  
Each cancer has different response towards cytotoxic drugs; some are relatively sensitive and 
some are more refractory.  Multidrug resistance (MDR) describes the phenomenon of an 
acquired simultaneous resistance to unrelated drugs. Multidrug resistance was first described in 
1969 and than in 1970 when chinese hamster ovarian cancer cells were exposed to increasing 
concentration of actinomycin D (Biedler & Riehm, 1970; Simard & Cassingena, 1969). Though 
these cells were selected with one drug, they were later found to be resistant to a range of 
clinically important natural products, including anthracyclines (doxorubicin and duanomycin), 
the vinca alkaloids (vincristine, vinblastin and vindesine), etoposide and colchicine.  Extensive 
studies with cell lines and transplantable tumors have shown that MDR can develop rapidly. The 
genes involved in MDR have been identified and their role in drug resistance has been confirmed 
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by gene transfer. Mechanisms identified to date include reduced drug accumulation, involved the 
P-glyco-protein (Pgp; mdr1 gene) (Childs & Ling, 1994) mainly, but also the MDR-associated 
protein (mrp) gene (Cole et al., 1992).  MDR cells overexpressing MDR1 show resistance to a 
broad spectrum of drug structures and thus it has been thought that Pgp may be acting by altering 
the intracellular pH or modifying membrane potential.  Classic studies demonstrated that cells 
exposed to increasing concentrations of any of the natural products (except bleomycin) 
underwent amplification of the mdr gene, with the appearance of homogeneously staining 
regions in CHO cells (Biedler & Riehm, 1970) and double minute chromosomes in mouse and 
human cells (Biedler & Riehm, 1970). Studies done with purified MDR1 and functionally 
reconstituting it into liposomes to investigate its properties show that Pgp alone is sufficient to 
transport many drugs.  
4.5.1.1 MDR1 and mutant p53 
The most frequently expressed drug resistance genes, MDR1 and MRP1, occur in human tumors 
with mutant p53 and their over expression is correlated with the presence and transcriptional 
activity of mutant p53 (de Kant, Heide, Thiede, Herrmann, & Rochlitz, 1996; Fukushima et al., 
1999; Galimberti et al., 1998; Oka et al., 1997; Sampath et al., 1204). Sampath et al showed that 
mutant p53 did not activate either the MRP1 promoter or the endogenous gene but strongly up-
regulated the MDR1 promoter and expression of the endogenous MDR1 gene. Transient 
transfection of mutant p53 caused increased expression of endogenous MDR1 in comparison to 
empty vector or transcriptionally inactive mutant p53 transfection.  Oka et al studied some 
surgically removed colorectal tumors using immuno-histochemistry and found that p53 and 
MDR1 were co-expressed in a significant number of samples (P < 0.002).  Although they did not 
find any relationship between MDR1 or p53 protein accumulation with histologic grade or stage 
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but their study clearly demonstrated that MDR1 expression is closely associated with p53 protein 
accumulation in human colorectal cancers (Oka et al., 1997). 
4.5.1.2 MDR1 and cancer   
There are several studies, which suggest that levels of MDR1 are correlated with poor prognosis 
of cancer chemotherapy.  The most significant observations were made in leukemia and pediatric 
cancers. For example, using an anti-MDR1 monoclonal antibody, Ma et al. were the first to 
demonstrate that MDR1 may be overexpressed in acute myelogenous leukemia (AML) (Ma et 
al., 1987).  In two patients, leukemia cells were negative for MDR1 at diagnosis of AML, but 
one patient became positive at first relapse and the other on recovering from second induction 
chemotherapy.  Subsequently, two large studies correlated mdr1 mRNA expression with 
response to treatment in acute leukemia and showed that the higher the expression of MDR1, the 
worse was the response of the disease to chemotherapeutics.  (Pirker et al., 1991; SSato et al., 
1990). Development of agents to overcome multidrug resistance (MDR) is important in cancer 
chemotherapy.  
4.5.2 Nuclear factor Kappa B 2 (NFkB2) 
The Rel/NFkappaB family of transcription factors is involved in multiple cellular processes, 
including inflammation, cell cycle regulation, apoptosis and oncogenesis.  Constitutive activation 
of NFkappaB has been described in a great number of solid tumors and this activation appears to 
support cancer cell survival and to reduce the sensitivity against chemotherapeutic drugs (Scian 
et al., 2005). Additionally, some of these drugs induce this transcription factor and, through this 
mechanism, lower their cytotoxic potential (Bug & Dobbelstein, 2011). Nuclear factor-κB2/p100 
has been reported to promote endometrial carcinoma (a common cancer in females) cell survival 
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under hypoxia in a HIF-1α independent manner.  Inhibition of NFkappaB has been shown to 
enhance the sensitivity to antineoplastic- or radiation-induced apoptosis in vitro and in vivo 
(Yeramian et al., 2011) 
  
4.5.3 AXL 
The Axl subfamily of mammalian receptor tyrosine kinases (RTKs), also known as the TAM 
family, consists of Axl, Tyro3 (or Sky), and Mer.  Axl was first isolated during a transfection 
experiment using cDNA from a patient with myeloproliferative disorders (Crosier & Crosier, 
1997; Neubauer et al., 1994). Axl is a 140 kDa protein has been found to be involved in the 
transformation of various cell types and thus believed to have oncogenic potential (Janssen et al., 
1991; McCloskey, Pierce, Koski, Varnum, & Liu, 1994). Axl expression is observed 
predominantly in fibroblasts, myeloid progenitor cells, macrophages, neural tissue, ovarian 
follicles, cardiac and skeleton muscle but rarely present in normal epithelial cells (Crosier & 
Crosier, 1997).  
TAM receptor tyrosine kinases are known to play a role in cell adhesion as well as in 
intracellular signaling. In fact, it was observed that Axl mediates adhesion of 32D myeloid cell 
line (McCloskey et al., 1997), whereas Lee et al. (1999), demonstrated that increased expression 
of the Axl receptor induces transformation of NIH 3T3 cells into highly tumorigenic cells in 
nude mice (W. P. Lee et al., 1999).  
4.5.3.1 Axl and cancers 
Axl was described in CML patients and its overexpression in fibroblasts suggested Axl’s 
transforming activity (Janssen et al., 1218; McCloskey et al., 1994; O'Bryan et al., 1991). 
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Following its original identification, upregulation of Axl has been reported in a variety of 
cancers including breast, gastric, prostate, ovarian and lung cancers (Berclaz et al., 2001; Jacob 
et al., 1992; Shieh et al., 2005; W. Sun, Fujimoto, & Tamaya, 2004; Wimmel, Glitz, Kraus, 
Roeder, & Schuermann, 2001b; Wu et al., 2002) 
4.5.3.2 Metastatic potential of Axl 
The expression of Axl was found to be higher in the metastatic prostate carcinoma cell line 
DU145 than in the less aggressive prostate carcinoma cell line PC-3 or in normal prostate cells 
(Jacob et al., 0805; Sainaghi et al., 2005). Moreover, Sainaghi et al. also showed that Axl/Gas6 
interaction induces mitogenic activity in DU145 and PC-3 cell lines, which is not mediated by 
inhibition of apoptosis and is proportional to Axl expression (Sainaghi et al., 2005). 
4.5.3.3 The role of Axl in non-small cell lung cancer (NSCLC): A key player in resistance 
against chemotherapy.     
Overexpression of Axl has been related to increased resistance of cancer cells to 
chemotherapeutic drugs in numerous types of cancer.   Axl has been shown to be overexpressed 
in NSCLC (Shieh et al., 0221; Wimmel, Glitz, Kraus, Roeder, & Schuermann, 2001a) and, 
recently, two independent studies reinforced the idea that Axl is important for NSCLC and 
demonstrated that Axl plays a key role in acquiring resistance to chemotherapy.  One of these 
reports by Zhang et al. (2012) demonstrated increased activation of Axl and evidence for 
epithelial-to-mesenchymal transition (EMT) in the mutant epidermal growth factor receptor 
(EGFR) lung cancer models with acquired resistance to erlotinib (a tyrosine kinase inhibitor used 
in the treatment of lung cancer) in vitro and in vivo.  Inhibition of Axl led to restoration of 
sensitivity to erlotinib, indicating that Axl may represent a promising therapeutic target to 
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prevent or overcome acquired resistance to drugs (Zhang et al., 2010).  
4.5.3.4 The role of mutant p53 in Axl transcription regulation 
The receptor protein tyrosine kinase Axl is upregulated at both RNA and protein levels in H1299 
lung cancer cells expressing any of a few mutant p53s-R175H, -R273H, and -D281G. On the 
other hand, knockdown of endogenous mutant p53 levels in human lung cancer cells H1048 
(p53-R273C) and H1437 (p53-R267P) resulted in reduction in the level of Axl as well.  Using 
ChIP, they showed the direct nucleation of GOF p53 on the Axl promoter and facilitation of the 
acetylation of the Axl promoter, suggesting that mutp53 regulates transcriptional activation of 
the Axl gene.  Furthermore, knockdown of Axl using siRNA led to decrease tumorogenicity and 
migration of cancer cells, suggesting that increase in Axl levels by mutp53, help in cancer 
progression and survival.  (Vaughan et al., 2012).  
4.5.4 Proliferating Cell Nuclear Antigen (PCNA) 
PCNA is known to be involved in the DNA replication and thus molecular marker for cell 
proliferation.  PCNA was first identified in the sera of group of patients with systemic lupus 
erythematosus, as an antigen to an autoimmune antibody (Mathews, Bernstein, 
Franza,BR,Jr,Garrels., & Garrels, 1984). Later studies showed that this antigen was actively 
expressed in proliferating human cancer cells and showed a pattern of expression similar to a 
‘cyclin’ protein with peak expression during the late G1 and S phase (Bravo R FAU - Fey,,S.J. et 
al., 0222). Three identical PCNA molecules associate in a head-to-tail fashion to form a 
homotrimeric ring that encircles the DNA double helix as a sliding clamp and make a critical 
platform on replicating DNA for the coordinate recruitment and regulation of other proteins 
essential for DNA replication.  PCNA-interacting proteins important for DNA metabolism 
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include polymerases, ligases, topoisomerases, and proteins controlling replication initiation, cell 
cycle control, chromatin and epigenetic regulation, gene transcription, cell survival, and 
metabolism (Maga & Hubscher, 2003; Moldovan, Pfander, & Jentsch, 2007; Naryzhny & Lee, 
2010; Ulrich & Takahashi, 2013; Warbrick, 2000).  
4.5.4.1 PCNA and Cancer 
PCNA engenders special interest among cancer researchers because of its role in cell 
proliferation. Because cell growth is a requirement for cancer progression at both primary and 
metastatic sites, and PCNA is an essential factor for DNA replication, inhibition of PCNA has 
been exploited as an anticancer strategy.  Due to its involvement in more than one cell survival 
mechanisms, circumvention of its inhibition by cells (developing resistance) is less likely than 
therapies targeting other signaling pathways (Stoimenov & Helleday, 2009). Small molecule 
inhibitors and peptides against PCNA have been used to target it and study its mechanism and 
function.  PCNA has also been widely used as a tumor marker, but there are conflicting results 
regarding the correlation between PCNA expression in tumor tissues and patient prognosis 
(Grossi et al., 2003; Heimann, Ferguson, Recant, & Hellman, 1997; Wang et al., 2006).  
4.5.4.2 The role of mutant p53 in transcription of PCNA 
Shivkumar et.al have shown that low levels of wild-type p53 transcriptionally activate the human 
PCNA promoter but higher levels of wild-type p53 inhibit promoter activation in vivo. 
Interestingly, in contrast to what is seen with wt p53, expression of tumor derived mutant p53 at 
low levels failed to activate the PCNA promoter but at higher levels significantly increased the 
transcription of PCNA (Shivakumar, Brown, Deb, & Deb, 1995).  This study indicated that mild 
DNA damage which moderately elevates wt p53 levels increases the expression of PCNA, 
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probably to assist DNA repair.  As mutant p53 is always present at high levels in tumor cells, 
they constitutively induce the expression of PCNA to avail the cell proliferation property of 
PCNA. They also showed that where wild-type p53 binds to the human PCNA promoter in a 
sequence specific manner, a tumor-derived p53 mutant does not require the wild-type p53 
response element for transactivation of the human PCNA promoter (Shivakumar et al., 1995). 
4.5.5 Human Telomerase Reverse Transcriptase (HTERT) 
The ribonucleoprotein complex telomerase is continuously expressed in stem and germ cells and 
repressed in most normal somatic cells. Almost 70–90% of cancer cells stably express this 
enzyme (Shay & Bacchetti, 1997), which is reactivated during malignant transformation. This 
reactivation grants unlimited proliferation capacity for the tumor cells by de novo synthesis of 
telomeric (TTAGGG)n sequences, circumventing the ‘‘end-replication problem’’ of DNA 
synthesis (Dahse, Fiedler, & Ernst, 1997; N. W. Kim et al., 1994; Mansfield et al., 2007; 
Smogorzewska & de Lange, 2004). Inactivation of mammalian telomerase leads to telomere 
attrition, eventually leading to uncapped telomeres, which elicit a DNA damage response and 
cell cycle arrest or death. 
4.5.5.1 hTERT and cancer 
It has been shown that telomerase activity is strongly correlated with the state of malignancy and 
metastatic potential of cancer cells.  hTERT has been suggested to be a useful molecular marker 
in cancer prognosis.  hTERT represents the catalytic subunit of telomerase with reverse 
transcriptase activity (Albanell et al., 1997; Bryan, Sperger, Chapman, & Cech, 1998; 
Smogorzewska & de Lange, 2004; Triginelli et al., 2006; Uen et al., 2007).  Telomerase as an 
enzyme consist of two subunits, an RNA template molecule known as hTERC and enzyme unit 
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hTERT.  To render its enzymatic activity hTERT needs hTERC (Albanell et al., 1997; Bryan et 
al., 1998; Dahse et al., 1997; N. W. Kim et al., 1994; Mansfield et al., 2007; Smogorzewska & de 
Lange, 2004; Triginelli et al., 2006; Uen et al., 2007) and various telomerase associated proteins 
(Smogorzewska & de Lange, 2004).  
4.5.5.2 Transcription of hTERT by mutant p53 and other oncogenic factors.   
Since transcription activity of mutant p53 has been correlated with transcription regulation of 
various genes, Scian et al. in 2004, investigated and, indeed, showed that hTERT is a 
transcriptional target of GOF mutp53 using microarray analysis, later confirmed by qPCR 
analysis (Scian et al., 2004).  Transient transcriptional assays, testing the ability of tumor derived 
mutant p53 to mediate transactivation of hTERT promoter, suggested that mutp53 transactivates 
the hTERT promoter.  ChIP followed by qPCR analysis demonstrated that mutp53 was present 
on the hTERT promoter suggesting its involvement in transactivation of the gene (Scian et al., 
2004). 
 
4.5.6 Heat Shock protein 70 (hsp70)   
One class of the heat shock proteins (Hsp70s) are 70 kDa, conserved, ubiquitously expressed and 
consist of eight homologous chaperones.  These proteins play a crucial role in protein folding 
and their translocation from one compartment to the other of the cell.   Hsp70, a protein 
unfolding machine, binds and releases stretches of hydrophobic amino acids in an ATP 
dependent process (Morano, 2007; Tavaria, Gabriele, Kola, & Anderson, 1996).  Hsp70 proteins 
have a substrate-recognizing domain, which interacts with sequences of hydrophobic amino acid 
residues in newly synthesized proteins as they emerge from the ribosomes.  Hsp70 binds tightly 
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to partially synthesized protein sequences and prevents them from aggregating and being 
rendered nonfunctional.  When the protein is synthesized, a nucleotide exchange factor 
stimulates the release of ADP and binding of fresh ATP, opening the binding pocket of Hsp70. 
Then the client protein is free to fold on its own, or to be transferred to other chaperones for 
further processing 
4.5.6.1 Hsp70 and cancer and its transcriptional regulation by mutant p53 
Hsp70 has been implicated in four crucial steps of tumorigenesis: (Ciocca, Arrigo, & 
Calderwood, 2013) (1) stabilizing oncogenic proteins (Gray, Prince, Cheng, Stevenson, & 
Calderwood, 2008; Khaleque et al., 2005) (2) inhibiting programmed cell death (Garrido et al., 
0212) and replicative senescence; (3) induction of tumor angiogenesis (J. Sun & Liao, 2004) (4) 
activation of invasion and metastasis (Durech, Vojtesek, & Muller, 2012; J. Sun & Liao, 2004).  
Most of the client proteins for the hsp70-hsp90 complex participate in functions that promote cell 
growth, proliferation, and cell survival associated with carcinogenesis.  The mechanisms of the 
induction of HSP70/90 in cancer are not fully clear. Tsutsumi-Ishii et. al showed that mutant p53 
transactivates HSP70 and analysis using in vitro mutagenesis of the heat shock response element 
(HSE) suggests that a HSE with heat shock factor binding ability is required for transactivation 
of the heat shock protein70 promoter by mutated p53 genes. (Tsutsumi-Ishii, Tadokoro, 
Hanaoka, & Tsuchida, 0519) 
4.5.7 Epidermal growth factor receptor (EGFR) 
The ErbB transmembrane receptor family consist of various members including, EGFR (ErbB1), 
ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4).  These receptors are structurally similar 
and consist of three domains: an extracellular domain, a trans-membrane domain, and an 
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intracellular domain.  The extracellular domain has a ligand-binding region, and several ligands, 
including Epidermal Growth Factor (EGF) bind to it.  The ligand binding leads to receptor 
homo- or hetero-dimerization between EGFR and other ErbB family members at the cell surface, 
causing internalization of the dimerized receptor.  The receptor dimerization results in 
autophosphorylation of the intracellular EGFR tyrosine kinase domain.  The phosphorylated 
tyrosine kinase stimulates an intracellular signal transduction cascade which leads to activation 
of several downstream pathways (including the Ras-Raf-MEK-ERK, PI3K- AKT-mTOR, and 
JAK-STAT3 pathways), leading to cell proliferation and growth (Scaltriti & Baselga, 2003; 
Toyooka et al., 2011).  
4.5.7.1 EGFR and Cancer 
EGFR tyrosine kinase mutations are one of the most frequent mutations in human cancers, which 
usually occur between exons 18 to 21 of the EGFR gene.  These mutations leads to constitutively 
activated ligand-independent EGFR protein production, leading to carcinogenesis (Lynch et al., 
2004; Paez et al., 2004).  About 80-90% of EGFR mutations are either short in-frame deletions 
in exon 19 or point mutations resulting in substitution of arginine for lysine at codon 858 
(L858R) in exon 21(Mitsudomi & Yatabe, 2007).  Cancer cells with constitutively active mutant 
EGFR are highly dependent on the ligand-independent activity of this protein or its 
overexpression, a phenomenon called “oncogene addiction” (Gazdar, Shigematsu, Herz, & 
Minna, 2004).  This constitutive expression or activity allows cancer cells to circumvent the 
normal cell growth and proliferation regulation mechanism and, at the same time, the resulting 
oncogenic addiction leads to a greater sensitivity of these cancers towards small molecule 
inhibitors of these oncogenic proteins.  In first line treatment, EGFR inhibitors show 
approximately 75% response rate in patients with typical EGFR mutations (Mok et al., 2009). 
 249 
4.5.7.2 Transcription regulation of EGFR by mutp53 
wt and tumor derived mutp5, can both transactivate the EGFR promoter (S. P. Deb, Munoz, 
Brown, Subler, & Deb, 1994).  Transient transfection assays with a promoter-CAT construct 
containing the entire EGFR promoter (pER-1.CAT) were performed to compare the 
transactivation efficiency of wt and mut p53.  This experiment suggested that, although wt p53 
can transactivate the EGFR promoter, it is a very weak transactivation in comparison to that 
caused by several mutants of tumor-derived p53.  Although each p53 mutant had a different 
efficiency toward transactivation of EGFR, p53-R281G was proven to be the strongest 
transactivator of this promoter (Ludes-Meyers et al., 1216).  
4.6 POST TRANSLATIONAL MODIFICATION OF MUTP53 
The posttranslational modification of wt p53 has been studied extensively.  However, a 
knowledge base of PTMs on mutp53 is not well established, although it has been demonstrated 
that PTMs play some role in the activity of mutp53.  One would think that, as PTMs are thought 
to play a major role in the activity and function specificity of wt p53, mutation on these residues 
would abolish the function of wt p53 and should be frequently observed in cancers.  Interestingly 
enough, whereas mutations have been indicated in all coding exons of p53, more than 95% of the 
base substitution mutations are located in exons 4-9, which encode the DNA binding domain of 
the protein.  About 30% of mutations locate within six “hotspot” residues that are frequently 
mutated in almost all cancer types (Hollstein et al., 1994) that is, Arg175, Gly245, Arg248, 
Arg249, Arg273, and Arg282, none of which are known to be post-translationally modified. As 
indicated previously, most frequent mutations are on residues not subject to post translational 
modification. A probable explanation of this is that a mutation in a residue of p53 subject to a 
controlling PTM have a survival disadvantage or that, the PTM is important for mutp53 function 
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so is not selected in vivo.   Whereas most of the PTM sites described in the DNA binding domain 
(DBD), do not fall in a hotspot for tumor mutations, the codons for Lys132, Thr155, Ser215, 
Glu258, Asp 259, and Cys277 have been suggested to have over 90 cancer-associated 
mutations/codon. (Cross ref. (Nguyen, Menendez, Resnick, & Anderson, 2014)) 
4.6.1 Phosphorylation of Serines and Threonines in mut p53 
Like wt p53, mutp53 can also be post-transnationally modified in response to various stress and 
DNA damage signals.  In 1993, one of the pioneering studies by Ullrich et al showed that, in the 
absence of stress signals, the posttranslational modification pattern of mutp53 is different than 
that of WT p53 (Ullrich et al., 1993). Later, it was shown that phosphorylation and acetylation of 
p53 was substantially higher in tumor cells than in non-transformed cells. This pattern was true 
irrespective of tumor types or the presence of mutp53.  Out of 10 sites analyzed, phosphorylation 
at residues 15, 81, and 392 were the most frequently observed modifications along with some 
acetylation sites. (Minamoto et al., 0802). Conservation of PTM residues in tumor cells suggests 
that mutp53 function may either needs these PTMs or atleast these PTMs do not affect mutp53 
oncogenic activity negatively (M. Matsumoto, Furihata, & Ohtsuki, 1222; M. Matsumoto et al., 
2004). Perhaps the most studied PTM of WT and mutant p53 is Ser15.  One of the major 
limitations in the studies of mutp53 is that each mutant protein behaves very different in different 
conditions and cell types, which may make the conclusions from one study contradictory or not 
in accordance with the conclusions of the other studies.  Indeed, different studies to understand 
the importance of Ser15 modification in mutp53 show contradictory results (Nagata et al., 1999; 
Ullrich et al., 1993).  However, later studies that included many more cells lines and conditions 
suggested that there is no conclusive correlation between ser15 modification and stability, 
localization DNA binding, transcriptional activity of mutp53 under stressed and unstressed 
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conditions (Liu et al., 2013; Minamoto et al., 0802; Ray, Murphy, & Gal, 2012).  
4.7 FOCUS OF THIS CHAPTER 
Mutation of p53 is one of the most common genetic alterations in human cancers and tumors that 
express mutant p53 are usually more aggressive, resistant to chemotherapy, and show worse 
prognosis then p53-null tumors.  This tumor promoting activity has been correlated with the 
transcription activity of mutant p53.  One of the main foci of this dissertation was to understand 
why PTX effects on mTORC1 regulation are independent of wt p53 (chapters 2 and 3). This 
chapter is mainly focused to understand the effects of PTX on the transcription activity of tumor-
derived mutp53. As we found that PTX blocks transcriptional activation of WT p53 towards its 
target genes, we hypothesized that PTX might block the transcription activation of GOF mutp53 
as well. As discussed in the introduction of this chapter, novel transcription targets of this 
neomorphic mutp53 are chemoresistance, cell growth and proliferation promoting genes. 
Therefore, blockade of transcription of these genes by mutp53, under PTX treatment, might offer 
a therapeutic advantage for cancers with mutp53 like lung cancer and breast cancer. 
4.8 RESULTS  
4.8.1 Sensitivity of mutant p53 cells lines to PTX  
PTX has been approved by the US FDA for first line treatment for non-small cell lung cancer.  
One of the most common genetic mutations in lung cancers is mutation of p53 and as PTX is the 
only antifolate with activity against lung cancer, we sought to understand the mechanism of the 
effects of PTX against lung cancer.  We used H1437 NSCLC cells with a R267P mutation in p53 
and H1048 NSCLC cells with R273P mutation in p53. These cells lines have been shown to have 
gain- of-function mutp53 activity (Vaughan et al., 2012).  
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We tested the growth suppression of these NSCLC cells lines by PTX treatment in the presence 
(Fig. 4-5A) or absence of thymidine (Fig. 4-5B).  Cells were treated for 72 hrs followed by 
electronic counting using a coulter counter (Fig 4-5).  We found that the growth of both lung 
cancer cell lines, H1437 (with a R267P mutation in p53) and H1048 (R273P) are suppressed by 
PTX. This suggested that both lung cancer cell lines, with mutant p53, are sensitive to PTX.  
4.8.2 PTX blocks mTORC1 pathways in mutp53 containing lung cancer cells  
We showed in the previous chapter that cell lines expressing mutant p53 have higher mTORC1 
activity than that with wt p53 (Chapter 2) and that PTX treatment mediates activation and 
phosphorylation of AMPK at Thr172 leading to inhibition of mTORC1 (Chapter 3).  This PTX-
activated AMPK mediated inhibition of mTORC1 was p53 function independent.  Therefore, we 
hypothesized that PTX will inhibit the enhanced mTORC1 activity in cells with mutp53.  Lung 
cancer cell lines H1437 and H1048 were treated with either thymidine or PTX (1µM) with 
thymidine (5.6µM) in order to determine the AMPK-mediated effects on mTORC1 in these cells. 
Phosphorylation of AMPK at P-Thr172 was enhanced in both H1437 (Fig. 4-6A) and H1048 
(Fig. 4-6B). This activation of AMPK leads to a decrease in the phosphorylation of pT70 4EBP1 
suggesting that PTX inhibits mTORC1 via activating AMPK in cells with mutp53 (Fig. 4-6).  It 
is shown previously in this thesis (Chapter 2) that mTORC1 activity is remarkably higher in cells 
with mutp53 have mTORC1 activity than in isogenic cells with WT p53.  Now, this data 
suggests that PTX can decrease the mTORC1 kinase activity in the cells with gain of function 
mutp53.  
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Cells were treated for 72 hrs followed by counting by coulter counter. A. Cells were treated with 
PTX (+/- TdR), B. Cells were treated only with PTX 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Growth suppression curve of H1437 and H1048 cells after PTX (+/-TdR) 
treatment 
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Figure 4-6 Effects of PTX on AMPK and mTORC1 pathway.  
Cells were treated either with thymidine (Tdr) or PTX (1µM) + Tdr (5.6 µM) for 24 hrs followed 
by immunoblotting to analyze the P-Thr172 AMPK, pT704EBP1, 4EBP1 and p53 in A) H1437 
cells B) H1048 cells.  
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4.8.3 PTX increases the levels of mutp53 without increasing the levels of its transcription 
targets 
We have shown in chapter 3 that treatment of p53+/+ HCT116 cells with VP16, AICAR, or PTX 
leads to accumulation of WT p53.  VP16 mediated activation of p53 leads to transactivation of 
its target genes such as p21, Sestrin2, Bax and HDM2, whereas the p53 accumulated in PTX 
treated cells is transcriptionally inactive. As a logical extension of that study we sought to 
understand how PTX affects gain of function mutant p53.  Bug et al. (2011) showed that 
treatment with the anthracyclines, doxorubicin or duanorubicin induces the accumulation of 
mutant p53 and this may augment any new oncogenic functions of mutp53 (Bug & Dobbelstein, 
2011).  We decided to compare the effects of PTX and DNA damaging agents on mutp53. 
We first studied the effects of PTX on mutp53 levels and on its transcription target Axl.  
Treatment of lung cancer cells, H1437 (Fig. 4-7A) and H1048 (Fig.4-7B) with PTX in the 
presence of thymidine increases the protein levels of mutp53.  Surprisingly, PTX was not only 
inhibiting the increase in mutp53 transcription target Axl, it was causing a decrease in this 
protein. (Fig. 4-7).   In chapter 3, we found that PTX accumulated p53 is transcriptionally 
inactive; hence, we asked whether PTX treatment would augment the oncogenic transcriptional 
activity of mutp53.  
We treated H1048 (R273P) cells either with VP16 (20µM), Doxorubicin (2µM) or PTX (1µM) 
with TdR (5.6µM) for given time periods, followed by immunoblotting to check the levels of 
mutp53 and two of its transcription targets Axl and NFκB2 (Fig. 4-8A,B). Treatment with 
doxorubicin and PTX both leads to increase in mutp53 levels (Fig. 4-6,7,8).  Considering that the 
basal levels of mutp53 in these cells are significantly higher than the basal levels of wt p53 in 
cancer cells, it is an interesting effect exerted by PTX. As expected, doxorubicin (Fig. 4-8A) and 
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VP16 (Fig. 4-8B) treatments activate mutp53 transcription activity towards its target genes Axl 
and NFκB2 but PTX does not (Fig.4-8). Axl and NFκB2 are known to promote tumor 
progression, providing a survival advantage to the cancer cells. This data suggests that whereas 
mutp53 cells, upon treatment with either VP16 or doxorubicin, will have the survival advantage 
provided by mutp53 transcription targets, PTX treated cells will not. 
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Figure 4-7 Effects of PTX on mutp53 and its transcription target Axl.  
Cells were treated either with thymidine (Tdr) or PTX (1um) + Tdr (5.6 um) for 24 hrs followed 
by immunoblotting to analyze the levels of mutp53 and of Axl in A) H1437 cells B) H1048 cells.  
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Figure 4-8 Effects of VP16, doxorubicin and PTX on mutp53 levels and its transcription 
targets.  
H1048 cells were treated either left untreated or treated with (A) doxorubicin (2um) for 3, and 6 
hrs or PTX (1um) + Tdr (5.6 um) for 24 hrs (B) VP16 (20um) for 6,12,and 24 hrs or PTX (1um) 
+ Tdr (5.6 um) for indicated time durations followed by immunoblotting to analyze the levels of 
p53 and its transcription targets.  
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4.8.4 Unlike etoposide and doxorubicin, PTX does not lead to an increase in the 
transcription of mutp53 target genes 
In these initial experiments, we saw that DNA damaging agents mediated an increase in the 
abundance of two mutp53 transcriptional targets, Axl and NFkB2, but that the time dependency 
of these increases could not be predicted and were different for the two transcriptional targets.  
Hence, we tested if that regulation was at the levels of transcription, as would be expected by 
analogy with the effects of wt p53.  We first started with analyzing the levels of mutant p53 in 
four NSCLC cell lines; H1437, H1048, H661 and H441 (Fig. 4-9). As expected, the levels of p53 
in H1048, H661 and H441 cells were very high in comparision to HCT116 with wt p53. 
Interestingly the level of mutant p53 was remarkably low in H1437 cells (Fig. 4-9). We treated 
four NSCLC cell with VP16 for 3, 6, 12 and 24 hrs, doxorubicin for 3,6 and 12 hrs and PTX 6, 
12 and 24 hrs followed by RNA extraction.  In this analysis, we were looking for increases in the 
abundance of mut53 transcriptional targets, and we considered that mRNA levels might show a 
more consistent pattern.  A cDNA synthesis reaction was performed from these RNA 
populations using random hexamer followed by RT-qPCR analysis to measure steady state levels 
of mRNAs.  Drug-treated H1048 (R273P) lung cancer cells were analyzed for steady state 
mRNA levels of several mutp53 transcription targets: NFκB2, HSP70, Axl, PCNA, and hTERT.  
The mRNA levels of NFκB2, HSP70 and PCNA were increased after treatment with either 
etoposide or doxorubicin.  The levels of Axl and hTERT mRNA levels were increased after 
etoposide but not after doxorubicin (Fig. 4-10).  These increments were time course dependent as 
levels of mRNA of different genes are enhanced at different time points by the same drugs.  
None of these mRNAs were increased after PTX treatment (without thymidine) at any time point 
(Fig. 4-10).  
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Upon observing no increase in the mRNA levels of these genes after PTX treatment, we further 
tested if PTX in the presence of TdR would also have similar effects.  Indeed, the effects of PTX 
with or without thymidine were almost identical (Fig. 4-11) as none of mutp53 targets showed 
any increase at the mRNA level after PTX or PTX + TdR treatment.  
In order to understand if these effects of PTX on mut p53 were cell line dependent or more of 
general effects in different cell lines, we performed similar experiments in H1437, which bear a 
p53 gene with a mutation that confers a R to P change at codon 267.  The levels of NFκB2, Axl, 
EGFR, MDR1, HSP70, and PCNA were increased by both VP16 and doxorubicin, however 
hTERT mRNA was increased only after etoposide treatment but not by doxorubicin (Fig 4-12).  
Once again the effects of the two DNA-damaging drugs were different for different genes.  As 
expected, PTX did not increase the levels of mRNA of any of these neomorphic target genes.  
Interestingly, we saw an increase in p21, a wt p53 transcription target upon VP16 and 
doxorubicin but not after PTX treatment in this cell line that had no wt p53 allele (Fig. 4-12).  
This suggests that this p53 mutant itself still had some remaining wt p53 activity.  The level of 
p53 in these cells also supports the similarity of behavior between the R267P mutant and wt p53, 
in that the levels of the R267P mutant p53 were maintained at lower levels than the levels 
expected for gain of function mutant p53s (Fig. 4-9).   H1437 cells were also analyzed for 
differences in response after PTX and PTX + TdR.  H1437 cells also showed almost identical 
results when treated with PTX in the presence or absence of thymidine (Fig. 4-13). 
Two other lung cancer cells H441 (R158L) and H661 (R158L) were also tested to investigate the 
generality of the PTX mediated effects.  H441 cells were treated in the same way as H1048 and 
H1437 , and the data are shown in Fig 4-14.  Levels of NFκB2, EGFR, HSP70, PCNA, and 
hTERT increased after VP16 or doxorubicin treatment in a time-dependent manner in H441.   
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The mRNA levels of hTERT were not affected by doxorubicin, there was an evident increase in 
the levels of hTERT mRNA after VP16 treatment.  The levels of Axl mRNA were increased by 
VP16 but not by doxorubicin (Fig. 4-14).  Again, none of the mRNAs levels for any of these mut 
p53 neomorphic targets was increased after PTX treatment (Fig. 4-14), suggesting that it was a 
generality that PTX does not increase mutp53-mediated GOF transcription of these oncogenic 
genes. 
When H661 cells were studied, which have a mutation in p53 at codon 158 (R158L) NFκB2, and 
hTERT were increased after either VP16 or doxorubicin treatment.  The mRNA levels of Axl, 
HSP70 and PCNA were increased only after doxorubicin treatment with no evident increase after 
VP16 treatment. As seen in the other three cells lines, none of these mRNAs were increased after 
PTX treatment (Fig. 4-15). 
Overall this data suggested that, whereas both DNA damaging agents, VP16 and doxorubicin, 
lead to enhanced transcriptional activity of mutp53 in several lung cancer cell lines, PTX does 
not cause transcriptional activation of mutp53 transcription targets in any.  These data is 
summarized in table 4-1.  Hence, mutp53 containing lung cancers can exploit the survival 
advantage provided by the increased levels of oncogenic transcription targets of mutp53 
followed by VP16 or doxorubicin, but not following PTX treatment.   
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Figure 4-9. Protein levels of p53 in different cell lines  
All the cells were cultured in the same conditions and harvested. Equal levesl of protein was 
loaded to compare the p53 levels in these cells lines.  β-actin is used a loading control.     
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Figure 4-10. mRNA levels of various oncogenic genes in H1048 cells after DNA damaging 
drugs increased but not after PTX.   
H1048 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12 
hrs and PTX (1um) for 6,12, and 24 hrs. Steady state mRNA levels were analyzed using RT-
qPCR. This experiment has been repeated twice.                
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Figure 4-11. mRNA levels of various oncogenic genes in H1048 cells after DNA damaging 
drugs increased but not after PTX.  
H1048 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12 
hrs and PTX (1um) +/- TdR (5.6um ) for 24 hrs. Steady state mRNA levels were analyzed using 
RT-qPCR. This experiment ahs been repeated twice. 
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Figure 4-12. mRNA levels of various oncogenic genes in H1437 cells after DNA damaging 
drugs increased but not after PTX.  
H1437 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12 
hrs and PTX (1um) for 6,12, and 24 hrs. Steady state mRNA levels were analyzed using RT-
qPCR. This experiment has been repeated twice. 
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Figure 4-13. mRNA levels of various oncogenic genes in H1437 cells after DNA damaging 
drugs increased but not after PTX.  
H1437 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12 
hrs and PTX (1um) +/- TdR (5.6um ) for 24 hrs. Steady state mRNA levels were analyzed using 
RT-qPCR. This experiment has been repeated twice. 
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Figure 4-14. mRNA levels of various oncogenic genes in H441 cells after DNA damaging 
drugs increased but not after PTX.  
H441 treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12 hrs , 
PTX (1um) for 6, 12 and 24 hrs. Steady state mRNA levels were analyzed using RT-qPCR. This 
experiment has been repeated twice. 
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Figure 4-15. mRNA levels of various oncogenic genes in H661 cells after DNA damaging 
drugs increased but not after PTX.  
(A)  H661 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 
12 hrs and PTX (1um) for 6,12, and 24 hrs. Steady state mRNA levels were analyzed using RT-
qPCR. This experiment has been done once. 
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Table 4-1  Summary: the highest increase in levels of mRNA in RT-qPCR analysis.  
 
 
These numbers represent the highest fold increase in the mRNA levels upon indicated 
treatments. Numbers represent the ratios of mRNA levels found in the treated cells devided by 
that in untreated cells. Experiments done on H1437, H1048 and H441 cells were repeated twice 
and pattern of change in mRNA levels is reproducible. Experiment on H661 cells was done once. 
 
 
 
 
 
 
Cell$line$ Drug$ NFkB2$ PCNA$ hTERT$ Axl$ MDR1$ EGFR$ Hsp70$
H1048$$
(R273C)$
VP16 10 3 4 4 ---- ---- 2.5 
$ Doxorubicin 5 3 1.7 0.7 ---- ---- 2.7 
$ PTX (+/-  
TdR) 
1 1 1.1 0.5 ---- ---- 1.1 
H1437$
(R267C)$
VP16 3 2 6 1 4.5 2.6 1.02 
$ Doxorubicin 7.3 3.5 1.1 3 2.5 2.9 5.2 
$ PTX (+/-  
TdR) 
0.8 0.6 1 1 1 1.1 1 
H441$
(R158L)$
VP16 10 2 4 2.3 ---- 2.9 1.9 
$ Doxorubicin 6 2.5 2 1.1 ---- 2 2.3 
$ PTX (+/-  
TdR) 
1 1 1 1.2 ---- 1 0.8 
H661$
(R158L)$
VP16 2 1.2 2 1.2 ---- ---- 1 
$ Doxorubicin 2.2 2.7 2.2 2 ---- ---- 2 
 PTX (+/-  
TdR) 
1 1.1 1.1 1 ---- ---- 1 
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4.8.5 PTX can block the VP16 mediated transcription activation of mutant p53 
It has been previously reported that an increase in NFκB2, PCNA, MDR1, EGFR, Axl, Hsp70, 
and hTERT caused by transcriptional activation by mutp53 may lead to survival advantage to 
cancer cells and allow the development of chemo-resistance. We also had shown in Chapter 3 
that PTX did not activate wt p53 and, in addition, could block the transcriptional activation of the 
p21 gene by wt p53.   Because PTX does not cause activation of mutp53 transcription activity, 
we hypothesized that combining PTX with VP16 might block VP16 mediated the GOF 
transcriptional activation of mutp53 and inhibit the enhancement of oncogenic targets of mutp53.  
H1048 cells containing mutp53 (R273P) cells were either left untreated or treated with VP16 
(20µM) for 6 hrs or PTX (1µM) in the presence or absence of TdR (5.6µM) for 24 hrs.  For 
combination treatment, H1048 cells were treated with PTX for 20hrs followed by VP16 
treatment for 6 hrs.   Cells were harvested in Trizol and RNA was extracted. RT-qPCR analysis 
was performed to measure the steady state levels of mRNAs for the several genes discussed 
above.  We found that, after 6 hrs treatment with VP16 alone, the levels of mRNA from genes of 
interest were increased significantly; NFκB2 increased 10-14 fold, PCNA increased 2.5-3 fold, 
AXL increased 3-3.5 fold, Hsp70 2-2.5 fold, and hTERT 5-8 fold (Fig 4-16).   However, when 
cells were pretreated with PTX (+/- TdR) for 20 hrs followed by 6hr exposure to VP16, there 
was a 50-60% blockade of VP16-mediated increase in NFκB2 mRNA levels, a remarkable effect 
considering that NFκB2 is strongly transactivated by VP16 activated mutp53.  More 
interestingly, we found a complete suppression of VP16 mediated increment in PCNA, AXL, 
Hsp70 and hTERT mRNA levels when cells were pretreated with PTX in the presence or 
absence of TdR (Fig. 4-16).  This clearly suggests that pretreatment with PTX does not allow the 
VP16 mediated transcriptional activation of mutp53.  This led us to hypothesize that if PTX can 
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block the transcription activation of mutp53 transcriptional targets induced by DNA-damaging 
drags, then combination treatment of PTX will increase the cytotoxic effect of these drugs.   
4.8.6 Combination drug treatment shifts the growth curve towards left 
As we found that PTX can block the VP16 mediated enhancement of the transcriptional activity 
of mutp53, we hypothesized that combination treatment of these two drugs might lead to better 
cell growth suppression.  H1048 and H1437 cells were either treated separately or co-treated 
with various concentrations of PTX and VP16 for 72 hrs followed by measurement of cell 
densities by coulter counter.  We found that combination treatment of PTX and VP16 shows 
better growth suppression of H1437 and H1048 cells in comparison to either of the two drugs 
alone (Fig. 4-17), as evidenced by a shift of the dose-response curves for PTX to the left.  It now 
remains to be proven whether blockade of transcriptional activity of mutp53 might be playing 
role in the cell growth suppression of the combination treatment. 
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Figure 4-16. PTX can block the VP16 mediated transcription activation of mutant p53.  
H1048 cells were either left untreated or treated withVP16 (20µM) or PTX (1µM) in the 
presence or absence of TdR (5.6µM) for 24 hrs. For combination treatment H1048 cells were 
treated with PTX for 20hrs followed by VP16 treatment for 6 hrs. Steady state mRNA levels 
were analyzed by RT-qPCR. This experiment has been repeated twice and effects shown in this 
experiment are reproducible. 
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(A,B) H1048 cells treated with increasing concentration of VP16 and PTX and cell densities 
were measured by coulter counting after 72 hrs. C,D) H1437 cells treated with increasing 
concentration of VP16 and PTX and cell densities were measured by coulter counter after 
72 hrs. Data is plotted after normalizing with untreated cells, which is considered as 100% 
growth. 
 
 
  
Fig.6$
A B
C$ D$
Combination of PTX and etoposide increases the sensitivity of GOF mutant p53 containing cells 
Figure 4-17. Combination of PTX and etoposide increases the sensitivity of GOF mutant p53 
containing lung cancer cells.  
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4.9 DISCUSSION 
We asked a fairly simple but important question of how PTX will affect the cells with gain of 
function mutp53. We addressed this question using lung cancer cell lines with gain of function 
mutp53, because the most frequent gene mutated in lung cancer is p53. 
As, in the third chapter of this thesis, we showed that cells with mutp53 have equivalent 
mTORC1 activity as isogenic p53 null cells, but much higher levels of p53.  Hence, this study 
becomes very important, because it suggests that PTX can block the effects of loss of p53 as well 
as the effects of mutp53 on mTORC1.  
We asked if PTX can inhibit transcriptional activity of mutp53 as it does the transcriptional 
activity of wt p53.   Indeed, PTX blocks the transcriptional activation of GOF mutp53. This is a 
therapeutically very important phenomenon as it has been previously reported that treatment with 
DNA damaging drugs leads to enrichment in chemoresistant cells in cell culture due to increase 
levels of mutp53 (Blandino et al., 2002).  It has been suggested that DNA damaging drug leads 
to increase in mutp53 levels, increasing the expression of proteins responsible for or factors in 
the development of chemo-resistance in these cancers and that, hence, provide growth advantage 
in the faced of drug treatement by supporting tumor progession ((MDR1) (Y. Matsumoto, 
Takano, & Fojo, 1997; Y. Matsumoto, Takano, Kunishio, Nagao, & Fojo, 2001; Y. Matsumoto, 
Tamiya, & Nagao, 2005)  (NFKb2) (Harte et al., 2014; Ludes-Meyers et al., 1216; Scian et al., 
1203; Scian et al., 2004; Shivakumar et al., 1995; Vaughan et al., 2012).  This is the first time 
that it has been shown that a chemotherapeutic drug can inhibit the activation of GOF 
transcription from mutp53 and suggests that this effect may by involved in the therapy with PTX.  
As PTX can block the transactivation of transcriptional target of mutp53 gene, it suggests that 
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combination treatment of PTX with other drugs that usually stimulate mut p53 GOF transcription 
can be therapeutically more effective than these drugs alone. 
Interestingly we found H441 and H661 cells, both of which have the same mutation in p53 
(R158L) show different transcriptional activation profiles after doxorubicin or etoposide 
treatment.  This suggested that mutation of other genes, perhaps KRAS in H441 and p63 in 
H661, was affecting the mut p53 selectivity towards its transcriptional targets as well as the 
intensity of transactivation.  It is clear that each mutant p53 behaves differently and responds 
differently towards different DNA damaging drugs, with an overall of similarity but quite 
different details of the response.  This complexity is rather daunting to explain.   There are 
several questions left unanswered by my studies that beg experimental explanation. Some of 
those are discussed below; 
 
1.  Why do PTX and DNA damaging drug treatments lead to increased protein levels of mutp53 
?  Our current understanding of mutp53 indicate that the untreated levels of mutp53 are much 
higher than untreated levels of wt p53 due to an increased half life, most likely due to a lower 
binding of mdm2 to the mutant forms of p53.   Out of the several theories to explain this, he most 
likely one is that mutp53 is constantly phosphorylated at ser15 and thus not allow the binding of 
MDM2, avoiding degradation; the well studied mechanism of wt p53 stabilization after 
genotoxic stress. This raises a question that if mutp53 is already phosphorylated at ser15 than by 
what mechanism do these treatments increase mutp53 levels?  However, we know by our studies 
in chapter 3 that PTX (with thymidine) does not mediate phosphorylation of ser15 of WT p53, 
but we don’t know what happens in the case of mutp53.  
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2.  Why is the transcription activity of mutp53 compromised after PTX treatment: Studies in the 
chapter 3 done on PTX mediated effects on transcriptional activity of wt p53 suggests that PTX 
stabilizes a transcriptionally compromised p53 and we propose that this p53 is transcriptionally 
inactive due to the inability of PTX to induce a DNA damage signal.  As we see that PTX leads 
to an increased levels of mutp53 without enhancing its transcriptional activity, it would be 
interesting to analyze the status of H2A.X in cells treated with VP16 or PTX to see if PTX 
effects on DNA damage are the same in cells with mutp53. 
 
3.  What are the post-translational modifications of mutp53 under PTX vs VP16 and 
doxorubicin. In Chapter 3, we examined the posttranslational modifications after PTX treatment 
and after VP16 treatment, and found that the post-transcriptional modifications of p53 were a 
reflection of the type of genotoxic stress induced by the drugs.  Therefore, it will be interesting to 
know the posttranslational profile of mutp53 after different treatment to predict the underlying 
mechanism of action of these drugs. 
 
4.  What are the mechanism(s) of the PTX-mediated effects on transcriptional activation by wt 
p53 and mut p53. Our current understanding suggests that transcriptional activity of mutp53 is 
regulated very differently than that of wt p53.  As PTX affects are similar towards transactivation 
inhibition of both wt and mut p53, this suggests a common mechanism by PTX is at play which 
interfers with ctranscription from both wt and mutp53.  Thus a better understanding of the 
mechanism by which PTX blocks transcriptional activity of wt and mut p53 might improve the 
fundamental understanding of this field. 
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Chapter 5 
5 Overview and perspective 
It has been shown previously that some of the very frequent mutations in lung cancers, like 
EGFR mutations and amplifications, K-Ras mutations, and PI3K muations act upstream of 
mTORC1 and feed into hyperactivity of mTORC1 in these cancers. However, the most frequent 
mutations found in lung cancer is p53, but it is not known how loss or mutation of p53 affects 
mTORC1 kinase activity. 
My PhD. thesis work started by addressing the fairly simple but very important question of how 
p53 regulates mTORC1 activity. Later, after understanding the affects of deletion or hot-spot 
mutation of p53 on mTORC1 activity, we explored how this regulation may affect the 
therapeutics of PTX on cancer. This dissertation has also discovered a very important mechanism 
of the regulation of the mTORC1 pathway by mutp53 and how PTX affects the oncogenic 
affects of GOF mutp53 in lung cancer cells.  
 
The loss or hotspot mutation of p53 enhance mTORC1 activity.  
Our very initial studies in this quest led to the discovery that p53 null cells have higher mTORC1 
activity because p53 null cells had lower levels of TSC2 and sestrin2.  The mTORC1 complexes 
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in cells null for p53 had lower levels of TSC2 and PRAS40 bound with a increased levels of 
mTOR suggesting that upon loss of p53 more mTOR is present as mTORC1 complex and 
something fundamentally different was happening with the recruitment of components of the 
complex. These finding were confirmed and strengthened by experiments by my colleague 
Catherine M. Bell who performed subcellular fractionation and confocal microscopy studies to 
analyze the distribution and co-localization of mTOR, TSC2 and Rheb in cells with or without 
p53.  The site of function of mTORC1 is currently thought to be the lysosomal membrane and 
TSC2 has been reported to be localized at this site under serum starved condition.   Accordingly 
Ms Bell found that the levels of TSC2 are decreased in the lysosomal membrane of p53 null 
cells, and the decreased levels of TSC2 were concomitant with an increased level of Rheb at 
lysosomal membrane of p53 null cells.  We also showed that cells with gain of function mutant 
p53 also have enhanced mTORC1 activity and this is also due to decrease in TSC2 and Sestrin2 
levels in absence of WT p53 and its transcription activity. This is first time anyone had showed 
these effects.  We concluded that deletion or hotspot mutation of p53 enhances mTORC1 activity 
by decreasing TSC2 levels, its localization at lysosomal membrane and at least partially as result 
of increased levels of Rheb at lysomal membrane. 
Future perspective  
We still don’t understand the reasons for the differences seen in the components of mTORC1 
complexes from wt and null p53 cells. 
1. More mTOR present as mTORC1 complex: mTOR can be present in the form of two 
complexes, mTORC1 and mTORC2.  Using an anti-raptor antibody for 
immunoprecipitations of mTORC1, more mTOR was pulled down in p53 -/- cells.  As 
the levels of mTOR and Raptor are the same in the lysates from both cell lines this 
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suggested that, in p53 null cells, more Raptor-bound mTOR is present i.e, more 
mTORC1 complex is present.  It seems as if the dynamic distribution of mTOR 
between mTORC1 and mTORC2 complex might be of importance for the mechanism 
of regulation of mTORC1 activity.  
2. Lower levels of PRAS40 bound to the complex: PRAS40 is an inhibitor of mTORC1 
kinase activity unless phosphorylated by AKT at T-246. In our immunoprecipitation 
studies, we saw that the levels of PRAS40 bound to mTORC1 complex is decreased 
in p53 null cells.  We think that possibly PRAS40 interacts with mTORC1 complex 
via TSC2 and that the lower levels of TSC2 in p53-/- cells led to decreased levels of 
PRAS40 binding to mTORC1 in these cells, contributing to the higher mTORC1 
activity. However, there is no direct experimental evidence for this hypothesis, and 
studies to confirm or negate it will be very useful. 
3. Higher levels of Rheb in lysosomal membranes of p53 null cells: Subcellular 
fractionation and confocal microscopy studies done by Ms. Bell, indicated  that the 
levels of Rheb are increased at the lysosomal membrane of p53 null cells. Although 
we don’t understand the mechanism of this difference yet as there was no difference 
in the total Rheb protein levels and steady state mRNA levels in the cells. We think 
that possibly Rheb-GTP has higher affinity for lysosomal membrane than Rheb-GDP 
and this could explain the increased localization of Rheb in p53 null cells.  
Immunoprecipitations using an anti-raptor antibody also suggested more Rheb present 
in the mTORC1 complex from p53 null cells, an extremely controversial observation.   
4. Colocalization of TSC2 and Rheb with mTOR in mutp53 cells: We showed that the 
levels of TSC2 are decreased in cells with mutp53 in comparison to p53 competent 
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cells and this phenomenon was consistent with the increased levels of mTORC1 
activity. It would be of interest to see if the localization of TSC2 and Rheb in mutp53 
cells are similar to that seen in p53 null cells. 
 
Because p53 negatively regulates mTORC1, it was expected that loss of p53 would diminish 
the therapeutic effects of PTX; it did not. 
 
 
My initial experiments of this study showed that PTX can effectively down-regulate the 
enhanced mTORC1 activity in p53 null cells.  This result was more interesting than surprising.  
We continued on this study and sought to understand the mechanism of the p53-independent 
mechanism of PTX mediated inhibition of mTORC1.  We found that, whereas AICAR-activated 
AMPK phosphorylates both TSC2 and Raptor, PTX-activated AMPK only phosphorylates 
Raptor but not TSC2.   We discovered that the levels of TSC2 are not increased in p53 
competent cells after PTX treatment because of a failure to activate p53 transcription.  Therefore, 
we concluded that PTX-stabilized p53 does not increase levels of TSC2 and Setsrin2, so that, as 
in p53 null cells, PTX treated cells cannot phosphorylate and activate TSC2.  We proved this 
postulate and showed that Raptor phosphorylation was sufficient for mTORC1 inhibition.  We 
tried to understand the transcriptional incompetence of the p53 stabilized by PTX.   It was not 
due to the binding of p53 at the promoter of p21, nor the recruitment of HATS to regional 
histones.  We shifted our attention to the clues left by the pattern of PTMs in p53 after PTX. 
 
We concludeded that PTX (±TdR) does not cause transcriptional activation because it does 
not cause DNA damage of the nature caused by drugs such as VP16 or AICAR, which do 
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activate transcription by p53.  
Studies done to test this hypothesis brought several surprises to us. As expected, cells treated 
with PTX in the absence of TdR led to increased levels of H2A.X pS139, indicating genotoxic 
stress but we still did not observe any increase in the levels of p21.  
Future perspectives  
 
 
1. How does AMPK activation by PTX stabilize p53 ?.  
PTX in the presence of thymidine stabilizes p53 without causing phosphorylation of p53 at 
S15, a PTM thought to be required for the stabilization of p53 after DNA damage as it inhibit 
the interaction of p53 with it E3 ubiquitin ligase and protects p53 from proteolysis. How p53 
can be stabilized without phosphorylation of S15 is as yet unknown.  
2. Why does PTX in the absence of TdR not induce p53 transcription ?  PTX without 
thymidine allows the effects of inhibition of thymidylate synthase to be expressed, 
including the incorporation of dUMP into DNA and subsequent damage to DNA 
following patch excision.   It is of great interest that how inhibition of thymidylate 
synthase is not sufficient to activate p53 transcriptional activity.  It seems that 
phosphorylation of p53 at S15 works as an enhancer of p53 stabilization but it is not a 
mandatory event for p53 stabilization, as we see higher levels of p53 in treatments that 
induce phosphorylation at S15 (VP16, AICAR and PTX (-TdR)), than in PTX+ TdR. 
 
3. Chk1 activation has been reported to inhibit transcriptional activity of p53.  Studies 
done by Beckerman and Prives suggested that HU-stabilized p53 is transcriptionally inactive due 
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to activation of Chk1.  Following inhibition of Chk1 activation by an ATR inhibitor or by 
knocking down Chk1 using siRNA, p53 transcriptional activity can be regained.  Interestingly, in 
my studies VP16 activates Chk1 and AICAR does not, however they both stabilize 
transcriptionally active p53, suggesting that the presence or absence of Chk1 activation is not 
mandatory for p53 transactivation.  This is of great interest to dissect the phenomenon of how the 
activation of Chk1 can play as an inhibitor of p53 transactivation under one stimuli (HU), an 
activator in other (VP16) or just remain a non-affecting factor in another (AICAR, PTX (+TdR)). 
 
4. PTX (+TdR) can block the DNA damage by VP16 or AICAR and blocks p21 
transcription.  
We found that cells pretreated with PTX (+TdR) blocked the VP16 or AICAR mediated DNA 
damage signal and increase of p21 levels. This is strong evidence that DNA damage is required 
for VP16 or AICAR mediated transcriptional activation of p53.  A former PhD. student of our 
lab, Dr. Scott Rothbart showed that cells treated with PTX with thymidine are arrested at G1 
stage of cell cycle, while cells treated with only PTX (- TdR) are arrested in S phase.  This 
suggested that blockade of cells at the G1/S border or in S-phase does not allow the DNA 
damage to occur even after VP16 treatment, thus blocking DNA damage signaling, leaving p53 
transcriptionally inactive.  However, PTX in the absence of TdR blocks cells at S phase, 
probably due to a replication halt caused by thymidylate synthase inhibition. This replication halt 
allows the increased levels of pS139 H2AX but does not induce DNA double strand break DNA 
damage signal and thus does not allow p53-mediated induction of p21 levels.  This also explains 
the PTX (+/-TdR) mediated block of VP16 and AICAR effects on p53 as cells are already 
arrested at G1 and S phase under PTX (+TdR) or PTX, respectively, without double strand 
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break. Therefore addition of VP16 or AICAR is incapable to induce DNA damage and in the 
absence of a certain type DNA damage (DSBs and SSBs), p53 is transcriptionally inactive. 
 
5. PTX-activated AMPK does not cause DNA damage and does not activate p21 
transcription. Whereas AICAR-activated AMPK causes DNA damage and leads to induction of 
p21 mRNA and protein levels, PTX-activated AMPK neither causes DNA damage nor induction 
of p21 levels. This suggests that AMPK activation per se does not induce DNA damage and 
AICAR induced DNA damage proceeds via an unknown mechanism.  
 
6. The relationship between activation of Chk1 and Chk2, phosphorylation of p53 at S15, 
and p53 transactivation. 
A great deal of research has been done in order to understand how DNA damage leads to 
stabilization, post-translational modification and transactivation of p53. A general understanding 
is that DNA damage leads to stabilization of p53 by multiple and specific posttranslational 
modifications by the activity of several kinases: ATM/ATR/ Chk2/Chk1, leading to 
transcriptional activation of p53.  My studies are suggesting that the correlation of S15 
phosphorylation of p53 with p53 stabilization does not necessarily apply to conditions other than 
DNA damage.  Also, multiple phosphorylations at specific residues of p53 have been reported to 
be necessary for p53 transactivation, which dos not seem to be a case, at least under the 
condition of AICAR treatment. In addition, Chk1/Chk2 have been shown to be involved in the 
S15 phosphorylation of p53, which is also not in accordance with our studies as AICAR shows 
pS15 but no p-S345 Chk1 and PTX (-TdR) shows p-S15 but no pChk2. Therefore, dissection of 
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the interdependence of these events would be a great contribution in the field of p53 signaling 
pathways, especially after treatment with AMPK activators.  
 
Transactivation of unique genes by GOF mutant p53 and PTX 
We found that PTX does not activate transcriptional activity of wt p53 and it blocks VP16 
mediated transactivation of mutp53.  In four lung cancer cell lines with different hot-spot 
mutations  I analyzed the transcriptional activity of mutp53 at 7 different genes after treatment 
with the DNA damaging agents, VP16 and Doxorubicin or PTX (+/- TdR).  All of these genes 
have been described in prior literature as being transcriptional targets of GOF mutp53.  The 
overall pattern suggested that, whereas treatment with VP16 and doxorubicin leads to 
transactivation of mutp53 and increases the levels of mRNA from these several genes (albeit to 
different levels in different cell lines), PTX (+/-TdR) does not allow the transactivation of these 
genes in any cell line.  More interestingly, PTX can block the VP16 mediated transactivation of 
GOF mutp53.  This finding is very important as this suggests that where cancer cells with 
mutp53 can have a survival advantage upon treatment with VP16 or doxorubicin due to 
increased expression of the proliferative and cell survival genes, treatment with PTX will block 
this effect.  
 
Future perspectives 
 
1. Mechanism of transactivation of mutp53: Not much is known about the transactivation 
of mutp53.  The fact that PTX can block the transactivation of both wt and GOF mutp53 
suggests the use of some common mechanism of transactivation.  Therefore, analysis of 
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DNA damage signaling under PTX treatment in mutp53-carrying cells might be of 
interest and may reveal the mechanism of  these neomorphic properties.  
2. Why do PTX or DNA damaging drugs lead to increased protein levels of mutp53: As 
little is known about the stabilization of mutp53, these drugs can be used as a tool to 
manipulate the pathway and understand the possible mechanism of mutp53 accumulation 
in cancer cells.  
3. Importance of post translational modification of mutp53 in its oncogenic activity: 
Understanding the levels of various posttranslational modification of mutp53 after 
different drug treatment or genotoxic stresses might help in understanding the mechanism 
of transactivation of this protein.  
4. Understanding the protein-protein interaction: mut p53 has been reported to interact 
with p53 family proteins (p73 and p63) and inhibit their p53-like activity as one of its 
several mechanisms by which mutp53 provides survival advantage to cancer cells.  
Therefore, it will be interesting to understand if these different drugs lead to different 
protein-protein interactions with p73 or p63, providing or avoiding a survival advantage. 
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